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Abstract 
 
A demand exists for a fast, sensitive, reliable and economical test for pyogenic sepsis 
that provides a “real time” bed-side assessment.  Detection of significant intra-
abdominal sepsis can be particularly problematic in the ICU setting and in patients with 
multi-system organ failure.  
 
Lysozyme, first reported by Fleming (1922), is a bacteriolytic enzyme released during 
phagocytosis.  Previous studies have shown significant correlation between lysozyme 
levels and the presence of intra-abdominal abscess in both animals and humans.  A 
method which determines and quantifies lysozyme as part of an assessment of an 
acutely ill patient in whom major sepsis is suspected; would significantly aid diagnosis 
and prescription of  the most effective form of treatment. To date measurement of 
lysozyme has been by turbidometry, with consequent poor sensitivity and reliability.  
Other methods of assay include fluorescence, radial immunodiffussion and enzyme 
linked immunosorbent assay (ELISA).  
 
This study reports a modified ELISA technique which provides a cheap, sensitive and 
reliable method of lysozyme determination, producing results in <100 minutes.  The 
ELISA has been tested with ~200 clinical samples provided by the patients at the Great 
Western Hospital, Swindon.  Two ELIFA techniques were also developed for lysozyme 
and E.coli detection.  These techniques also provide a cheap and rapid alternative to the 
more traditional immunoassays.  Results from the ELIFA and mini-ELIFA were 
obtained qualitatively after only 10 minutes.  An SPR detection technique was also 
devised.  The BIAcore 3000 was used to create a biosensor for serum lysozyme using 
an artificial receptor in the form of an aptamer.  This system was tested with clinical 
serum samples, is reusable and took <80 minutes to immobilise a ligand on a blank 
sensor and analyse a serum sample for lysozyme. 
 
Although further research and development is required on the mini-ELIFA and 
lysozyme biosensor, the ELISA detection system may prove a useful tool in the 
diagnosis of sepsis in critically ill patients. 
Chapter 1 1
Chapter 1 - General Introduction 
 
1 Sepsis  
Sepsis is the leading cause of death in Intensive Care Unit (ICU) patients worldwide; in 
excess of 18 million cases of sepsis are recorded each year.  Mortality rates have 
decreased only slightly over recent years, but incidence has continued to rise to an 
unacceptable rate.  Even with advances in critical care medicine, numerous treatments 
developed and profound investment, 56% of all septic ICU patients die each year; 
suggesting that more immediate exploratory work is needed (Edbrooke et al., 1999). 
 
In 2002, the Surviving Sepsis Campaign was spearheaded by the European Society of 
Intensive Care Medicine, International Sepsis Forum and Society of Critical Care 
Medicine.  Their mission was to create a clearer clinical definition, develop and 
instigate better standards of care leading to enhanced diagnosis,  effective management 
and ultimately to increase the number of sepsis survivors.  Currently sepsis is placing a 
huge burden on worldwide healthcare resources.  It is estimated that ICU expenditure 
for sepsis alone is costing €7.6 billion annually in UK and Europe and a staggering 
€16.7 billion in the US each year.  Clearly this huge investment is not having the 
desired effect of reducing death by sepsis and alternative solutions are required without 
delay. 
 
1.1 Introduction to Sepsis 
Sepsis was defined in 1914 by Schottmuler “as a state of microbial invasion from a 
portal of entry into the blood stream, which causes illness”.  A more recent definition by 
Bochud & Calandra (2003) distinguishes between sepsis, septic shock, septicaemia, and 
severe sepsis.  Sepsis is the condition resulting from the presence of bacteria or their 
toxins or pathogens, in the blood or tissues.   
 
1.2 Classification of Sepsis 
Basic signs and symptoms of systemic sepsis show 2 or more of the following; fever, 
due to the resetting of hypothalamus; chills, resulting from muscular contraction to 
generate heat; heart rate above 90bpm; respiration rate above 20bpm; pCO2 less than 
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32mmHg and leukocyte count greater than 12,000cells/ml3 (Sharma & Eschun, 2004).  
Septicaemia is the presence of dividing bacteria caused by a persistence of pathogenic 
organisms or their toxins in blood.  Septic Shock is sepsis as defined above, (resulting 
from bacteria/toxins present in blood/tissues) along with hypotension and may also 
include, lactic acidosis, oliguria (reduced urination) or an acute alteration in mental state 
(Bochud & Calandra, 2003).   
 
Septic shock is most commonly associated with Gram positive bacteria, fungi and 
endotoxin-containing gram negative bacteria.  In the 1970’s, Gram positive bacteria 
accounted for 10% of all causative bacteria, now it is 50% (Bochud & Calandra, 2003).  
This increase is said to be caused by the increased use of intravascular devices (Daikos, 
1994).  The commonest Gram negative bacteria which cause sepsis include E.coli, 
Klebsiella species, and Pseudomonas aeruginosa.  Gram positive bacteria include 
Staphylococcus aureus and coagulase negative staphylococci, as well as Streptococcus 
pyogenes, pneumoniae and viridans streptococci.  Sepsis caused by fungi (most 
commonly Candida) only account for 5% of cases, but like Gram positive bacteria this 
is increasing with time. 
 
Gram negative bacteria usually cause infections in the lungs, abdominal cavity, blood 
stream, and urinary tract.  Whereas Gram positive bacterial infections occur in the skin, 
soft tissue, primary blood stream, upper respiratory tract and are also associated with 
infections of intravascular devices (e.g. vascular grafts), (Bochud & Calandra, 2003).  
Of these bacteria, the products/components that are released include endotoxin, teichoic 
acid antigen, and exotoxins.  All these stimulate the release of endogenous mediators 
from endothelial cells, plasma cells (which also include dendritic cells, natural killer 
cells, monocytes, macrophages, and neutrophils) and plasma cell precursors.  These 
mediators have their effects on the heart, vasculature, and body organs and produce the 
clinical picture of sepsis.  The next stage is severe septic shock followed by death 
caused by singular or multiple organ system failure (Vosylius et al., 2004).   
 
Early administration of antibacterial therapy is essential.  A broad spectrum therapy is 
used because Gram negative sepsis can develop to death within two days, which is not 
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enough time to identify the causative bacteria, as microbiological confirmation takes 48 
hours.  However, the administration of antibiotics so soon into an infection may mask 
bacteriological diagnosis.  This is also true for postoperative infections.  The symptoms 
of the primary illness (i.e. the reason for the surgery) can mask the presence of the 
infection. 
 
1.3 Diagnosis of Sepsis 
A patient’s response to infection is unique, no two patients present with the same 
symptoms, which can therefore make diagnosis of sepsis difficult.  The symptoms that 
do present in a patient can be indicative of other diseases.  An example of this is put 
forward by Petersdorf et al. (1983).  This report found that 18% of appendectomies that 
were based on acute abdominal pain turned out to be negative.   
 
Diagnosis is made by analysing the patient history, a physical examination, Gram stains 
from biological fluids and results from blood cultures.  Signs and symptoms can include 
hypotension, inadequate organ perfusion, fever, chills, tachycardia (>100bpm), 
tachypnoea (excessively rapid breathing), and altered mental state.  The circulatory 
insufficiency is characterised by a lower systemic vascular resistance along with a 
reduced contractile function and pooling with altered distribution of blood in the 
microcirculation (Daikos, 1994). 
 
1.4 Signs & Symptoms of Intra-abdominal Infections (IAI) 
Intra-abdominal infections are the commonest form of sepsis.  Three classifications of 
Intra-abdominal infections are observed; primary, secondary and tertiary peritonitis.  
When primary peritonitis occurs the infection is localised, but it can develop into a life 
threatening disease with high morbidity (percentage of disease leading to disease) and 
mortality (percentage of death), but this is rare. 
 
Primary peritonitis is especially prevalent in infants, children, cirrhotic patients, the 
immuno-compromised and patients with ascites and diabetes.  Monomicrobial 
infections are caused by Enterobacteriaceae, Pneumococci, Streptococci, Staphylococci, 
other anaerobes, or Candida, (Barie, 1999).  These organisms are derived from the 
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intestinal tract, ascension via the female genital tract or by direct transmural migration 
into the peritoneal cavity.  Where peritonitis is associated with chronic ambulatory 
peritoneal dialysis, causative organisms include vancomycin resistant Staphylococci, 
Candida and other opportunistic fungi and Pseudomonas.   
 
In secondary peritonitis, peritoneal infections are due to intra-abdominal infections 
caused by perforation of hollow viscous bowel, (60-80% of all cases), other causes 
include ischemic bowel wall necrosis, infection of intra-abdominal organs, secondary 
infection (e.g. pancreatitis), tumours, trauma, appendicitis, diverticulitis, perforation of 
peptic ulcers or post-operative infection associated with suture leakage.  Polymicrobial 
infections in the intestines are usually caused by Bacteroides fragilis, enteric Gram 
negative bacilli and isolates of Clostridia, Enterococci and Pseudomonas.  Infections in 
the liver and biliary tract are caused by E. coli, Klebsiella species, Enterococci and 
anaerobes in patients over the age of 70 or with Diabetes mellitus (Barie, 1999).  
Polymicrobial infections of the female genital tract are caused by Chlamydiae, 
Bacterioides fragilis and enteric gram negative bacilli.  Mortality rate where peritonitis 
is due to untreated appendicitis is 8%.  However, in secondary peritonitis, the progress 
is also dependent on pre-operative physiological derangement, age and pre-existing 
diseases.  Farthman & Schöffel (1998) in their study showed that 25% of all Intra-
abdominal infections cause multiple organ failure.   
 
Tertiary peritonitis is characterised by bacterial contamination of the peritoneal cavity.  
The progress from contamination to infection of the peritoneum depends on growth 
characteristics of the bacterium, adherence capabilities, and the invasiveness of the 
particular bacterial species; which explains why there are over 400 species present in 
the human bowel yet only 10-20% are commonly found in intra-abdominal infections.  
Tertiary peritonitis is caused by Enterococci, Pseudomona, Staphlyococcus epidermidis 
and Candida, however as tertiary peritonitis is characterised by the failure of host 
defences in the peritoneal cavity is debatable whether more could be added to this list,  
(Barie, 1999).  As previously mentioned IAI has a high mortality rate, when IAI occurs 
in the peritoneal cavity, as a result of colonic perforation of an abscess, the mortality 
rate is 25% however, where patients with Multiple Organ Dysfunction Syndrome 
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(MODS) (the physiological failure of several interdependent organs) are associated with 
IAI the mortality rate exceeds 90%, (Sharma & Eschun, 2004).  Even if radiological 
techniques or surgical exploration techniques are employed, the mortality rate is still 33-
71% (Burgess et al., 1994).  Successful bacterial characteristics include adaptability to 
environmental changes, metabolic changeability to anaerobic conditions present in the 
peritoneal cavity, resistance to antibiotics and adhesion to serosal surfaces.  When 
intestinal perforation occurs most bacterial species are killed due to the lack of suitable 
environment outside the bowel lumen.  Most bacteria that survive are saprophytic 
organisms, not causing infection but contributing to providing the right conditions for 
the few organisms which are able to adhere to the peritoneum and initiate the 
inflammatory response. 
 
Mechanisms of the host defence are subsequently activated.  Immediate clearance is a 
dual effort of peritoneal absorption and phagocytosis by peritoneal macrophages.  The 
result may be complete control of the infection.  However, if adjuvants are present 
bacterial numbers may thrive.  The adjuvant’s primary function is to obstruct host 
defence mechanisms and increasing the immunogenicity of the antigen, mainly by 
preventing phagocytes reaching their targets. Bacterial infection grows progressively 
over time without host defence intervention.  In 24 hours 100million organisms per 
milligram serosal tissue will develop.  By this point the adhesion will be a stable 
complex pathogenic flora resistant to lavage (Jonjic et al., 1992).   
 
1.5 Incidence of Sepsis 
Edbrooke et al., (1999) reported the incidence of sepsis in the UK with their study of 
patient related costs in intensive care units.  Their study found that 56% of patients who 
were admitted to the ICU with sepsis died within 3.3days.  The same mortality rate was 
shown in patients who developed sepsis after 1 day in the ICU, but they lived 13.2days 
longer before death.  Patients who developed sepsis after their 2nd day in the ICU had a 
mortality rate of 60%.  The Edbrooke et al., (1999) study showed patients with sepsis, 
or who developed sepsis while in hospital, stayed in the ICU for prolonged periods of 
time, at considerable expense to the hospital and resulted in high numbers of deaths. 
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Daikos (1994) reported the incidence of sepsis in the US to be 400,000 cases of sepsis 
per year, 200,000 cases of septic shock per year, and 100,000 cases that resulted in 
death.  Gram negative bacteria are the leading cause of sepsis but sepsis by Gram 
positive bacteria have increased by 20% over the last 25 years (Daikos, 1994).  Werden 
(1999) also reports sepsis and septic shock as the leading cause of death in intensive 
care units.  Bochud & Calandra (2003) reported severe sepsis to account for 2-11% of 
all hospital admissions in the US and Europe.  Bochud & Calandra’s (2003) study also 
reported that severe sepsis is the cause of 30% of all hospital deaths and more than 60% 
of hospital deaths being caused by septic shock.  Currently diagnosis of IAI relies on a 
doctor’s interpretation, observations of signs and symptoms from the patient, 
radiological investigation and blood analysis.  The result in some instances is a 
diagnosis with grey-areas of uncertainty.  This leads to unnecessary antibiotic use and 
unnecessary surgery.  As sepsis has such a high mortality rate, additional methods of 
diagnosis are crucial for a more dependable diagnosis.  
 
In addition to the high death rate caused by sepsis a number of key factors mean the 
situation could pose an even greater threat in future years.  These factors include the rise 
in life expectancy in developed countries.  Due to the ever increasing sophisticated 
medical technologies, society is living longer, and as a result of this their risk of 
developing sepsis increases, as sepsis-induced mortality increases with age.  The rise in 
bacterial resistance is also an important factor.  Multi-drug resistant bacteria are 
becoming a huge problem in both nosocomial and community-acquired infections.  And 
the numbers of immunocompromised patients are also increasing due to acquired 
immuno-deficiency syndrome (AIDS).  All significant factors have lead to sepsis being 
the threat it is today, and will continue to increase mortality rates unless action is taken. 
 
1.6 Sepsis Diagnosis & Treatments 
A major problem with diagnosing sepsis is due to sepsis being a multifactorial condition 
and the course of sepsis varies from patient to patient.  Currently diagnosis of sepsis is a 
collaboration of blood analysis and the signs and symptoms of the patient.  Appendix A 
shows the sepsis grading system, as adapted from Elebut & Stoner (1983) which is an 
example of a scoring system.  The signs and symptoms and blood analysis of the patient 
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are simply recorded over time and correlated with the sepsis grading system to 
determine the severity of the infection.  Appendix A does not take into account 
dysfunction of the pulmonary and cardiovascular system, which are highly important in 
early sepsis diagnosis (Bosscha et al., 1997); thus a superior diagnostic tool is required.  
The Acute Physiology and Chronic Health Evaluation (APACHE) (Zimmerman et al., 
2005) system takes into account neurological, cardiovascular, respiratory, renal, 
gastrointestinal, metabolic and haematological variables along with incorporating 
comorbid conditions such as Diabetes mellitus and cirrhosis.  The APACHE system is a 
comprehensive evaluation of the patient’s condition. 
 
Management of sepsis usually begins with admittance to an intensive care unit if the 
patient is haemodynamically unstable (bp, respiration rate etc), and prompt 
administration of a broad-spectrum antibiotic.  Sepsis can develop rapidly so immediate 
administration of antibiotics is essential.  Bacteriological tests to identify the causative 
bacteria can take >2 days to be performed.  If the antibiotic administration was delayed 
until after these tests and administered based on antibiotic sensitivities to the specific 
bacteria, the infection would inevitably be far worse and increase mortality.  On the 
other hand, unnecessary use of broad spectrum antibiotics can cause multi-drug 
resistance leading to a more severe form of sepsis by opportunistic pathogens.    
 
Other immediate treatments include fluids through an intravenous catheter, inotropic 
drugs (such as catecholamines) to raise blood pressure and organ support such as 
artificial ventilators or continuous external filtration of the blood for kidney support.  
Identifying the source of the infection also helps in the determination of treatments to be 
prescribed.  This process involves white blood cell counts, microbiological cultures (of 
urine, blood, sputum, aspirates, from intra-abdominal, joint or wound sites), Erythrocyte 
Sedimentation Rate (ESR) indicative of the acute-phase response to infection, 
malignancy or trauma, C-Reactive Protein (CRP) an acute phase marker released in the 
immunological and inflammatory response and Disseminated Intravascular Coagulation 
(DIC) where clotting factors are exhausted leading to severe haemorrhaging.   
Identifying the source of sepsis may be supported by a number of radiological 
techniques.  Chest x-rays may show pneumonia, intra-thoracic collections, effusions 
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(seepage of bloody fluid into body cavity) or empyema (pus in body cavity).  
Abdominal x-rays may show free intra-abdominal gas indicating a visceral perforation.  
Computerised Axial Tomography (CAT) and ultrasound scans are also highly sensitive 
techniques to identify collections or abscesses within the thorax or abdominal cavity.  
Magnetic Resonance Imaging (MRI) is useful if infection is suspected in bone 
(osteomyelitis) or in soft tissue or joints.  Labelled white cell scans can also be used 
when a source of infection is suspected but identifiable by other screening methods.  
The labelled white cell scan involves radio-labelling the patients white cells, and re-
injected into the patient.  The white cells congregate at the infection site, and are 
detected using a gamma camera to indicate sepsis (Vezina, 2004).  Again this 
identification process takes time to execute and analyse, and some patients are simply 
too ill to under go some of these investigations.  Also false positives are common 
among patients with haematomas (mass of extravasated blood in tissues) and 
inflammatory bowel disease and false negatives may occur in chronic sepsis (Vezina, 
2004).  When critically ill patients, in an intensive care unit setting are suspected of 
having intra-abdominal sepsis which cannot be confirmed by non invasive techniques; a 
blind laparotomy (incision into abdominal wall) is required but is associated with a very 
high mortality rate (Polk et al., 1993). 
 
Thus there is a need for a real time bed side test which will aid the clinician managing a 
critically ill patient in determining whether there is significant sepsis present 
(www.survivingsepsis.com).  
 
1.6.1 Novel Management Techniques 
A study by Kubler et al. (2006) demonstrated a significant decrease in mortality with 
the use of Protein C (Drotrecogin Alfa [Activated] – DAA) in severe septic patients in 
Poland.  The Kubler et al. study showed Protein C treated patients had a 31% reduction 
in their risk of death compared to non treated patients with the same diagnosis.  This 
addition of protein C is supported by a report by Lindstrom et al. (2006) which showed 
that in acute pancreatitis patients a significant decrease in protein C was correlated with 
multiple organ failure.   
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A further novel treatment is reported by Orozco et al. (2006).  This study describes the 
use of Molgramostim (human granulocyte macrophage colony-stimulating factor - GM-
CSF) in addition to antibiotics for the treatment of abdominal sepsis.  The report 
concluded that the addition of GM-CSF to the antibiotic therapy reduces the rate of 
infectious complications, decreases length of stay in hospital and overall costs to the 
health service. 
 
1.7 Potential Indicators of Sepsis 
A potential early indicator of sepsis includes white blood cell counts.  A noticeable 
increase (>12x109/L) or a marked decrease (<4x109/L) of white blood cells is an 
indication of a septic condition (www.survivingsepsis.com). However, white blood cell 
counts are inconsistent, for example patients with appendicitis often have normal white 
blood cell counts. 
 
Other early indicators of sepsis which have been proposed include increased C-reactive 
protein levels.  CRP is released by hepatocytes in response to infection and tissue 
inflammation in pneumonia patients.  Studies have been conducted to show the 
usefulness of CRP levels to be unreliable in the diagnosis of sepsis (Meer et al., 2005).  
A comparison by Meisner et al. (1999) also showed that CRP was not a useful indicator.  
This study compared the CRP with procalcitonin (PCT) in two groups of patients with 
MODS and system inflammation.  All 40 patients were assessed with the Sepsis-related 
Organ Failure Assessment (SOFA) (assessment of the severity of organ function 
impairment, Vosylius et al., 2004).  Those patients with high SOFA scores had 
significantly raised PCT concentrations, after 4 days of MODS.  However, the MODS 
patients and systemic inflammation patients all had elevated CRP regardless of their 
SOFA score.  Therefore, PCT is a better indicator of sepsis than CRP, but is only an 
indicator after significant progression of sepsis and cannot distinguish between viral 
infections and inflammation, (Chan et al., 2004).  Harbarth et al. (2001) also reported a 
study on the use of PCT as a marker for sepsis.  This study showed that PCT can 
distinguish between sepsis, septic shock, and severe sepsis conditions.  PCT increases 2-
4 hours after bacterial/endotoxin challenge is initiated.  However, the Harbarth et al. 
study also showed that PCT is not a reliable sepsis marker in patients who have 
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undergone kidney transplants or cardio pulmonary bypass surgery and has only yet been 
tested with patients undergoing antibiotic therapy; concluding that PCT is not a 
definitive test for sepsis but may, if combined with already established tests, give a 
clearer prognosis. 
 
The Harbarth et al. (2001) study also investigated the use of the cytokines Interleukin 6 
(IL-6) and interleukin 8 (IL-8).  Interleukin 6 implements the proliferation of acute 
phase proteins and interleukin 8 is a pro-inflammatory cytokine.  Both IL-6 and IL-8 are 
inflammatory factors and this study showed they could not be used as indicators of 
sepsis because they couldn’t distinguish between non-infectious and infectious 
conditions.   
 
A study by Collighan et al. (2001) also showed that the cytokines IL13 and Tumour 
Necrosis Factor α (TNFα) expression only increased for 3 days in septic shock patients 
but then decreased to non-septic levels; concluding that neither were effective markers 
for sepsis. 
 
Neutrophil levels have also been studied as an indicator in sepsis patients.  An increase 
by 10% in immature neutrophils (left shift) can be an indication of infection.  Hansen & 
Andersen’s study (1973) relates primarily to the release of lysozyme and neutrophil 
turnover rates.  This study distinguished between intra-neutrophil lysozyme and serum 
lysozyme.  Their findings showed intra-neutrophil lysozyme to decrease with increasing 
severity of infection.  This was also heightened by the decrease in the neutrophil granule 
production in infectious patients (Hansen & Andersen, 1973). 
 
A more recent study by Guo et al., (2002) showed myeloperoxidase levels increasing 10 
fold in rats using ceacal ligation/puncture models.  β1 and β2 integrin content on blood 
neutrophils also showed a dependent 10 fold increase in the lungs; mechanisms which 
were only induced in the septic state. 
 
Lysozyme as a possible indicator for sepsis, has also been extensively explored, and due 
to its promising potential has been chosen in this study for further investigation.   
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1.8 Discovery of Lysozyme 
Lysozyme (1, 4-N-acetylmuramidase, E.C.3.2.1.17) is a small cationic protein first 
reported by Laschtschenko in 1909, (Burgess, 1973).  Lysozyme’s discovery however is 
attributed to Alexander Fleming, a bacteriologist in London, who was the first to report 
the finding to the Royal Society of London.  His report stated that lysozyme was a 
“powerful bacteriolytic element found in human tissues and secretions” (Fleming, 
1922).  Fleming was at the time suffering from a cold and he is reported to have allowed 
drops of his nasal secretions to have fallen onto a blood agar culture plate which was 
thickly colonised with bacteria.  The plates were incubated at 37oC for 24hrs; bacteria 
grew extensively.  There was complete radial inhibition of about 1cm beyond the nasal 
mucus on the plate.  This experiment was later termed the lysoplate.  Fleming 
concluded that the nasal secretions contained an enzyme capable of bacterial lysis; later 
named Lysozyme.   
 
With the success of his preliminary experiment, Fleming continued to work with 
Lysozyme testing its antibacterial properties with several different bacteria.  Fleming 
reported the discovery of a small round bacterium, particularly vulnerable to the effects 
of lysozyme.  This bacterium was named Micrococcus lysodeikticus (now referred to as 
Micrococcus luteus or M. luteus) due to its ability to display lysis (Fleming, 1922). 
Fleming diluted the nasal secretions in saline and added it to a thick suspension of the 
M. luteus.  Within minutes of incubation at 37oC the opaque bacterial solution had 
cleared.  This experiment was later termed the Turbidimetric test, (Fleming & Allison, 
1927).  Fleming (1922) is quoted as saying his experiments “clearly demonstrated the 
very powerful inhibitory and lytic action which nasal mucus has upon Micrococcus 
lysodeikticus”.  Fleming also showed increased levels of lysozyme in patients with 
pyogenic infections (pus producing) such as meningitis; the first indication that 
lysozyme could be a marker for sepsis. 
 
1.9 Lysozyme Structure 
Since Fleming’s report, the potential of lysozyme has attracted considerable interest 
over many years (Gorin et al., 1971).  Hen egg white (HEW) lysozyme is very similar 
to human lysozyme with 129 amino acids (Jolles, 1969).  Human lysozyme has ~148 
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amino acids and is 3-4 times more reactive than HEW lysozyme as tested with the 
turbidimetric test.  However, due to its structural similarity, availability and 
inexpensiveness, HEW lysozyme has been used as a model for human lysozyme 
experiments, making it one of the most studied enzymes (Lollike et al., 1995).   
 
In 1965, the 3 dimensional structure of lysozyme was determined by David Philips and 
his colleagues (Blake et al., 1965).  A molecule of lysozyme can be analysed in 2 parts.  
The 1st 40 residues form the right-hand wing.  This region coils around a core non-polar 
segment twice to stabilise the conformation.  Residues 41-95 form the left-hand wing.  
These contain many polar residues and form a less rigid conformation.  As for the 
remainder of the chain this slightly narrows the gap between the right and left wing, 
whilst wrapping around the right (Jolles, 1969). 
 
1.10 Lysozyme Activity & Function 
Meyer continued Flemings work by purifying lysozyme from acetone dried egg white 
describing it as a “basic polypeptide having a nitrogen content of 15.3%” (Meyer et al., 
1946).  Human Lysozyme is a ~148 amino acid single polypeptide chain with a low 
molecular weight of around 14.6kDa (Cabellero et al., 1999).  Its elevated isoelectric 
point (pI 11) means lysozyme is a cationic protein, positively charged at biological pH’s 
(Sophianopoulus & Sassa, 1965).  Lysozyme is recognised to be non-dialyzable, soluble 
in water and weak saline, insoluble in alcohol and ether, resistant to heat and 
desiccation, and stable at room temperature (Burgess, 1973), stable at acid pH and labile 
at alkaline pH (Jolles, 1969).   
 
Human Lysozyme is present in the lysosomes of phagocytic cells, granulocytes and 
monocytes (Burgess, 1994).  It is released as part of the non-specific immune response, 
and exists among cells of the blood system, especially leukocytes.  Lysozyme is found 
in all stages of the maturation of the myelocytic series, but not in the myeloblast, 
eosinophil or basophil, (Davis, 1971).  Monocytes contain large amounts of lysozyme, 
but none is found in the lymphocytes.   
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In tissues lysozyme is mainly found in bone marrow, lungs, intestines, spleen, and 
kidneys.  Lysozyme exists here due to the breakdown of neutophilic granulocytes in 
these organs, (Hansen et al., 1972).  Tissue macrophages discharge lysozyme into 
serum, nasal and lacrimal secretions along with various other bodily secretions.   
 
Figure 1.1 shows the phagocytosis of bacteria.  At stage one the bacterium attaches to 
the pseudopodia of the phagocyte.  By stage two the bacterium has been ingested inside 
a phagosome, a small pocket inside the phagocyte.  Granules in the phagocyte act as 
storage for lysozyme, acid hydrolases, myeloperoxidases and complement activators, 
(Farthman et al., 1998).  These granules move towards the phagosome and merge.  At 
stage 3 the phagosome membrane fuses with the granules, releasing the lytic enzymes 
into the phagosome.  By stage 4, digestion by the lytic enzymes begins and at stage 5 
the digested bacterium is released from the cell.   
 
 
 
 
 
 
 
Figure 1.1 Phagocytosis, adapted from Goldsby et al., 2000.  The attachment of the 
bacterium to the pseudopodia (1), encapsulation in the phagosome (2),  merging of 
phagosome and granules (3), digestion of bacterium (4) and excretion (5). 
 
Lysozyme exerts its antibacterial activity by promoting the degradation of the 
prokaryotic cell wall (Francina et al., 1986).  When the bacteria’s cell wall is broken 
down the cell bursts due to the high internal osmotic pressure and the cell lyses.  
Bacterial cell walls are highly complex macromolecular structures, resistant to most 
solvents.  The cell wall is composed of polysaccharide chains N-acetylglucosamine 
(NAG) and N-acetylmuramate (NAM).  Muramic acid residues attached by amide 
bounds through the carboxyl groups to the peptide moieties act as bridges linking the 
polysaccharide chains, known as the “murein sacculas” (Weide & Pelzer, 1964).  
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Lysozyme exerts its effects on the tetrasaccharide structure of the cell wall and 
hydrolyses the NAG and NAM β 1-4 glycosidic linkage.  The result is a disaccharide 
and consequently the death of the bacterium, (Sharon, 1967).  
 
Figure 1.2 Hydrolysis of Bacterial Cell Wall by Lysozyme.  Diagram shows the 
hydrolysis of the tetra-saccharide cell wall construction.  
 
Gram positive cell walls are especially susceptible to the lytic action of lysozyme, but 
its effectiveness is limited, due to a bacterial capsule.  Bacterial resistance is well known 
and reports of resistant strains of Streptococcus were first reported by Fleming & 
Allison in 1927.  Weeks after their initial lysoplate experiments, bacterial colonies 
began to appear in the zones of inhibition.  Over the course of 9 months their colonies 
were repeatedly sub-cultured at intervals of 1-2 weeks and tested with HEW lysozyme.  
Fleming & Allison found that these colonies were then totally resistant to further 
treatment by lysozyme and remained resistant over the entire 9 months.  The colonies 
were then resistant not only to the tissues and secretions which they had grown in 
contact with but all other lysozyme containing tissues and secretions from plants and 
animals.   
 
Fleming & Allison’s work continued into the nature of the bacterial resistance.  Several 
strains of bacteria were tested with the tears from Fleming’s patients.  Fleming found 
lysozyme was not effective against a range of bacteria.  These included Haemophilus 
influenzae, Neisseria meningitidis, Escherichia coli, Streptococcus pneumoniae, 
Klebsiella pneumoniae and group B Streptococci.  Lysozyme resistance is caused by an 
inability to break down bacteria that are encapsulated with a gelatinous polysaccharide 
layer.  This dramatically limits the effectiveness of lysozyme to bacteria that have no 
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capsule.  Lysozyme is therefore of little value as a therapeutic agent against bacterial 
growth but the release of lysozyme as a product of phagocytosis and white blood cell 
turnover may be a useful marker for sepsis. 
 
1.11 Determination of Lysozyme 
A study by Burgess et al., (1994) showed that Lysozyme levels increased in the 
presence of Intra-abdominal Abscess.  This study showed, where high serum lysozyme 
levels were recorded, they were correctly correlated with Intra-abdominal Abscess 
diagnosis.  Serum lysozyme levels were high upon onset, predating any signs and 
symptoms of the infection.  This is thought to suggest the sequestration of leucocytes, 
phagocytes and pus formation at the infection site.  Lysozyme was not shown to 
increase after surgery, trauma, or major lung infections; and is therefore a good 
indicator of sepsis onset.  There are currently several tests on the market which measure 
Lysozyme content in biological fluids.   
 
1.11.1 Turbidimetric 
The first tests to be discussed are based on Fleming’s turbidimetric assay.  This assay is 
based on a clearing phenomenon.  A bacterial suspension is prepared and the clinical 
sample is added.  The rate of optical density reduction is measured to determine the 
lysozyme content of the clinical sample (Ronan et al., 1975). 
 
Many of the turbidimetric methods used are relatively similar and differ only with 
respect to the lysozyme activity and sample preparation.  These differences might 
include buffer composition, pH, ionic strength, concentration of M. luteus substrate, 
temperature, duration of incubation and preparation of enzyme (Houser, 1983). 
 
Klass et al. (1977) described the turbidimetric technique as having a high sensitivity and 
a rapid turnover rate, as each sample only takes one minute to process.  The Klass et al. 
(1977) method has a detection limit of 1µg/ml whereas the Ronan et al. (1975) method 
has a detection limit of 1.5mg/ml.  The Klass et al. method is the preferred method for 
routine testing of clinical samples, but is not the most reliable as it produces a high 
inter-batch variability of results, with a precision of 2.5% as obtained by Gorin et al., 
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(1971).  Gorin actually did not look favourably on this precision as they compared their 
data with that of Bergmeyer (1965) who achieved a higher rate of precision.  This study, 
by Gorin et al., (1971) also showed that not all commercially available lysozyme 
substrates (e.g. lyophilised M. luteus from Sigma, Calbiochem etc.) produce the same 
effects, even though they may all be labelled M. luteus.  This study showed that 
different companies produce different preparations of the bacteria, giving varying 
degrees of clearing rates, with a reported difference of up to 30%.  This is caused by the 
various physical and chemical treatments they subject their bacteria to, which 
consequently alters the vulnerability of M. luteus to lysozyme and ultimately leads to 
unreliable results for diagnosis of diseases.  Regardless of its unreliability, this assay is 
easy to perform, requires small sample volumes, can be used with serum, urine and tears 
and is sensitive. 
 
A method which was built on the principles of the turbidimetric assay was devised by 
Caballero et al. (1999).  Cabellero et al. described a micro-particle enhanced 
nephelometric immunoassay using serum and urine patient samples.  This assay 
involved the use of polystyrene particles covalently bound with anti-lysozyme 
antibodies.  The polystyrene particles formed larger particles due to the binding with 
free lysozyme in the sample which scatters light.  The scattered light at the start of the 
reaction was compared with that at the end and used to calculate the lysozyme 
concentration in the patient sample.  The assay detection limit was 0.58mg/l.  Even with 
this assay Caballero et al. recognised there was still room for improvement with the 
long incubation periods, need for biological fluid pre-treatment and poor detection limit. 
 
Terry et al. (1971) published work using an automated turbidimetric assay.  This assay 
involved the use of 2 colorimeters which corrects the urine and serum discolouration 
problems experienced with controls (causing turbid solutions for blank samples).  The 
bacterial suspension and clinical sample were continuously stirred and standards were 
run simultaneously.  This automated assay was able to process 20 samples per hour and 
had an increased (undisclosed) sensitivity. 
 
Chapter 1 17
An assay currently on the market that employs the principle of turbidimetric assays is 
the EnzChek® Lysozyme by Molecular Probes (Leiden, Netherlands).  This test 
measures lysozyme in solution at levels, as low as 20U/ml (equivalent to <0.5µg/ml).  
The assay measures lysozyme activity using M. luteus cell walls on substrate.  The 
bacteria’s cell walls are specially labelled with a fluorophore in such a way that the 
fluorescence is quenched.  Activated lysozyme reduces the quenching thus increasing 
the fluorescence.  The fluorescence therefore is proportional to the lysozyme activity.  
The increase in fluorescence is measured using a spectrofluorometer, mini-fluorometer 
or a fluorescence microplate reader.  Each assay takes around 30 minutes with less than 
an hour preparation time.  The assay lays claim to being “simple and sensitive” 
(www.probes.com). 
 
1.11.2 Lysoplate 
The lysoplate method, Fleming’s second experiment, has also been used as the basis for 
assay development.  However, Fleming’s experiments were more complex than the 
methods used today.  Fleming began by boring a well into the agar in a petri dish.  A 
mixture of molten agar and nasal secretions containing lysozyme were added to the 
wells and a second layer of agar was applied covering the whole plate.  The top layer of 
agar was then inoculated with a layer of M. luteus bacteria and incubated for 24 hours.  
Fleming’s experiment showed that lysozyme was able to diffuse through the agar and 
prevent growth of the bacteria (Fleming & Allison, 1922). 
 
Osserman et al., (1966) showed that Fleming’s lysoplate technique still worked even 
when simplified.  In these experiments the agar was mixed with heat killed inactivated 
bacteria so that it appeared turbid, allowed to solidify and then wells were bored into the 
agar.  Lysozyme samples from serum and urine were added to these wells and allowed 
to diffuse over 12-18 hours.  The zone of turbidity clearing is proportional to the 
concentration of lysozyme (Osserman et al., 1966).  The Osserman et al. experiments 
involved serum and urine samples taken from patients with monocytic leukaemia.  They 
found large quantities of lysozyme in serum samples, 40-150µg/ml, and 7µg/ml in their 
control samples taken from healthy patients.  A big advantage of using this method is its 
simplicity.  Very little training is required to complete the test in a clinical environment.  
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However, this advantage is marred by lack of sensitivity, large volumes of samples used 
and the long incubation time.  A test currently on the market which uses this technique 
is produced by ARUP Laboratories (Mexico, South America).  They offer a service 
using the lysoplate method which takes 2 days before results are received.  When 
diagnosis may depend on these results this service does not seem a viable option. The 
lysoplate is also said to have a further flaw pointed out by Reitamo et al. (1981).  This 
paper states that the lysoplate cannot be automated for high through-put use, and where 
the agar contains sulphates, the chemical complex forms mucins which affect 
determination of lysozyme (Reitamo et al., 1981). 
 
1.11.3 Immunoassays 
Fleming’s turbidimetric and lysoplate techniques have been shown to lack sensitivity 
and have lengthy performance times; immunoassays offer an important alternative to 
the determination of lysozyme.  Immunoassays rely on the reaction between the target 
analyte and a specific binding molecule of biological decent (the antibody).  They can 
produce both quantitative and qualitative results and have shown considerable 
improvements in sensitivity (Ekins et al., 1997). 
 
Porstmann et al. (1989) developed an enzyme immunoassay for the detection of 
lysozyme in patients with Crohn’s disease and rheumatoid arthritis.  This study took 
urine samples from patients and these were tested using 3 variations of the same 
method.  The method which showed the highest sensitivity involved pre-coating a 
microtitre plate with anti-lysozyme IgG overnight at 4oC, 2 hours incubation at room 
temperature with the clinical sample and IgG-HRP conjugate.  The assay was ended 
with 15 minutes incubation with o-phenylenediamine.  The detection limit for this assay 
was 0.2µg/l.   
 
Francina et al. (1986) also reports of an immunoassay developed to test lysozyme 
secretion in serum of acute myeloid leukaemia patients.  A microtitre plate was 
incubated at 4oC overnight with anti-lysozyme IgG.  After a wash, the plate was 
incubated for a further 1 hour at 37oC with the clinical sample.  Biotinylated anti-
lysozyme was added and the plate was again incubated for a further 1 hour.  The plate 
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was washed and incubated with avidin peroxidase solution for 10 minutes at room 
temperature.  The assay was ended with 5 minutes incubation with an enzyme substrate.  
The total assay time was ~14.5 hours.  The assay time was reduced by decreasing the 
two 1 hour incubations to 20 minutes and the enzyme substrate incubation to 5 minutes, 
but the total assay time was still over 12 hours.  The detection limit for the standard 
assay was 0.1ng/ml and for the rapid assay 1ng/ml.   
 
Taylor et al., (1992) also presents an immunoassay for the detection of lysozyme.  This 
test was developed to measure lysozyme in healthy adult’s serum and urine samples.  
The method involved pre-coating a microtitre plate with rabbit anti-human lysozyme, 
then adding the clinical sample and incubating for 90 minutes at room temperature.  A 
conjugated sheep anti-human lysozyme was added and incubated for a further 90 
minutes at room temperature.  Finally enzyme substrate p-nitrophenyl phosphate 
sodium was added and incubated for 30 minutes at room temperature.  The total assay 
time was 15 hours and the detection limit was 1µg/litre. 
 
Immunoassay kits available on the market include the Biomedical Technologies 
(Stoughton, USA) EIA Kit for Human Lysozyme.  This sandwich ELISA detects 
lysozyme from serum, plasma, urine, tears and saliva.  The reference value for human 
lysozyme from serum ranges from 3-10µg/ml.  In this assay, specific lysozyme 
antibodies bound to polystyrene wells are incubated with a sample.  A second human 
lysozyme-specific antibody is added as well as a horseradish peroxidase conjugated 
secondary antibody.  The total test time is 41/4 hours and costs around £275 for 96 tests.   
 
Orgentec (Mainz, Germany) is another company that supplies a kit known as the ANCA 
Combi kit for lysozyme in serum and plasma.  This test only requires 10µl of patients 
sample and involves a plate pre-coated with antibody.  The antigen from the patients 
sample is added along with a horseradish peroxidase conjugate and then TMB (a colour 
substrate).  The reaction is stopped using Hydrochloric acid and the total time for this 
assay is 2 hours, due to the plates being purchased pre-coated.  During this time 96 
patient samples can be processed. 
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All these kits have the advantage of conducting analysis on several patient samples 
using minimal biological fluid.  This not only alleviates discomfort and distress to 
patients, but also the costs to lab facilities.   
 
1.11.4 Other Detection Methods 
Besides the turbidimetric and lysoplate assay for the determination of lysozyme there 
are other methods described in the literature.  Montagne et al. (1998) reports of a 
microparticle enhanced nephelometric immunoassay for lysozyme primarily in breast 
milk.  The method is based on the measurement of scattered light during the competitive 
immuno-agglutination of microparticle-lysozyme conjugate with an anti-lysozyme 
antiserum.  Poly-functional hydrophilic microspheres were covalently coated with 
human lysozyme and mixed with breast milk taken from lactating patients.  After 1.5 
hours at room temperature the scattered light from the mixture was measured and the 
lysozyme content calculated.  The assay was adapted for serum and urine samples, but 
all procedures had to be carried out on the day of testing due to the microparticle-
lysozyme conjugates agglutinating during storage.  The assay had a detection limit of 
0.8µg/ml. 
 
Another lysozyme determination method was put forward by Gao et al. (1995).  The 
Gao et al. research concerned the faecal lysozyme expression in patients with 
inflammatory bowel disease indicative of Crohn’s disease.  This assay is a sensitive 
solid-phase competitive luminescence immunoassay.  Polyclonal capture antibody 
coated to polystyrene beads were used with an acridinium ester-labelled human 
lysozyme was used as a tracer.  Patient’s samples were incubated with the beads and 
tracer over night at 4oC.  After a washing phase the emitted light was measured by a 
luminometer for 2 seconds to determine the lysozyme content.    The assay sensitivity is 
0.02µg/ml. 
 
A final method for the determination of lysozyme was established by Yuzuriha et al. 
(1979).  Yuzuriha et al. reported three methods using radioimmunoassay and 
enzymoimmunoassay techniques.  In the first competitive radioimmunoassay I-labelled 
human milk lysozyme was mixed with antiserum and incubated for 2 hours at 37oC.  
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Dextran coated charcoal was added and centrifuged for 15 minutes.  The radioactivity of 
the solution was then measured to determine lysozyme content.   
 
The second radioimmunoassay was a sandwich configuration.  Standard human milk 
lysozyme was added to a microtitre plate pre-coated with antibody and incubated for 2 
hours at 37oC.  I-labelled antibody against human milk lysozyme was added to the plate 
and incubated for a further 1 hour at 37oC.  Sodium hydroxide was added finally and the 
radioactivity measured to determine lysozyme content.  Concentrations from 5-
250ng/ml were measured.   
 
Yuzuriha et al. (1979) reported a sandwich enzymoimmunassay.  Antibody against 
human milk lysozyme was incubated over night in a microtitre plate well at 4oC.  
Human milk lysozyme was reacted with pre-coated plates for 1 hour at 37oC.  Alkaline 
phophatase-antibody conjugate was added and allowed to bind for 1 hour at 37oC before 
washing.  The alkaline phosphatase activity was then measured as increased levels 
indicated increased lysozyme concentration in the human milk sample.  This assay was 
also tried with human urine, placenta, serum and leukocyte lysozyme samples.  The 
lysozyme detection range was 5-250ng/ml and over other methods reported by Yuzuriha 
et al. showed better precision, reproducibility, and simplicity. 
 
1.12 Aims & Objectives of Project 
Sepsis has been described as one of the most frustrating diseases of modern medicine.  
Even with the advances in intensive care, growth in understanding of the human 
immune system and inflammatory mechanisms and increasing developments in 
antibiotics; the overall prognosis of septic patients has hardly changed.  One of the 
highest causes of death in the Western World still remains to be by sepsis (Hack et al., 
1999).  Early identification of sepsis would be clinically useful, particularly in intensive 
care units.  Lysozyme has been shown to be released before the signs and symptoms 
present in a patient.  Therefore a test for lysozyme would speed up the diagnosis process 
and increase the patient survival rate.  
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The aim of this project was to produce a rapid, sensitive, inexpensive, and accurate 
method to aid in the diagnosis of sepsis.  At present the methods used have a lengthy 
turn around time which means the patient is given non-specific antibiotics and in some 
cases surgery before the infection has been clinically confirmed.  A test that is rapid, 
with the possibility of being carried out at the patient’s bedside would reduce antibiotic 
resistance, speed up diagnosis, and aid management of seriously ill patients. 
 
Surface Plasmon Resonance technology, the more traditional immunoassay based 
techniques and modified/optimized immunoassay-based techniques; were explored in 
order to propose a new test for sepsis in this project.  Due to the promising potential of 
lysozyme as an indicator for sepsis, this assay would then be further evaluated by 
measuring serum lysozyme concentration from septic patients at the Great Western 
Hospital, Swindon and correlating the responses to the occurrence of sepsis.   Ethical 
approval was gained by the Swindon Research Ethics Committee prior to 
commencement.   
 
1.13 Specific Aims & Objectives 
1.13.1 ELISA (Chapter 2) 
The aims of the ELISA work were to produce and optimize an in-house ELISA system.  
Once a working immunoassay had been developed, several clinical samples were 
assayed and the lysozyme concentrations recorded.  The clinical samples were taken 
from patients at the Great Western Hospital in Swindon.  These patients were suffering 
from a range of illnesses related to sepsis.  Samples were also taken from patients in the 
hospital who had been deemed non-septic and also control samples were collected from 
non-hospitalised patients.  A comparison will be made between these groups, comparing 
both controls with the septic lysozyme concentrations.  All samples will then be assayed 
using a commercially available kit.  A comparison between the results gained from the 
kit and the ELISA will then to be made.  An assessment will also be made between the 
commercially available kit and the ELISA.  Consideration will be given to the repeated 
freezing and thawing of the serum samples.  As the serum samples have been frozen 
after collection and then defrosted before transportation to the University, an experiment 
will be carried out to test the viability of lysozyme after several freeze-thaw cycles. 
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Along with the serum samples provided by the Great Western Hospital, routine blood 
analysis results will also be provided including white blood cells, haemoglobin levels, 
ESR, CRP where available.  Patients were classified according to the presence of sepsis 
dependent on positive microbiological and radiological evidence.  An assessment will 
then be carried out to evaluate the lysozyme level results from the ELISA and the actual 
diagnosis of the patients.  Attention is also to be paid to the blood analysis results and 
any relationships between those and the lysozyme concentrations. 
 
1.13.2 ELIFA (Chapter 3)  
The main aims of the ELIFA section of work were to build on the progress from the 
ELISA immunoassay.  As the ELISA produced good results the aim was to capitalise on 
the good aspects of the assay and to improve on the aspects which show room for 
improvement.  The aspects of the ELISA which could be improved upon included the 
total time the assay took, the level of skill required to carry out the assay and the cost of 
the overall assay.   
 
Initially the aim was to develop the ELIFA system with lysozyme in buffer samples.  If 
time allowed clinical samples would also be assayed with this system. A method for 
accurately recording the ELIFA results would also be sort after.   
 
1.13.3 Mini-ELIFA (Chapter 4) 
The aims of the mini-ELIFA work were mainly to develop the ELIFA system further.  
The ELIFA system had many good aspects over and above the ELISA system.  These 
aspects included, cost effectiveness, ease of use and its fast turn-around time were again 
to be capitalised upon when developing the mini-ELIFA system.  Also the 
disadvantages of the ELIFA system, including the non-specific binding, were addressed 
and solutions were sort to eradicate these problems. 
 
Preliminary experiments would include E. coli solutions for immediate binding onto the 
membrane.  This system would build on the idea of using E. coli as an alternative 
indicator for sepsis.  Initially a series of E. coli dilutions will be used to create a 
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calibration curve, with the assay being modified for the use of lysozyme concentration 
measurements and then possibly for lysozyme determination in serum samples. 
 
1.13.4 Lysozyme Biosensor (Chapter 5)  
The aims of the biosensor work include the development of a detection method for 
lysozyme using SPR technology.  With the ELISA method already established the next 
step was to produce a detection system with a greater through put and a greater limit of 
detection. 
 
The work in this section will be based on the IgE Biosensor work in Appendix B.  
Procedures for the use of a BIAcore SPR affinity assay instrument would be established 
using IgE and the aim will be to produce a similar system using lysozyme as the target.  
Another aim of this section of the work will be to incorporate the use of aptamers into 
the detection system.  An anti-lysozyme aptamer would be used as a receptor for 
lysozyme in buffered samples.  Part of the lysozyme Biosensor method will include the 
regeneration of the sensor chip for further lysozyme measurements.  Once this system 
had been established and optimized then serum samples provided from the Great 
Western Hospital in Swindon will again be tested.  A comparison of the lysozyme 
content as measured by the ELISA and the biosensor method with the actual clinical 
diagnosis of the patient will also be carried out.   
Optimization results will include a calibration curve for samples containing known 
amounts of lysozyme in buffer, as well as known amount of lysozyme in serum samples 
(where lysozyme was not present) and a calibration curve of results from serum samples 
which are known to have high levels of lysozyme present (as established by the ELISA 
method).  The results gained from these tests would then be compared with those gained 
from the ELISA and the clinical diagnosis of the patients. 
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Chapter 2 -ELISA 
 
2.1 Introduction  
The first detection system to be employed for the measurement of lysozyme was the 
traditional Enzyme Linked Immunosorbent Assay (ELISA).  The ELISA experiments in the 
project involved directly immobilizing lysozyme onto the surface of a microtitre plate.  
With the addition of primary and secondary antibodies along with a substrate, a colour 
reaction was produced which was then read with a spectrophotometer wavelength to 
indicate the presence of lysozyme.  This type of assay is known as an indirect 
immunoassay. 
 
2.1.1 ELISA Use 
The ELISA assay was used to quantify lysozyme in both lysozyme buffered samples and 
serum samples provided by the Great Western Hospital, Swindon, (Appendix C & D).  
Samples were randomly taken from patients with a variety of illnesses and conditions over 
a 12 month period.  Including patients who had developed abdominal tumours (n=10), 
pneumonia (n=28), leukaemia (n=9), pregnancy (n=6), chronic renal failure (n=4), 
abdominal pain (n=15), appendicitis (n=5) and septic patients (n=42 including patients with 
multi-drug resistant Staphylococcus aureus (MRSA) positive infections, urinary tract 
infections (UTI) and upper respiratory tract infections (URTI)).  Two control groups were 
used; in the first group serum was taken from non-hospitalised volunteers (n=14) who were 
deemed healthy and the second from hospitalised patients who were negative for sepsis 
(n=109).  All serum samples were used with the ELISA protocol upon arrival.  The serum 
was then divided into aliquots and stored at -20oC until further use.  
 
Patient demographic details were collected but remained anonymous.  Patient data 
including, age, gender, date of sample, haemoglobin count, platelet count, differencial 
white blood cell count (WBC), neutrophil and lumphycyte count, erythrocyte sedimentation 
rate (ESR), C-reactive protein (CRP) and their clinical diagnosis were collected and stored 
on a password protected computer file (Appendix E).  Samples were also taken from 
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patients who subsequently died while in hospital (n=37).  Patients who were deceased were 
recoreded and the causes of death, from the list above were noted. 
 
2.2 ELISA Variety   
This section describes all the different configurations of ELISA’s which can be produced.  
Descriptions of non-competitive, competitive, direct, and indirect ELISA’s will be included 
(Figure 2.1).  
 
 
Figure 2.1 Types of ELISA; (a) Direct ELISA, (b) Indirect ELISA, (c) Non Competitive 
Direct Sandwich ELISA, (d) Non Competitive Indirect Sandwich ELISA, (e) Sandwich 
ELISA, (f) Competitive Antigen-Enzyme Conjugated ELISA & (g) Competitive Enzyme-
Labelled ELISA. 
 
2.2.1 Non-Competitive Assays 
The first type of non-competitive assay described here is known as the single site non-
competitive ELISA or Non-Competitive Direct Sandwich ELISA (Figure 2.1).  With this 
assay an antibody is immobilised to a solid phase.  Test antigen from a sample is added and 
binds to the antibody.  An enzyme-labelled antigen is then added and this binds to any 
immobilised antibody that has not reacted with the sample.  An enzyme substrate is added 
and the enzyme-product concentration is inversely proportional to the concentration of the 
test antigen.  There are in fact two forms of this single site non-competitive assay.  In the 
second assay the test antigen is incubated with an enzyme-labelled antibody.  This mixture 
is then transferred and added to an immobilised antigen.  The antigen then binds to any un-
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reacted enzyme-labelled antibody.  The concentration of the enzyme product is inversely 
proportional to the test antigen (Butler et al., 2000).   
 
A second type of non-competitive immunoassay is the Non-Competitive Indirect Sandwich 
ELISA (Figure 2.1).  Here an antibody is immobilised onto the solid surface of the 
microtitre plate.  The test antigen is added and this binds to the antibody.  A secondary 
antibody that is unlabelled sandwiches the antigen together.  An enzyme labelled 
antiglobulin is added and directed to the secondary antibody.  When the substrate is added a 
colour change occurs and the reaction is quantified in relation to known controls.   
 
The final type of non-competitive assay is called either the two site assay or the Sandwich 
ELISA in which the antibody, not the antigen is immobilised on a microtitre well.  An 
antigen (from a patient’s sample) is added and allowed to bind and then an enzyme-linked 
antibody is added to react with the antigen.  The substrate is then added to produce the 
colour reaction.  The enzyme product is directionally proportional to the antigen content. 
 
2.2.2 Competitive Assays 
Besides Non-Competitive assays there is the Competitive ELISA.  There are two forms of 
this assay that can be used, incorporating either the antigen-enzyme conjugate or the 
enzyme-labelled antibody.  In the Competitive Antigen-Enzyme Conjugate version an 
antibody is attached to the bottom of the well.  An antigen labelled with enzyme is 
incubated with this antibody along with free antigen present in the analyte sample.  There is 
then competition between the labelled and unlabelled antigen to bind with the antibody.  
Once washed, the enzyme substrate reaction is initiated, run for a fixed time, and stopped.  
The measured enzyme product concentration is inversely proportional to the concentration 
of the standard or test antigen.  This means that if there is no analyte (or test antigen) the 
assay output will be high and if there is a high analyte content then the colour output will be 
low. 
 
Chapter 2  28 
 
The second form of Competitive assay is the Competitive Enzyme-Labelled antibody 
version.  Here an antigen conjugated with BSA is attached to the surface of the well.  An 
enzyme-labelled antibody is then incubated in this well with unlabelled analyte antigen.  
When the antigen and antibody bind, the enzyme conjugated to the antibody subsequently 
produces a colour change.  Again if there is no analyte (test antigen) then a high colour 
change will occur, but if there is high analyte content a low colour change will occur. 
All these assays can be described as analytical comparative assays as all tests carried out 
using these methods are measured against standards.  The benefits of using these assays 
have been recognised by companies who have produced kits for the biomedical sciences.   
 
2.3 Commercial Kit 
A commercial kit was purchased to compare with the ELISA.  The commercial kit was a 
non-competitive indirect ELISA bought from Biomedical Technologies Inc. (USA).  The 
microtitre plate supplied was pre-coated with monoclonal human lysozyme antibody.  The 
antibodies supplied would then bind to any lysozyme in the serum sample that had bound to 
the plate surface.  A colour reaction was produced which was directly proportional to the 
amount of lysozyme in the sample. 
 
Before the commercial kits were applied, another ELISA test was carried out on the serum 
samples, to check the lysozyme was still present and detectable in the samples as they had 
been frozen for some time.  The ELISA test showed that lysozyme was still detectable and 
in comparable quantities to the results gained when samples were assayed on receipt. 
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2.4 Materials & Methods -ELISA 
All buffer recipes can be found in Appendix G. 
 
2.4.1 Lysozyme Coating 
Purified Lysozyme (Sigma-Aldrich Ltd, Dorset, UK) from human milk (10% lyophilized 
powder in sodium phosphate/sodium chloride) was dissolved in a 10ml coating buffer 
solution to make a 75µg ml-1 stock solution.  The lysozyme stock was stored at -20°C until 
use, (Appendix G).  Dilutions ranging from 0.05µg ml-1 – 0.25µg ml-1, were diluted in 
coating buffer.  This range was used to create a calibration curve.   
 
An aliquot (150µl) of lysozyme (0.05-0.25µg/ml) was added to each well of a 96 well 
microtitre plates (Immunolon 4HBX, Thermo Labsystems, Helsinki, Finland).  Each 
dilution was pipetted from a fresh Petri dish to prevent cross contamination of the dilution, 
with an 8 channel pipette.  The microtitre plate was sealed and then incubated for 30 
minutes at 37°C.  After incubation the plate was washed 4 times using an 8 Channel 
Immunolon plate washer (A/S Nunc, Roskilde, Denmark) and a wash buffer.  Excess wash 
buffer was removed by inversion and taping.  
 
2.4.2 Blocker 
A blocking agent was added to each well (250µl) and the plate was sealed and left at room 
temperature for 15 minutes.  After incubation the plate was washed twice with wash buffer 
and inverted.  
 
2.4.3 Primary Antibody Coating 
Rabbit Antihuman Lysozyme (A0099, Dako, Cambridge, UK) 7.1mg/ml was diluted 1:500 
with the wash buffer as described above.  Aliquots of 150µl was added to each well and 
incubated for 30 minutes at 37°C shaking at 100rpm (iEMS incubator/shaker HT, Helsinki, 
Finland).  Following incubation the plate was washed 4 times as described previously.  
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2.4.4 Secondary Antibody Application 
The secondary antibody, Peroxidase Conjugated Goat Anti-Rabbit 0.3mg/ml (P0448, Dako, 
UK) was diluted in wash buffer 1:1000.  Secondary antibody (150µl) was added to each 
well and the plate was incubated for a further 30 minutes at 37oC, and shaking at 100rpm. 
Following the incubation the plate was washed using the plate washer 4 times. 
 
2.4.5 TMB Application 
A TMB cocktail (150µl) was added to each well whilst in the fume hood.  The plate was 
then incubated for 6 minutes unshaken at room temperature in the dark.  The reaction was 
stopped with 50µl of 1M sulphuric acid.  The absorbance was then read at 450nm (Dynex 
Plate Reader, MRX Revelation, Thermo Labsystems, Helsinki, Finland).   
 
2.4.6 Calibration Curve 
A calibration curve was constructed using the results from the range of known Lysozyme 
samples, (0.05µg ml-1 – 0.25µg ml-1).  This was then used to determine the Lysozyme 
content of all unknown samples. 
 
2.4.7 Serum Samples 
Whole blood samples were collected from patients in accordance with ethical approval (SW 
87/2003) from the Great Western Hospital, Swindon, UK (Appendix C & D).  Samples 
were taken from a range of hospitalised patients (listed in section 2.1.1), from patients who 
were negative for sepsis and from healthy volunteers.  Whole blood samples were collected 
in Heparin tubes, centrifuged and the serum stored at -20oC in the Hospital for 24 hours 
after collection from patients.  The serum samples were then transported back to Cranfield 
University where work was undertaken.  The serum were divided and stored at -20°C in 
100µl aliquots, diluted 1/200 in 25mM pH8 Tris buffer. Serum Lysozyme was quantified 
using the above protocol omitting the blocking step (2.5.2) from the procedure.  The 
blocking step was used with buffered lysozyme samples to block unbound lysozyme sites, 
this step is not required when using serum.  Four replicates of each serum sample were 
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executed using the ELISA protocol.  The results were then quantified using the calibration 
curve produced with known lysozyme samples. 
 
2.5 Commercial Kit Materials 
The Human Lysozyme EIA kit (BT-630) was purchased from Biomedical Technologies 
Inc., USA (Appendix H) and consists of a 96 well microtitre plate coated with a 
monoclonal human lysozyme antibody.  The kit was used according to the manufacturer’s 
instructions.  A summary of the protocol is given below. 
 
A 1000ng lyophilised Human lysozyme standard was provided and a dilution range (0.78-
50ng/ml) was prepared in Phosphate Saline washing buffer.  A human lysozyme control 
(urine, lyophilised) reconstituted in 1ml washing buffer was also provided.  All serum 
samples were diluted in 1/2000 in washing buffer.  An aliquot (100µl) of each of the 
standards, control and serum samples was pipetted in duplicate, into the wells of the plate 
and the plate was sealed and incubated at room temperature for 2 hours.  After incubation 
the plate was washed 3 times with the automatic plate washer and washing buffer.  
Lysozyme antiserum (100µl) was added to each well, covered and then incubated at room 
temperature for a further 1 hour.  The plate was then washed as above and 100µl of Donkey 
anti-Goat IgG peroxidase was added to each well.  The plate was resealed and incubated for 
a further 1 hour at room temperature. The plate was washed for the final time and 100µl of 
a 1:1 mixture of TMB and Hydrogen peroxide solution was added to the wells.  The plate 
was then placed in dark storage for 15 minutes at room temperature. A 100µl of the Stop 
Solution was added and the absorbance measured at 450nm. 
 
2.5.1 Additions to Kit Supplied 
Reverse osmosis water was used to dilute the washing buffer supplied.  The Dynex reader 
as mentioned in the above section was used to measure optical density at 450nm.  The 
microtitre plate washer used with the ELISA method was also used. 
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2.5.2 Calibration Curve 
When the assay was completed, a calibration curve was produced.  Each kit came with a set 
of standards (which had known amounts of lysozyme) to be assayed.  Therefore a separate 
calibration curve was produced for each kit to determine the lysozyme content of unknown 
patient samples.   
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2.6 ELISA Results 
This section details all the results gained from the ELISA and commercial kit 
experiments.  Some graphs contain Standard Deviation error bars. 
 
2.6.1 Reference Range  
Table 2.1 shows the lysozyme levels from 14 non hospitalised healthy volunteers.  This 
data was then used in the comparison of hospitalised patient’s lysozyme levels with the 
patient’s clinical diagnosis.  The control lysozyme level range was 2-5.8µg/ml, with an 
average of 4.37µg/ml. 
 
Table 2.1 Lysozyme concentrations from healthy patients, used as a reference range. 
Patient ID Lysozyme Concentration (µg/ml) 
V1 3.7 
V2 2.0 
V3 3.8 
V4 4.6 
V5 5.8 
V6 5.7 
VN1 3.7 
VN2 4.4 
VN3 3.8 
VN4 5.4 
VN5 5.4 
VN6 5.4 
VN7 3.8 
VN8 3.7 
Mean 4.37 
Standard Deviation 1.07 
 
2.6.2 Calibration Curve  
Figure 2.2 was used to determine the lysozyme levels for all patient samples.  Several 
sets of lysozyme standards were carried out using the ELISA’s (n=17) during the 
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assaying of the patient samples.  This data was then collated in a table and the averages 
calculated.  Figure 2.2 below was then used to determine the lysozyme concentration for 
all patient samples. 
R2 = 0.8711
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Figure 2.2 Calibration Curve for ELISA, this graph was used for the determination of 
unknown samples. 
 
2.6.3 Freeze-Thawing Effects 
Figure 2.3 shows the results from a series of assays completed over 10 weeks.  Ten 
random samples were chosen from the clinical samples batch and assayed on 6 
occasions during a 10 week period.  Each sample was allowed to thaw fully before each 
assay and to freeze fully after each assay process. The results show the freeze thaw 
process had very little effects on the overall results.  Even with repeated freezing and 
thawing the lysozyme content was virtually the same as when the sample was first 
assayed after being drawn from the patient.  The small differences that were seen can be 
put down to assay variation. 
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Figure 2.3 Results of Freezing and Thawing serum Samples over 10 Weeks, graph 
shows very small variations. 
 
2.6.4 Commercial Kit Results 
The table below (Table 2.2) shows the results from the clinical samples.  Bacteraemia 
patients included all patients who were positive for sepsis, septicaemia, MRSA, UTI 
and URTI. All samples were assayed using the two techniques; ELISA and a kit 
purchased commercially.  The results show the mean lysozyme levels in each group of 
patients.   
 
The commercial kit results show the highest levels of lysozyme to be in the pregnancy 
patients; where as the ELISA results show the highest levels to be in the pneumonia 
patients.  The commercial kit also shows that the lowest levels of lysozyme in the 
patients with positive blood cultures; whereas the ELISA revealed the lowest lysozyme 
levels to be in the chronic renal failure and non septic patients.  Appendix I shows the 
results (in pink) gained from the commercial kits.  As these graphs show, the 
commercial kit results did not compare with the ELISA results, in any of the cases.  All 
commercial kit results were much lower than those from the ELISA kit. 
 
 
Chapter 2 36
Table 2.2 Comparison of the mean clinical sample results generated by two different 
assays; ELISA and Commercial Kit. 
Diagnosis 
Sample  
No. 
ELISA 
Mean LZ 
µg/ml 
Std. Dev. 
Com. Kit 
Mean LZ 
µg/ml 
Std. Dev. 
Tumours 10 6.05 1.77 0.00016600 0.000135
Bacteraemia 42 6.14 2.06 0.00003259 0.000102
Pregnant 6 6.10 0.89 0.00425000 0.000724
Non Septic 109 5.69 1.48 0.00023800 0.000269
Pneumonia 28 7.06 3.26 0.00006092 0.000124
Leukaemia 9 6.59 2.22 0.00009100 0.000183
Deceased 37 6.30 3.00 0.00009073 0.000220
CRF 4 5.28 2.00 0.00014700 0.000194
Appendicitis 5 5.84 1.28 0.00007300 0.000155
Abdo Pain 15 6.13 1.28 0.00012300 0.000256
 
2.6.5 Confirmation Assay  
Figure 2.4 below shows the results from three assays carried out on the same set of 
clinical samples.  When the commercial kits were purchased the samples had been in 
the freezer for several weeks.  This assay was to check immediately before the 
commercial kits were used, that the samples still had detectable lysozyme. The first set 
of ELISA Lysozyme results were completed when the clinical samples arrived in the 
lab.  The second ELISA lysozyme results (repeats) were completed directly before the 
commercial kits were carried out. The results show that the commercial kit distinctly 
lacks sensitivity.  Both ELISA’s showed a very similar lysozyme content regardless of 
the time lapse between uses.  No trend can be seen between the results either; where the 
lysozyme levels are high in the ELISA results the Lysozyme levels are low in the 
commercial kit results. 
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Figure 2.4 Confirmation Assay, to compare the levels of detectable lysozyme in serum 
samples tested with two ELISA’s and the commercial kit; graph shows lysozyme was 
present in the serum, but not detectable by the Commercial kit. 
 
2.6.6 Commercial Kit Calibration Curve  
The graph below (Figure 2.5) shows the standards used in the commercial kit.  Each kit 
came with its own set of 7 known lysozyme dilutions (0.78-50ng/ml), which were 
assayed (listed as “Average Achieved”) and compared with the OD which was expected 
to be achieved from the standard curve graph which was provided with the kit (listed as 
“Com. Kit Standard”).  The OD of the controls were very similar to the expected 
results.  Figure 2.5 illustrates that the kit was working to an adequate standard.  The 
lysozyme in the standards was detectable and the results comparable to those expected.  
This graph shows that the kit should have been able to measure the lysozyme in the 
serum samples, but for unexplainable reasons the kit produced results which indicated 
that there was far less lysozyme in the samples than the ELISA revealed.  This suggests 
that the commercial kit lacks sensitivity in serum samples.  The problem could be the 
contaminants in the serum.  Many of the patients sampled had bacterial infections.  The 
serum was not centrifuged or prepared in any way other than dilution before use in the 
commercial kit.  The bacteria in the samples could be hindering the adherence of the 
lysozyme to the pre-coated micro-titre plate and also reducing the reactivity to the 
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primary antibody.  Other causes could include drugs the patients were taking or 
abnormal plasma proteins; these could have caused the lack in sensitivity. 
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Figure 2.5 Graph showing a calibration curve constructed from commercial kit 
standards; this graph as used to determine the unknown lysozyme content of samples. 
 
2.6.7 Clinical Sample Results Summary 
Table 2.3 Blood Analysis Summary; table showing the mean response to increases in 
Lysozyme for patients with various conditions 
Patient’s Condition 
Parameter Abdo.  
Pain 
Append. CRF Leukaemia Pneumonia Pregnant Tumour 
Haemoglobin ↓  ↓ ↓   ↓ 
Neutrophil ↓  ↓ ↑  ↓  
Lymphocyte ↑ ↓ ↑ ↓    
WBC ↓   ↑   ↓ 
Platelets   ↓ ↑ ↓ ↓  
CRP     ↑   
*↑ & ↓ indicate an increase & decrease in parameter value  
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2.6.8 Clinical Sample Results – Group Analysis 
2.6.8.1 Lysozyme Analysis for All Patient Groups 
Figure 2.6 below shows the lysozyme levels from all the clinical samples processed 
with the ELISA.  The control group, of non hospitalised, healthy patients clearly have 
lower lysozyme levels than any of the other groups sampled. The highest lysozyme 
levels were seen in the leukaemia patients, pneumonia patients, the abdominal pain 
patients, and the deceased.  The non septic group contained all patients who were 
deemed non septic by the sepsis scale but were hospitalised for other reasons not 
disclosed and who’s true diagnosis was not disclosed.  The lysozyme levels for this 
group were not significantly lower than other groups possibly due to these undisclosed 
illnesses which were affecting the patient’s lysozyme levels.   
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Figure 2.6 Graph showing the lysozyme levels in all patients sampled.  
 
2.6.8.2 White Blood Cell Count Analysis  
This graph (Figure 2.7) shows the highest white blood cell count to be in patients with 
leukaemia.  Deceased and appendicitis patients also have elevated white blood cell 
counts.  The main observation of Figure 2.7 is that white blood cell counts do not show 
a correlation with sepsis.  The control group was not included here as these blood 
samples were taken from non hospitalised patients so blood cell counts were not 
available, however, this would be a good comparison for future work.   
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Figure 2.7 Graph showing the white blood cell levels for all patient groups sampled.  
Stand deviation also shown. 
 
2.6.8.3 Lysozyme & White Blood Cell Count Analysis  
Figure 2.8 shows the comparison between lysozyme levels with white blood cell levels 
from all patients.  The graph shows lysozyme levels increasing with increasing white 
blood cell counts.   
0
5
10
15
20
25
0 1 2 3 4 5 6 7 8
Lysozyme   µg/ml
W
hi
te
 B
lo
od
 C
el
l C
ou
nt
s 
x1
09
/li
tr
e
Tumous Bactereamic Pregnant Non Septic Pnuemonia
Leukaemia Deceased CRF Appendicitis Abdo Pain
R2=0.0947
 
Figure 2.8 Comparison of mean lysozyme with mean white blood cell counts for all 
patients sampled. 
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2.6.8.4 Percentage Lysozyme Increase in Sepsis Patients  
Figure 2.9 shows the percentage increase in lysozyme in patients with sepsis compared 
to the non septic and control groups.  Even though the non-septic patients were deemed 
to have no sepsis from their signs and symptoms, from the doctor’s observations and 
from blood analysis, their lysozyme levels clearly show an increase which may have 
been overlooked by current tests as their mean lysozyme concentrations were 31% 
higher than controls.  Pneumonia patients display the largest increase in serum 
lysozyme concentration with a 62% increase.  However, all groups had elevated 
lysozyme concentration when compared to controls, (bacteraemia 41% increase and 
appendicitis 34% increase).  This graph shows that a difference is seen between controls 
and patients with proven sepsis and that lysozyme could be used to aid diagnosis.  
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Figure 2.9 Lysozyme Increase, graph shows the lysozyme increase for septic patient 
groups and compares them with two control groups. 
 
2.6.8.3 Lysozyme & Neutrophil, CRP, Platelets & Lymphocytes Analysis  
Figure 2.10 a, b, c & d shows a negative correlation between neutrophil levels and 
lysozyme; whereby neutrophil levels decrease as lysozyme increases.  The figure also 
shows positive relationships between CRP, platelets and lymphocytes with lysozyme 
concentration.   
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Figure 2.10 a, b, c & d Comparison of mean lysozyme levels with Neutrophils, CRP, 
Platelets & Lymphocytes for all patient samples.   
 
2.6.9 Additional Sampling  
Analysis of specific groups of patients and specific parameters can be found in 
Appendix I.  The suggestive relationship between the clinical condition of the patient 
and the results from blood assessments is given. No correlations could be seen for the 
following blood results and diagnoses:   
• Lysozyme from abdominal pain patients was compared with platelets and CRP.   
• Lysozyme from appendicitis patients and haemoglobin, neutrophils, white blood 
cells, platelets and CRP.   
• Lysozyme from chronic renal failure patients was also compared with white 
blood cell counts and CRP.   
• Lysozyme levels were compared with CRP from leukaemia patients.   
• Haemoglobin, neutrophils, lymphocytes, and white blood cell counts were 
compared with lysozyme from pneumonia patients.   
• Lysozyme from pregnant patients was compared with haemoglobin, CRP, 
neutrophils, lymphocytes and white blood cell counts.   
• Patients diagnosed with tumours had their lysozyme compared with neutrophils, 
lymphocytes, platelets, and CRP.   
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• Lysozyme from bacteraemia patients, non-septic and deceased patients were 
compared with all measured parameters (haemoglobin, neutrophil, lymphocytes, 
white blood cells, platelets, and CRP). 
• No correlation between male and female and age lysozyme levels for any of the 
patients conditions.   
 
2.6.10 Statistical Analysis, T-Test 
Table 2.4 shows the results from a statistical analysis test.  The Student t-Test was 
carried out on all the patient sample groups independently, rejecting the null hypothesis 
if the probability value was p<0.05.  The null hypothesis stated that there was no 
difference between each groups mean lysozyme and the control group.  Each diagnostic 
group was compared with the control group and the statistical difference was recorded.  
The statistical difference was also recorded for the control group v’s the mean of all 
lysozyme levels from all hospitalised groups.  The results showed that the majority of 
the lysozyme levels from each group were statistically different when compared to the 
lysozyme levels of the controls.  The only exception was the chronic renal failure group.  
This group had lysozyme levels which were very similar to the control lysozyme levels 
so therefore were not significantly different.  Patients with sepsis had mean serum 
lysozyme levels significantly higher compared to healthy controls. 
 
Table 2.4 Table showing Student t-Test results for all Patient Samples 
Diagnosis 
No of 
Samples 
Mean Std. Dev. t-Test Result P Value 
Controls 14 4.37 1.07   
Tumours 10 6.05 1.77 2.44 p<0.05
Bacteraemia 42 6.14 2.06 4.133 p<0.001
Pregnant 6 6.1 0.89 3.736 p<0.01
Non-Septic 109 5.73 1.48 4.212 p<0.001
Pneumonia 28 7.064 3.26 3.963 p<0.001
Leukaemia 9 6.587 2.22 2.793 p<0.05
Deceased 37 6.303 3 3.388 p<0.01
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CRF 4 5.28 2 0.875 N/S
Appendicitis 5 5.84 1.28 2.296 p<0.05
Abdominal Pain 15 6.13 1.28 4.021 p<0.001
All Patient Samples 279 5.96 0.468 5.422 p<0.001
*N/S, Not Significant 
 
2.6.11 Statistical Analysis, F-Test 
Table 2.5 shows the results from the ANOVA statistical F-test, rejecting the null 
hypothesis if the probability value was p<0.05.  Each test confirmed that the null 
hypothesis was to be rejected with the exception of ESR v lysozyme.  The null 
hypothesis states that lysozyme is affected by each condition equally.  The alternative 
hypothesis stated that one of the conditions had a greater affect on lysozyme levels more 
than the others.  In all cases of Table 2.5, the null hypothesis was rejected meaning there 
was a significant difference between factors. 
 
Table 2.5 Table showing F-Test ANOVA results for all Patient Samples 
Diagnosis ANOVA Result  P Value 
Controls v Tumours, Bacteraemia, Pregnant, Non-
Septic, Pneumonia, Leukaemia, Deceased, CRF, 
Appendicitis, Abdominal Pain 2.19 P<0.0190
Control v Non-Septic, Bacteraemia, Pneumonia & 
Appendicitis 5.59 P<0.0003
CRP v Lysozyme 4.12 P<0.0453
White Blood Cells v Lysozyme 6.59 P<0.0143
Neutrophils v Lysozyme 7.2 P<0.0081
ESR v Lysozyme 2.15 N/S
*N/S, Not Significant 
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2.8 Discussion 
This section discusses the results in 2.6.  
 
2.8.1 Reference Range 
Table 2.1 shows the lysozyme results from the non-hospitalised, healthy control group.  
The lysozyme average was 4.37µg/ml, which was the average taken from 14 volunteer’s 
results.  The results ranged from 2-5.8µg/ml.  This range was established from a group 
of non-hospitalised volunteers who deemed themselves to be healthy at the time of the 
test. 
 
Appendix J - Cited Lysozyme Reference Ranges, lists all the lysozyme reference ranges 
cited in journal publications.  The mean cited reference value for lysozyme was 
7.43µg/ml with a range of 0.54-25µg/ml.  These lysozyme values are much higher than 
the level established by the lysozyme ELISA of this project.  Appendix J shows that 
different experimental methods give dissimilar lysozyme ranges.  This therefore means 
that the ELISA reference is not necessarily wrong because it is different from those 
cited; it is just correct for this particular method and particular biological fluid type and 
should only be used with the ELISA protocol with serum.  This is reinforced by 
comments made on other kits (IgM ELISA, Research Diagnostics Inc.) that their kits 
only relate to specific assay ranges provided with the kit.  
 
2.8.2 Freeze-Thawing 
The freeze-thawing test was carried out due to the time scale the clinical samples were 
processed.  The clinical samples would arrive unfrozen in the lab and a selection of 
them would be assayed immediately.  The rest would be frozen and then thawed before 
assaying.  They would then be frozen and thawed a second time before being assayed 
with the commercial kit.  Figure 2.3 shows a selection of clinical samples which were 
frozen and thawed 5 times over 70 days.  The results from this experiment showed very 
little variation in the lysozyme content of the samples.  The commercial kit was able to 
process 40 samples per run, but did not arrive until some time after all the samples had 
been assayed with the ELISA, this meant the serum samples had to undergo another 
round of freezing and thawing before assaying with the commercial kit.  This lead to the 
Chapter 2 46
question of whether the samples were being affected by the freezing and thawing 
process. 
The results from this experiment showed that the serum was not being significantly 
affected by the freeze-thaw process and the commercial kit assay results should be 
unaffected.  This is conducive with the results from Cavalleri et al. (2004).  Their study 
measured free radical concentration in serum samples which had been repeatedly frozen 
and thawed over a two year period.  The free radical concentration did not significantly 
alter, leading to the conclusion that the freeze-thawing process was not detrimental to 
serum.  A study by Comstock et al. (2001) also showed that serum samples which 
underwent <3 freeze-thaw cycles (-20oC & -70oC) were not affected.  Serum which was 
subjected to more than 3 cycles were more affected showing 2-4% changes in hormone 
levels with even less changes in cholesterol and most micro nutrients.  Serum antibodies 
were also frozen and thawed several times by Pinsky et al. (2003) in the detection of 
measles, mumps, and rubella.  Pinsky et al. (2003) found “no clinically or statistically 
significant effect on measured antibody levels” and concluded by saying their 
experiments found “no discernible detrimental effect on the ability to measure these 
antibodies by enzyme-linked immunoassays”.  Therefore, the effects of freeze thawing 
on lysozyme in serum samples should be negligible and this is shown in Figure 2.3. 
 
2.8.3 Commercial Kit Results 
The Confirmation Assay (Figure 2.4) was carried out due to the poor quality of the 
results from the commercial kit.  A random selection of clinical samples were 
processed, both with the ELISA and the commercial kit.  The ELISA results were in-
line with those previously reported by the ELISA kit (Figure 2.4), but the commercial 
kit results were all far lower than expected.   
 
The calibration curve (Figure 2.5) for the commercial kit showed the kit was working 
properly.  The kit came with its own calibration curve and the results from the standards 
from the assay were compared with this.  The graph shows that the kit was working as it 
should be.  The kit was used as the instructions dictated and the only difference was the 
amount of clinical samples used.  The kit was designed to assay 10 samples, but here, 
due to budget constraints 40 samples (2 duplicates) were processed with this kit.  
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However, this should not have affected the overall performance of the kit in any way.  
The references on the instructions for the commercial kit assay (Appendix H) do not 
relate to the actual testing or development of the assay.  Therefore it is hard to say why 
these results did not compare with the ELISA results.  One explanation of why the 
commercial kit did not work as effectively as it should is because of its poor 
instructions.  In the “Other supplies required” section of the Appendix H, it clearly 
states that a 37oC incubator is required.  However, no where in any of the “Assay 
Procedure” section of Appendix H does it say when to use it.  Usually the 37oC 
incubator is used during the initial stages of the assay, during the ligand immobilisation, 
but this assay comes with a pre-coated plate, so this stage is missed out.  Also as the 
controls on the plate (Figure 2.5) showed the assay was working normally, it suggests 
that it was the serum which was the problem.  But as Figure 2.3 and 2.4 show the serum 
was fine, regardless of the amount of freeze-thawing it had under gone.  In conclusion, 
the incubator may simply be a typing error and not actually supposed to be used in this 
assay, but it also may be the reason behind the poor results. 
 
2.8.4 Comparison of Commercial Kit & ELISA 
All ELISA protocols have a similar setup, in that they have immobilisations of ligands 
and analytes, enzyme-substrate reactions, washing phases and incubation periods.  Even 
though all ELISA systems are different they still have the same disadvantages; they all 
have “position dependent differences in microtitre plates” (Goa, 1995) meaning the 
position of the well can dictate the quality of the results produced due to poor washing 
methods used.  The assay has very specific timing for the incubations which are critical 
to the overall result.  Most ELISA’s consist of more than 2 steps in the protocol giving 
the assay a degree of complexity warranting training. 
 
2.8.4.1 Analytical Sensitivity 
The ELISA has an analytical range of 1-400ng/ml and a limit of detection of 0.36ng/ml.  
The commercial kit has an analytical range of 0.78-50ng/ml and a sensitivity of 
0.78ng/ml.  As the limit of detection of the commercial kit is not disclosed it is difficult 
to say for certain if the commercial kit lacks sensitivity, however, as it could not detect 
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lysozyme in the serum samples then it’s the only conclusion that can be drawn.  This 
was also confirmed by the kits producers. 
 
2.8.4.2 Number of Samples Tested 
The number of samples each assay can test is the same due to the number of wells in a 
96 well micro titre plate.  The number of duplicates for each sample can vary.  With the 
commercial kit due to a limited budget, the number of samples processed by each kit 
was high (40 samples/plate) as each kit cost ~£300.  As the ELISA equipment and 
reagents were in ample supply each sample was replicated 8 times and an average taken 
for each. 
 
2.8.4.3 Ease of Performance 
The ELISA protocol took 96 minutes in total to complete one assay.  The preparation 
time varied depending on the number of clinical samples being processed, but was 
generally no more than 60 minutes. The commercial kit protocol took 4.5 hours to 
complete one assay and preparation time was more than an hour each time.  The 
commercial kit was a very laborious assay to carry out, and very demanding.  With the 
ELISA, 2 assays could be run simultaneously by being staggered by 30 minutes.  This 
would allow several assays to be carried out in one day, and if necessary repeat assays 
could be carried out and the clinical samples would not have to undergo another freeze-
thaw process. The commercial kit, however, took so long to prepare and execute that 
there simply wasn’t enough time in the day to carry out more than 2 assays. 
 
The commercial kit did not arrive with all the reagents needed.  Due to the number of 
clinical samples due to be processed with each kit extra buffer had to be purchased; thus 
adding further to the expense of the kit.  The commercial kit instructions also had in its 
requirements list, a 37oC incubator.  The protocol however, never mentioned the use of 
this.  This was a typing error which should not have been included as confirmed by the 
kits producer.   
The ELISA and commercial kit both had easy reagent preparation methods, an easy to 
use test procedure, required very little training on the equipment, used safe procedures 
and the results were easy to interpret. 
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2.8.5 Clinical Sample Results – Group Analysis 
2.8.5.1 Lysozyme & White Blood Cell Count Analysis 
Figure 2.8 shows the white cell count versus the lysozyme level in all hospitalised 
patients.  The graph shows the increasing white blood cell count with the increasing 
lysozyme level.  This is due to the number of white blood cells releasing lysozyme to 
fight the infection.  Figures 2.6 and 2.7 also show the distribution of lysozyme and 
white blood cell expression in the various patients sampled.  Leukaemia and pneumonia 
expressed the most lysozyme with leukaemia and deceased patients expressing the most 
white blood cells.   The pneumonia patient’s lysozyme levels do not correlate with the 
white blood cell counts.  This shows that white blood cell counts are not a good 
indication of sepsis in this group.  The bacteraemia and appendicitis patients white cell 
counts are also not elevated also showing that white cell counts are not indicative of 
sepsis.  During leukaemia, the body produces high levels of white blood cells which are 
characteristically dysfunctional; these then leak the lysozyme causing high lysozyme 
levels (Davis, 1971). 
 
2.8.5.2 Percentage Lysozyme Increase in Sepsis Patients 
Figure 2.9 shows the percentage increase in lysozyme in those patients with sepsis.  The 
statistical analysis of these results will follow this discussion.  Pneumonia patients had 
the highest increase in lysozyme levels of 62% above controls.  When compared to non-
septic lysozyme levels, also shown in this figure the increase in pneumonia lysozyme 
levels is also significant. This figure also shows the lysozyme increases in patients with 
appendicitis (34%) and bacteraemia (41%).  The figure shows these increases also to be 
significantly higher than the controls.  Lysozyme is therefore a good indicator of sepsis 
in patients with proven sepsis. 
 
2.8.5.3 Lysozyme & Neutrophil, CRP, Platelets & Lymphocytes Analysis 
Figure 2.10 a, b, c & d show the relationships between mean lysozyme levels and 
neutrophils, CRP, platelets and lymphocytes for all ill patients.  The figure shows a 
negative relationship between neutrophils and lysozyme, suggesting a defect in defence 
cell production caused by surgery stress.  There is a positive relationship between 
platelets, CRP and lymphocytes with lysozyme.  CRP is released in response to 
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inflammation, platelets are involved with blood clotting and lymphocytes release upon 
infection, therefore in septic conditions a positive correlation between these and 
lysozyme is to be expected. 
 
2.8.5.4 Statistical Analysis 
Table 2.4 shows the results from the student t-test, carried out on the clinical sample 
results.  Each patient group was statistically compared with the control (non-
hospitalised, healthy) patient group.  Table 2.4 shows that only one group, the chronic 
renal failure patients had lysozyme levels which were not significantly different from 
the control.  This is because the lysozyme levels were very similar to the control group.  
Also the amount of patients in this group was very small therefore, more testing of more 
chronic renal failure patients should have been carried out to make more substantiating 
conclusions. All other patient groups, (Tumours, Bacteraemia, Pregnant, Non-Septic, 
Pneumonia, Leukaemia, Deceased, Appendicitis, and Abdominal Pain) had lysozyme 
levels which were statistically significantly different when compared to the control 
group.  For a more accurate result more patient samples would have to be carried out.  
But these results do show that the ELISA method is capable of distinguishing non-septic 
and septic serum samples.  
 
The f-test also showed there was a statically significant difference between healthy 
control samples and diseased patients.  There was also a negative relationship between 
neutrophil and lysozyme levels and a positive relationship between white blood cells 
and lysozyme in bacteraemia patients. 
 
2.6 Advantages of ELISA 
The total ELISA assay time was 96 minutes.  This was a great improvement on current 
lysozyme immunoassays on the market.  Each ELISA assay can process 40 clinical 
samples per run with two replicates equalling an average of 2.4minutes per sample.  
Preparation time only usually amounted to an hour before the assay started due to 
buffers being very stable and lasting for several weeks before needing to be remade.  
Clean up time once the assay had finished, was also very short, as most of the 
equipment was single use only and therefore disposed of. 
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All immunochemicals and reagents are commercially available.  The total cost of one 
assay is around £17.00 for 40 samples.  This is a considerable difference in price 
compared to commercial kits available on the market. 
 
There are several types of immunoassay based on this idea of recognition and these are 
divided into competitive and non-competitive assays.  However, with all immunoassays 
the results obtained are quantitative.  These can then be compared with known 
standards.  With every assay known concentrations of controls are carried out so a direct 
comparison can be carried out leading to accurate results every time (Torrance, 1998). 
 
2.7 ELISA Synopsis 
The ELISA work reported was both a development of an in-house immunoassay and the 
progression into clinical sample testing for diagnostic use.  The work initially began 
with establishing a reference range for the ELISA assay.  The ELISA reference range 
was 2-5.8µg/ml.  The freeze thawing of serum samples showed no effects on the 
lysozyme at 4oC and showed the method used for thawing and refreezing the samples 
was having no detrimental effects on the lysozyme.   
 
A commercial kit was also used in the ELISA work.  This kit was bought to test the 
validity of the ELISA method.  All clinical serum samples were assayed using the 
ELISA initially and then the commercial kit.  The freeze-thaw experiment was therefore 
used to confirm lysozyme was not being affected during this process.  However, the 
commercial kit was far less sensitive than expected and the results generated did not 
compare to the ELISA results. 
 
A comparison of the two immunoassays was also carried out.  The ELISA proved to be 
far more sensitive than the commercial kit, the overall cost of the ELISA was much less 
than the commercial kit and the ELISA was both far easier to execute and takes less 
than half the amount of time to complete the assay than the commercial kit.  This 
therefore leads to the conclusion that the ELISA kit has many attractive characteristics 
over other commercially available kits. 
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The lysozyme levels from all clinical samples were compared to the blood results 
provided with each clinical sample.  The appendicitis patient’s results correlated with 
the expected results for this condition.  High lysozyme, lymphocyte and neutrophil 
levels were shown in these patients due to infection and the surgery-stress response. 
 
The abdominal pain group although had negative bacterial cultures showed an increase 
in white blood cell and lysozyme which may have indicated the start of an infection, 
possibly leading to appendicitis.   
 
The results from the leukaemia patients showed the white blood count markedly 
increased due to the characteristic mass production of dysfunctional white blood cells.  
The decreased haemoglobin levels results link with many patients suffering from 
anaemia and the high lysozyme is indicative of infection, to which leukaemia patients 
are particularly susceptible.  The prevalence of infections in the leukaemia group was 
also evident due to the high neutrophil levels. 
 
The results from the pneumonia group showed increased lysozyme levels representing 
phagocytosis.  Pneumonia occurs due to a suppressed immune system and an 
opportunistic infection.  The CRP levels in pneumonia patients show increasing levels 
with increasing lysozyme, which is indicative of infection. 
 
The pregnancy patient’s lysozyme results also indicated their physiological condition.  
The patients displayed increased neutrophils and lysozyme, either due to infection or 
their immune system heightening as a preventative defence against infection. 
 
Results from the patients with tumours showed low haemoglobin levels and a depressed 
white blood cell count.  Lysozyme levels were raised in these patients indicating 
possible infections or the release of lysozyme during white blood cell lysis. 
 
The collaborative group analysis data showed white blood cell count increasing with 
lysozyme and the highest distribution of lysozyme and white blood cells was in 
leukaemic and pneumonia patients.   
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Statistical analysis was carried out on each diseased patient group and the lysozyme 
level was compared to the non-hospitalised control group lysozyme level.  The results 
showed all diseased patient groups were statistically different.  The only exception was 
the CRF group due to small numbers.  Pneumonia patients had the highest mean 
lysozyme increase over other groups sampled.  Sepsis groups were compared to healthy 
controls showing there was a statically significant difference. These results showed the 
ELISA was a reliable diagnostic tool for detecting elevated lysozyme levels in septic 
patients. 
 
The ELISA therefore has been tested with both lysozyme in buffer and serum lysozyme 
from both healthy and diseased patients.  The ELISA has also been quantitatively and 
qualitatively compared to a commercially available anti-lysozyme kit and has succeeded 
to show it is the better test.  Further clinical samples should be assayed using the 
ELISA, but the results from the current clinical samples show a promising use for this 
diagnostic tool in aiding the diagnosis of future septic patients. 
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Chapter 3 -ELIFA 
 
3.1 Introduction  
The basic principle of Enzyme Linked Immunosorbent Flow-Through Assay (ELIFA) is 
to filter immuno-concentrates onto the surface of a membrane.  With the success of the 
ELISA assay, the main idea behind the ELIFA system was to build an assay which was 
faster, easier to use and cheaper to run.  The ELIFA has the potential of high levels of 
ligand binding compared to those assays where ligand are immobilised on a plastic 
surface, (Hermanson et al., 1992).  In theory the ELIFA, limits the diffusion at the 
surface of the porous materials, but allows the measurement of analytes in low 
concentrations. 
 
The ELIFA is an indirect immunoassay incorporating diffusion which takes place by the 
analyte when it reacts with the ligand immobilised on the solid surface.  The diffusion 
can be limited in the liquid-solid interface due to the difference in viscosity.  The 
ELIFA overcomes this because all ligand and analyte are deposited on the membrane 
and all solutions are sucked through the pores of the membrane.  A primary antibody 
then binds to any analyte present and a secondary conjugated antibody binds to the 
primary antibody.  A substrate then produces a discolouration on the surface of the 
membrane when all three are present.  The discolouration is directly proportional to the 
amount of lysozyme in the initial sample.  Each step is followed by a washing phase 
which is sucked through the membrane via a peristaltic pump.  The end product of the 
ELIFA is a soluble substrate solution which can be measured using a 
spectrophotometer.   
 
The ELIFA apparatus consists of a porous membrane in which the reaction occurs.  
Feadda (2003) trialled 5 different membranes, which were either neutral-hydrophilic or 
negatively charged.  This report found the Polyamide nylon membrane had up to 80% 
greater binding than other membranes; this membrane was therefore used in the ELIFA 
protocol.  The membrane was held immobilised in position by a flow cell.  The flow 
cells consisted of an inferior and a superior part in which a membrane was clamped.  
Tubing was connected to the cannula attached to the underside of the interior and to 
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tubing attached to the peristaltic pump; this allowed all fluid to be removed from the 
loading chamber of the superior flow cell (Figure 3.1). 
 
Figure 3.1 The Working ELIFA System; Photograph shows the flow cells assembled 
and linked via tubing to the peristaltic pump.  All fluids are sucked along this tubing 
from the loading chamber of the flow cell to the waste jar. 
 
3.2 Potential Improvements of the Lysozyme ELIFA compared to the ELISA 
Technically the ELIFA design was intended to produce homogeneous and slow flow 
through rates past the immobilised membrane.  This was to allow even distribution of 
lysozyme to be immobilised and to allow maximum binding with the primary and 
secondary antibodies; which means the ELIFA would have the potential to be more 
sensitive than the ELISA.   
 
The distribution of these reagents should also be uniform due to the peristaltic pump 
pumping rate being constant for all flow cells.  This could produce consistency to the 
delivery of the antibodies, whereas the ELISA is managed by operator control, which 
could lead to inconsistencies. 
 
3.3 ELIFA Application 
A general ELIFA system can be purchased from Pierce Science.  The “Easy-titre ELIFA 
system” can be used with any analyte and for any target for a costly sum of £1,000.  The 
assay takes 25 minutes to complete and a 96 well arrangement is used allowing multiple 
replicates and controls.   
 
Flow cells 
Peristaltic Pump 
Waste Jar 
Superior 
Inferior 
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An ELIFA assay proposed by Valkirs & Barton (1985) was for an early pregnancy test 
measuring the human choriogonadotropic hormone (HCG).  This ELIFA was a two-site 
immunoenzymometric assay, in which an antibody was seeded to a membrane, and the 
antigen (from either urine or serum) was passed through and a substrate was applied to 
create a colour reaction if the hormone was present in the sample.  The test could detect 
as low as 4µg/L in urine and 2µg/L in serum.  The high ratio of surface area to volume 
ensured short diffusion distances and a sensitive test. 
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3.4 Materials & Methods -ELIFA 
All buffer recipes can be found in Appendix G. 
 
3.4.1 General Reagents 
Hybond N (Amersham, UK) was used as hydrophilic neutral nylon membrane (0.45µm 
diameter).  A Blocker Casein in TBS from Pierce Science UK Ltd. (Tetterhall, UK) was 
used to minimize non-specific antibodies binding to the membrane.  The washing step 
was used to remove any unbound antibodies/antigen from the membrane. 
 
3.4.2 Peristaltic Pump Calibration 
A Spectec Perimax 12, 4 channel peristaltic pump was calibrated with water through 
both the sample and control flow cells.  A calibration curve of ml/minute at particular 
speeds of the pump was constructed.  The pump rate from the calibration curve was then 
varied during different parts of the immobilisation, injection of antibodies, staining and 
washes.  PVC tubing (0.76mm from Anachem, UK) connected to 0.8x1.5mm Teflon 
tubing (Ismatec, Zurich) was connected to the cannula of the flow cells and the 
peristaltic pump.  A Gilson Minipuls, 2 channel pump (Gilson, USA) was also used 
during these experiments. 
 
3.4.3 Flow Cell Construction 
Perspex flow cells were purpose designed (John Bolbot, Cranfield University) and made 
by Model Products Ltd (Bedfordshire, UK).  A circle of membrane was cut and placed 
in between the inferior and superior part of the flow cell.  The flow cell components 
were joined together by three screws to clamp the membrane in place.  A tube 0.76mm 
internal diameter (Anachem, UK) was connected to a cannula on the inferior part of the 
flow cell and attached to the peristaltic pump (Figure 3.2). 
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Figure 3.2 Parts of a Flow Cell; Picture shows all flow cell components including the 
inferior and superior elements, loading chamber and cannula.  The membrane is placed 
between the inferior and superior and held in place with three screws.  The cannula is 
screwed into the underside of the inferior element, and is connected to further tubing 
and a peristaltic pump. 
 
3.4.4 Lysozyme Coating & Blocking Step 
Lyophilised Lysozyme from human milk (L6394 Sigma-Aldrich, UK) was diluted in 
Coating buffer (Appendix G) and aliquots frozen at -20ºC.  An aliquot (500µl) of the 
lysozyme was loaded into the loading chamber of the superior flow cell.  This was 
pumped through the Hybond-N nylon membrane (Amersham Pharmacia Biotech, UK) 
at a flow rate of 0.04ml/min.  Blocking agent (200µl) was added to the flow cell and 
pumped through at a flow rate of 0.04ml/min. 
 
3.4.5 Antibody Application 
Antibodies used in the ELIFA were from DAKO (Cambridge, UK) (1o A0099 & 2o 
P0448).  The primary antibody (section 2.4.3) concentration was 1:6000 and the 
secondary antibody (section 2.5.4) 1:4000.  Both the primary and secondary antibodies 
were diluted using the WBTC, (Appendix G).  Primary antibody (200µl; 1:6000) was 
pipetted into the loading chamber and pumped at 0.02ml/min. The secondary antibody 
was loaded next.  A dilution of 1:4000 diluted in WBTC was prepared and 200µl was 
pumped through at a flow rate of 0.04ml/min.  The washing solution (200µl) was 
pumped through at 0.4ml/min and repeated 3 times. 
 
3.4.6 Colour Reaction 
Undiluted TMB cocktail (150µl) (T8665 Sigma-Aldrich Ltd, UK) was loaded into the 
chamber and pumped through the membrane for 30 seconds at 0.04ml/min.  The 
reaction was then allowed to continue under static conditions for a further 5.5mins.  The 
Inferior Superior 
Loading Chamber 
Screws 
Membrane 
Cannula 
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reaction was stopped by adding 50µl, 1M sulphuric acid to the remaining fluid in the 
flow cell. 
 
3.4.7 Collecting the Sample 
The sample was collected from the loading chamber by reversing the flow direction of 
the pump so the fluid in the tubing was forced back into the flow cell.  The sample was 
then collected via a pipette into a microtitre plate and optical density was read at 450nm. 
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3.5 ELIFA Development Results  
This section presents the initial ELIFA results.  Several tests were carried out to test and 
optimise the protocol.  The objective was to produce a calibration curve with a range of 
lysozyme concentrations, through a series of stained membranes and using the optical 
density of the filtrate.  Several abbreviations were used in the following tables; C refers 
to Controls, S refers to Sample and N/S refers to No Staining.  Where results are 
repeated for each test the characters (i), (ii) and (iii) are used. 
 
3.5.1 Preliminary Experiment  
The preliminary experiment was to test the equipment and the reagents.  The Gilson two 
channel peristaltic pump was the first peristaltic pump to be used in these experiments.  
The assay was very fast only taking 37 minutes.  Results showed the reagents and 
antibodies were viable.  Discolouration was only seen on the sample membrane but no 
difference was seen between the optical density of the control and sample filtrate (Table 
3.1). 
 
Table 3.1 ELIFA Results, shows the OD and membrane discolouration of various 
concentrations of lysozyme in buffer for the Preliminary Experiment. 
LZ Conc. OD Membrane Staining (C, control; S, sample) 
0µg/ml 
20µg/ml 
2.444 
2.781 
C N/S 
S discolouration 
 
3.5.2 Equipment Changes to Enhance Results 
3.5.2.1 Back Flush Test 
Due to the success in the preliminary experiment, the lysozyme concentrations were 
lowered to see if more discolourations could be seen on the membrane with lower levels 
of lysozyme and to see if this would reveal a difference in the optical density of the 
filtrates.   
 
The Gilson pump was again used in this second test with a wider range of dilutions of 
lysozyme.  A back flush method was also introduced, which involved pumping the 
TMB through the membrane for 0.5 minutes and allowing the reaction to take place in 
stationary conditions for 5.5 minutes.  The pump direction was then reversed so the 
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sample in the tubes flowed back into the loading chamber of the flow cells where it was 
pipetted out into a micro-titre plate for the optical density to be read.   
 
The back flush was incorporated as non-specific binding was suspected.  This is where 
binding of the HRP-conjugate is taking place not only on the membrane filter but also 
along the inside of the tubing, causing a purple discolouration.  When the TMB was 
administered it was not only binding to the HRP-conjugate on the membrane but also 
inside the tubing.  Therefore when the whole sample (lysozyme, 1o & 2o antibodies, and 
TMB) was eluted from the flow cells and tubing at the end of the experiment, an 
inaccurate sample was collected because so much was lost to the lining of the tubes and 
flow cells.  The results from Test 3.5.2.1 show that the back flush alone was not the 
solution to the non-specific binding (NSB).   
 
The results for all dilutions of samples tested showed no difference between the filtrates 
regardless of the lysozyme content (Table 3.2).  Membranes from all samples and 
controls were also unstained. 
 
Table 3.2 ELIFA Results, shows the OD and membrane discolouration of various 
concentrations of lysozyme in buffer for Test 3.5.2.1. 
LZ Conc. OD Membrane Staining (C, control; S, sample) 
0µg/ml 
0µg/ml 
1.615 
1.328 
0µg/ml 
10µg/ml 
1.167 
1.213 
0µg/ml 
15µg/ml 
1.158 
1.103 
0µg/ml 
20µg/ml 
2.766 
1.536 
All C N/S 
All S N/S 
 
3.5.3 Reagent Changes to Enhance Results 
3.5.3.1 Buffer Contamination 
In the third set of tests, contamination of the buffer solutions was considered.  All 
solutions had been kept out of the fridge on the bench during experiments and over 
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night.  When new buffers (including wash solutions, WBTC and blocking step) were 
made these were kept at 4oC to limit contamination from bacteria.   
 
The 5µl/ml dilution was tested several times because contamination was suspected.  
After this dilution, all solutions were changed and stored as mentioned above.  The 
other dilutions (10, 15 & 20µg/ml) performed in this test produced promising results. 
The results showed the control OD was low and the samples showed some pattern that 
corresponded to the actual lysozyme content.  The control was in line with those 
expected results from Appendix K.  The results for the lysozyme dilutions were also in 
line with those from Appendix K, with the exception of the 5µg/ml dilution which was 
higher than expected.  No staining was seen on any of the membranes with the 
exception of the 20µg/ml. 
 
Table 3.3 ELIFA Results, shows the OD and membrane discolouration of various 
concentrations of lysozyme in buffer for Test 3.5.3.1. 
LZ Conc. OD Membrane Staining (C, control; S, sample) 
0µg/ml 
5µg/ml 
1.530 
2.054 
0µg/ml 
5µg/ml 
1.740 
1.517 
0µg/ml 
5µg/ml 
2.357 
2.146 
0µg/ml 
10µg/ml 
0.614 
2.387 
0µg/ml  
15µg/m 
0.436 
2.145 
0µg/ml  
20µg/ml 
0.764 
2.494 
All C N/S 
S 20µg/ml discolouration 
 
 
3.5.3.2 Further Contamination Testing 
In a further test for contamination a fourth set of experiments were carried out where the  
only difference from the method used in Test 3.5.3.1 above was that the solutions were 
stored at 4oC over night then allowed to reach room temperature two hours prior to the 
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start of the experiment.  For (i) (Table 3.4) no staining was visible on the membranes 
which may be an indication of a lack of binding taking place on the actual membrane, 
suggesting a problem with non specific binding either on the flow cells or adherence 
inside the tubing. 
 
Table 3.4 shows the repeat (ii) of the 5µl/ml dilution from Test 3.5.3.2.  The repeat 
results (ii) show a small difference between the control and sample OD.  The sample 
membrane was fully stained, with the control remaining clear. The optical densities for 
both (i) and (ii) however, did show a difference between control and sample in all the 
dilutions tested.  But no correlation could be established; the OD did not increase with 
increasing lysozyme levels. 
 
Table 3.4 ELIFA Results, shows the OD and membrane discolouration of various 
concentrations of lysozyme in buffer for Test 3.5.3.2.  Initial tests (i) and repeats (ii). 
LZ Conc. OD Membrane Staining (C, control; S, sample) 
(i) 0µg/ml 
(i) 5µg/ml 
0.421 
0.803 
(i) 0µg/ml 
(i) 10µg/ml 
0.420 
1.915 
(i) 0µg/ml 
(i) 15µg/ml 
0.185 
0.481 
All C N/S 
All S N/S 
(ii) 0µg/ml 
(ii) 5µg/ml 
0.344 
0.791 
C N/S 
S 5µg/ml discolouration 
 
The assay seemed to be working in Test 3.5.3.1 with the addition of freshly made 
buffers in terms of OD.  However, in Test 3.5.3.2 the assay also seems to be working to 
a certain extent with old buffers that were stored at 4oC.  The filtrate OD for the sample 
and control for (ii) were in line with Appendix K.  This seemed to suggest the assay was 
working from these initial results, but the problem of stained flow cells was still an 
issue.  The Perspex flow cells also had a very distinct purple staining.  As a result the 
flow cells were washed in 3M hydrochloric acid (HCl) to remove non-specific binding.  
The non-specific binding meant the current wash procedure (overnight soak in 1M HCl) 
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was not effectively cleaning the bound antibodies and may be interfering with the 
results by increasing the control filtrate OD and causing a decrease in the sample OD. 
 
3.5.4 Wash Procedure Changes to Enhance Results 
3.5.4.1 Use of Harsher Acids in Wash 
The flow cells were soaked over night in the 3M HCl.  Table 3.5 shows a low control 
OD and a difference between the sample and control OD for both tests using 5µg/ml of 
lysozyme. The controls were reduced in optical density but were still slightly higher 
than expected (Appendix K).  The flow cells seemed to be adequately washed using the 
3M HCl as no flow cell staining took place.  But as the sample OD was very low when 
compared to Appendix K, this still did not provide the answer to the reduced sensitivity 
of the assay.   
 
Table 3.5 ELIFA Results, shows the OD and membrane discolouration of various 
concentrations of lysozyme in buffer for Test 3.5.4.1. 
LZ Conc. OD Membrane Staining (C, control; S, sample) 
0µg/ml 
5µg/ml 
0.576 
0.759 
0µg/ml 
5µg/ml 
0.506 
0.753 
All C N/S 
All S N/S 
 
3.5.4.2 Use of Detergent 
The flow cells were then washed in Ariel biological hand wash liquid (1 cap/10litres).  
The Ariel contained proteases which degrade proteins that might have adhered to the 
flow cells causing the staining of the Perspex and the NSB.  The results from this test 
are promising as the control is very low at 0.275 OD showing no unwanted binding.  
The sample also yielded a promising result in line with those expected (Appendix K).  
The limitation of this cleaning method was the time taken.  The flow cells were washed 
in the Ariel for 24 hours before used.  This meant that the assay took around 26 hours to 
complete one sample.   
The buffers made in Test 3.5.3 were used for Tests 3.5.3 and 3.5.4.  Test 3.5.3.1 (Buffer 
Contamination) results suggested that making the buffers fresh before running the assay 
would produce results in line with Appendix K.  However, Test 3.5.4.2 (Use of 
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Detergent) results show that this is not required.  Reusing refrigerated buffers also 
produced good results and shows that it was not an interfering factor. 
 
Table 3.6 ELIFA Results, shows the OD and membrane discolouration of various 
concentrations of lysozyme in buffer for Test 3.5.4.2. 
LZ Conc. OD Membrane Staining (C, control; S, sample) 
0µg/ml 
5µg/ml 
0.275 
1.210 
All C N/S 
All S N/S 
 
3.5.4.3 Reduction of Arial Wash 
Section 3.5.4.2 (Use of Detergent) produced promising results, however the flow cell 
wash time needed to be reduced to speed up the assay.  One hours soak in the Ariel was 
tried in Section 3.5.4.3.  The tubing was also changed in this test as it appeared 
restricted due to the clamps holding it in place in the pump channels.  The tubing 
needed changing quite often in this assay, as restriction meant the assay would run 
much slower than was intended making the conditions variable between assays.  The 
results in Test 3.5.4.3 show that the Ariel is removing the proteins adhered to the flow 
cells however not to the extent that a 24 hour soak, as the OD of the controls increased, 
ranging from 0.921-2.406; far higher than Appendix K.  The lysozyme samples showed 
no pattern either, as they did not increase with increasing lysozyme concentration.  The 
5µg/ml dilution was repeated twice with the OD from the second 5µg/ml being almost 
double the OD from the first dilution.  This clearly shows that non-specific binding was 
taking place as the lysozyme from the first dilution was still present when the second 
dilution was measured.  This test shows that the flow cells need washing between 
lysozyme measurements.    
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Table 3.7 ELIFA Results, shows the OD and membrane discolouration of various 
concentrations of lysozyme in buffer for Test 3.5.4.3. 
LZ Conc. OD Membrane Staining (C, control; S, sample) 
0µg/ml 
5µg/ml 
1.076 
1.754 
0µg/ml 
5µg/ml 
2.323 
3.312 
0µg/ml 
10µg/ml 
0.921 
3.211 
0µg/ml 
15µg/ml 
2.406 
2.625 
All C N/S 
All S N/S 
 
3.5.4.4 Increased Rinsing of Flow Cells 
This next test consisted of two injections of 15µg/ml lysozyme.  The control OD for 
both was very high and the samples OD were also higher than expected. The same 
conditions as used in Section 3.5.4.3 (Reduction of Arial Wash) were applied.  The 
results show the 1 hour of Ariel (1 cap/10litres) did not clean the flow cells well 
enough, resulting in poor reproducibility.  The flow cells were not visibly dirty so the 
cleanliness of them when used in this assay was unknown.  As a consequence of the 
results in Section 3.5.4.2 (Use of Detergent), 4 flow cells were left in Ariel overnight, 
and rinsed for half an hour before use in 3.5.4.4.  As the same dilutions were used with 
these flow cells, the assay results do show a degree of consistency, but the cleaning 
procedure was either not washing the flow cells adequately or was not being rinsed 
adequately and was masking the actual binding of the antibodies.   
 
The controls for both 15µg/ml were far higher than expected from Appendix K.  As the 
controls were high the true optical density of both 15µg/ml dilutions was again being 
masked by the non-specific binding either to the flow cells or the tubing.  Again, no 
staining on the membrane was seen. 
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Table 3.8 ELIFA Results, shows the OD and membrane discolouration of various 
concentrations of lysozyme in buffer for Test 3.5.4.4. 
LZ Conc. OD Membrane Staining (C, control; S, sample) 
0µg/ml 
15µg/ml 
1.711 
2.938 
0µg/ml 
15µg/ml 
1.153 
2.757 
All C N/S 
All S N/S 
 
3.5.5 Combination Cleaning of Flow Cell 
3.5.5.1 1M HCl & 3M HCl 
The experiment in Section 3.5.5.1 was carried out to study the effect of a combination 
of an overnight soak in 1M HCl and a wash with 3M HCl.  It is clear from all other tests 
that the use of either Ariel on its own or HCl on its own was not sufficient for cleaning 
the flow cells.  Therefore, initially two applications of HCl were used.  The flow cells 
were simply soaked in 3M HCl for 30 minutes prior to the experiment along with the 
1M HCl overnight soak.  The results show that the HCl alone did not remove the bound 
proteins adequately as the control OD was extremely high, suggesting that the HCl 
treatment was not sufficient for removing the bound proteins. 
 
Table 3.9 ELIFA Results, shows the OD and membrane discolouration of various 
concentrations of lysozyme in buffer for Test 3.5.5.1. 
LZ Conc. OD Membrane Staining (C, control; S, sample) 
0µg/ml 
5µg/ml 
2.177 
1.989 
All C N/S 
All S N/S 
 
3.5.5.2 1M & 5M HCl & Ariel 
The flow cells were flushed with 5M HCl, soaked overnight in 1M HCl, soaked for 10 
minutes in Ariel, and then thoroughly rinsed under running boiling water for 5 minutes.  
This combined effort was due to the results from Sections 3.5.4.2 (Use of Detergent) 
and 3.5.5.1 (1M HCl & 3M HCl) showing more vigorous treatments were needed to 
clean the flow cells of protein binding.  The results still show high OD for the control 
sample at 1.169 and 2.791.  Again no staining was seen on any of the membranes. 
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In this test, consideration was also given to the solutions used.  All buffers were remade 
and stored at 4oC and then incubated at room temperature before the experiment began.  
The control filtrate OD’s were still high, therefore the test was still not delivering the 
required performance.  The experiment shows that even raising the concentration and 
duration of the soak in hydrochloric acid and washing with Ariel was not effective at 
removing bound protein.  This was indicated again by the high control OD and the true 
sample OD being masked by the presence of the bound protein.  
 
Table 3.10 ELIFA Results, shows the OD and membrane discolouration of various 
concentrations of lysozyme in buffer for Test 3.5.5.2. 
LZ Conc. OD Membrane Staining (C, control; S, sample) 
0µg/ml 
15µg/ml 
1.169 
1.838 
0µg/ml 
15µg/ml 
2.791 
> 3.5 
All C N/S 
All S N/S 
 
 
3.5.5.3 Ariel, 1M HCl & 5M HCl Flush 
In this next test an hour long soak in Ariel was followed by a 30 minute rinse.  In 
addition to the overnight soak in 1M HCl a flush with 5M HCl was tried.  In this test 
two sets of flow cells (total=4) were washed using the above method and only used once 
for each assay.  The first test results (i) showed the flow cells were being cleaned by the 
Ariel as the control OD was low and the 15µg/ml was low but close to the expected 
value (Appendix K).  However, the second set of results (ii) do not follow this pattern as 
the control OD was far too high at >3.5.  The 5µg/ml of (ii) was also far too high when 
compared to the expected results of Appendix K.  As both sets of flow cells were 
washed using the same protocol, the same concentration of Ariel and hydrochloric acid 
at the same time, this was not anticipated.  No discolouration was seen on any of the 
membranes. 
 
As half the flow cells showed some elements of a working assay, it was concluded that 
the flow cells work better with a longer soak in the Ariel, as the control was reduced. 
This was also seen in Section 3.5.4.2 (Use of Detergent).   
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Table 3.11 ELIFA Results, shows the OD and membrane discolouration of various 
concentrations of lysozyme in buffer for Test 3.5.5.3. 
LZ Conc. OD Membrane Staining (C, control; S, sample) 
(i)0µg/ml 
(i)15µg/ml 
0.746 
1.949 
(ii)0µg/ml 
(ii)5µg/ml 
> 3.5 
3.260 
All C N/S 
All S N/S 
 
3.6 Calibration Curve Results 
Figures 3.3-6 show the attempts at calibration curves using the current method. 
 
3.6.1 Four-Channel Peristaltic Pump 
At this point a new 4 channel peristaltic pump was trialled, the Spectec Perimax 12.  
This pump was able to process three samples and a control per run. The flow cells 
(total=12) were soaked for two hours in the Ariel and rinsed under boiling running 
water for 30 minutes, in addition to a 5M HCl flush and 1M HCl overnight soak.   
 
In the first trial of this pump (i), the control reading reduced to an expected level which 
looked promising.  However, as (ii) and (iii) show the controls were not all as low as the 
control in (i).  Even though all flow cells were washed using the same protocol at the 
same time it did not produce the same effect across all flow cells.  The lysozyme 
dilutions did not correlate with the actual amount of lysozyme present either.  The 
membrane discoloured was also random, with heavily stained membranes for all control 
and sample membranes. 
 
The flow cell construction was unique in its delivery of the receptor and analyte in that 
it does not mix the different dilutions.  Therefore the only conclusion as to why the 
lysozyme concentrations did not result in high lysozyme concentrations producing high 
membrane staining and high OD, and alternatively low lysozyme concentrations 
producing low level membrane staining and low OD, is that the lysozyme was not 
depositing on the membrane effectively, causing less antibodies to bind and subsequent 
low levels of staining on the membrane in the filtrate. 
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Figure 3.3 ELIFA Results, shows the OD and membrane discolouration of various 
concentrations of lysozyme in buffer for Test 3.6.1. 
 
3.6.2 Lysozyme Reactivity 
The flow cells were soaked overnight in 5M HCl, soaked in Ariel for 1 hour and rinsed 
thoroughly.  Due to situations beyond control, the laboratory temperature dropped to 
16ºC.  The lab temperature may have affected the reactivity of the lysozyme with the 
antibodies, but as the control contained no lysozyme, low control OD’s were expected.  
Again the problem of cleaning the flow cells from protein build up from previous 
experiments was an obvious problem.  The control OD’s were still high at ranging from 
1.102-1.286.   
The laboratory temperature may have affected the lysozyme reactivity as all lysozyme 
concentrations were less than 2.0OD, (with the exception of (iii) 10µg/ml).  However, 
the issue of cleaning the flow cells was more significant, to the long term prospects of 
the assay.  
 
Again all flow cells were washed for the same duration, in the same concentration of 
Ariel and HCl and in the same bucket.  All buffers and antibody solutions were made up 
fresh on the day therefore, as all variables were kept constant, the results should have 
tallied.   
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Figure 3.4 ELIFA Results, shows the OD and membrane discolouration of various 
concentrations of lysozyme in buffer for Test 3.6.2. 
 
3.6.3 Manual Cleaning of Flow Cells 
The laboratory temperature remained 16ºC for this experiment also.  The flow cells here 
were physically scrubbed with Ariel and cotton wool buds and then soaked in Ariel for 
1 hour.  They were rinsed for 30 minutes and then dried ready for use. The results 
showed a small difference in the control and sample OD as with the test in Section 
3.6.2.  However, the control OD was still high compared to Section 3.5.4.2 (Use of 
Detergent) and Appendix K.  The laboratory temperature may have been affecting the 
reactivity of the lysozyme and antibodies as suggested in Section 3.6.2 (Lysozyme 
Reactivity).  Nonetheless, the cleanliness of the flow cells was clearly a major problem. 
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Figure 3.5 ELIFA Results, shows the OD and membrane discolouration of various 
concentrations of lysozyme in buffer for Test 3.6.3. 
 
3.6.4 Run Through of Complete Experiment 
The equipment was transferred to a 20ºC environment and the experiment was 
conducted twice, to eliminate the allegation that the lowering of the temperature was 
affecting the reactivity of the lysozyme.  The same wash protocol for the flow cells was 
used for this test as used in Section 3.6.3. i.e. physically scrubbed with Ariel and cotton 
wool buds and soaked in Ariel for 1 hour. A difference in OD between the control and 
the lysozyme dilutions is seen in part (i) of this experiment.  The control OD in (i) was 
much lower than previous Tests and a distinct difference was seen between the OD of 
the control and samples.  However, when repeated with the second set of flow cells, the 
results in part (ii) did not show a difference in control OD and did not suggest specific 
antibody binding was taking place.   
 
The flow cells used in part (i) were the same as those used for part (ii).  Those used in 
part (i) were simply washed using the protocol outlined above i.e. physically scrubbed 
with Ariel and cotton wool buds and soaked in Ariel for 1 hour.  When part (i) was 
finished the flow cells were washed as above and reused for part (ii).  As this was the 
same protocol the results in (ii) should have been similar to those obtained in part (i). 
 
Yet again, the only variable was the new wash protocol.  It appears that the bound 
proteins were not being cleared from the Perspex flow cells and each assay was building 
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up a coating of protein that was not removed by the cleaning procedures.  Therefore the 
non-specific protein binding in (i) was not removed during the wash procedure and 
remained for part (ii), which is why the OD for the control and samples in part (ii) are 
almost double those seen in part (i).  A different method for cleaning the flow cells is 
needed to ensure the flow cells are free from bound proteins for each new assay carried 
out.  
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Figure 3.6 ELIFA Results, shows the OD and membrane discolouration of various 
concentrations of lysozyme in buffer for Test 3.6.4. 
 
3.6.5 Validation Test using ELISA  
To test the reactivity of the chemicals, antibodies and the lysozyme being used in these 
experiments an ELISA was carried out.  The results from this (Figure 3.7) show that all 
chemical reagents were working sufficiently.   
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Figure 3.7 Validations ELISA for ELIFA Comparison 
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3.7 Discussion  
This section discusses the results in 3.5. 
 
3.7.1 ELIFA Comparison with ELISA 
Section 3.5 details the ELIFA method optimisation that was undertaken.  The basic 
ELIFA protocol was derived from the lysozyme ELISA.  Both the ELISA and ELIFA 
are indirect immunoassays wherein the antigen (lysozyme from a biological sample) is 
bound to a solid surface, either the bottom of a micro-titre plate or a membrane, and 
then bound to primary and secondary antibodies before reacting with a substrate to 
produce a colour reaction.  The expected advantage of using the ELIFA was to improve 
the sensitivity of the assay by using the membrane to trap and immobilise all available 
lysozyme antigens from the sample.  This would potentially produce the maximum 
response.  A further objective with the ELIFA was to reduce the total time of the assay.  
The ELISA time was 96 minutes, which rivals other commercially available lysozyme 
ELISA’s, but it was felt there was room for improvement.  With the elimination of the 
incubation periods, the ELIFA ran much faster than the ELISA, with an assay time of 
less than 40 minutes. 
 
3.7.2 ELIFA Results 
The ELIFA results are very limited due to problems with the optimisation.  Principally 
because of non-specific binding (NSB), it was not possible to obtain a calibration curve 
of lysozyme concentrations in buffer or in serum.  The possible nature of this problem 
and solutions will be discussed later in this chapter. 
 
3.7.3 Analysis of Advantages of ELIFA 
The ELIFA was designed to eliminate the disadvantages of the ELISA test.  The total 
ELISA assay time was 96 minutes whereas the ELIFA took 40 minutes due to the short 
incubation times at room temperature.  This was a great improvement on the ELISA 
time.  However, it is hard to comment on the actual antigen-antibody binding produced 
with the ELIFA, LOD and sensitivity.  The problem of NSB concealed the binding 
events to an extent that it is not known whether the lysozyme in the sample would have 
bound and produced good results for this system. 
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The ELIFA is also fast because of the limited wash steps in the protocol.  Most steps in 
the ELIFA do not incur a wash phase as any unbound analyte passes through the 
membrane into the waste chamber.  However fast, the ELIFA could not compete with 
the amount of samples the ELISA could process in one 96 minute run.  A total of 40 
samples (2 replicates of each), 8 control and 8 standards could be carried out in an 
ELISA experiment compared to the ELIFA which was only capable of processing 3 
samples plus one control per run with no replicates. 
 
Another potential advantage of the ELIFA was that all equipment used in the test was 
reusable.  The initial idea of the ELIFA was to cut costs by using equipment that could 
be washed and reused for subsequent tests.  The ELISA did not offer this as all 
materials used were single use only.  This was also true for all commercially available 
ELISA kits on the market.  The ELIFA did not fulfil this advantage as so many 
problems were faced with the actual wash procedure.  This meant that the ELIFA itself 
became a single use assay also.  However, if the NSB problem were to be tackled 
successfully, then after the initial cost of the flow cells the overall cost was around £5 
per sample. 
 
A further advantage is the total assay time for the ELIFA.  The assay time was reduced 
to 40minutes; from 96 minutes with the ELISA.  The preparation of this assay was very 
laborious and usually amounted to ~2 hours, which included the setting up of apparatus 
and the cleaning of the flow cells and far exceeded that of the ELISA.  Clean up time 
after the assay would also take as long as 24 hours due to the extent of non-specific 
binding on the flow cells.  The range of cleaning procedures employed is described in 
section 3.5.  This section shows that no matter what how long the flow cells were left in 
a variety of solutions for up to 24 hours they could not be cleaned effectively, which 
lead to the poor results.  Without a solution to the non-specific binding problem and an 
adequate reduction in preparation time the ELIFA system offers no improvement over 
the ELISA. 
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3.7.4 ELIFA Problem  
Section 3.5.4 shows how the flow cell problem was tackled by changing the wash 
procedure several times.  The flow cells were repeatedly washed with hydrochloric acid 
(1M & 5M) for up to 24 hours and also washed with a biological detergent Ariel for up 
to 2 hours as well as being physically scrubbed with cotton wool.   
 
Sections 3.5.5.3-3.6.2 describe several flow cells being washed simultaneously and then 
one set used immediately after washing while still wet and the other set(s) left to air dry 
until use.  According to Hayes et al. (1998) a phenomenon occurs during the drying of 
protein to solid surfaces.  This suggests that a flow cell which has not been dried will 
continue to elute protein from its surface and therefore at the end of the assay have less 
of a NSB build up.  Whereas a flow cell which is left to dry before use in the assay will 
have a dried layer of residual protein not removed by the wash phase and will therefore 
continue to bind NSB at a greater rate.  
 
The problem of non-specific binding of protein onto the Perspex flow cells was made 
worse with the harsh wash solutions.  The flow cells were used many times during the 
optimisation of the ELIFA and undertook several wash phases.  Overtime it appears the 
flow cell surface may have been degraded by the wash solutions and therefore 
encouraged further binding, which is why the results became progressively worse.   
 
3.7.5 ELIFA Problem Solving 
The poor results in sections 3.5 and 3.6 led to the conclusion that the cleaning method 
for the flow cells was actually degrading the Perspex and encouraging further protein 
binding.  A solution to this problem was to have the flow cell made using a different 
material, which would limit protein binding and withstand a wash phase that removed 
bound protein and did not degrade the surface.  Ideally the flow cells would be made of 
glass, but the cost of them to be commissioned was far too high.   
 
Another possible solution was to coat the loading chamber (Figure 3.8) with the 
membrane to eliminate all possible contact with the antigens/antibodies had with the 
Perspex.  If the membrane was custom made to be cone shaped it would prevent direct 
Chapter 3 77
contact with the Perspex and possibly reduce NSB.  The problem with this solution was 
again the cost of having the membrane cut to the exact shape.  An alternative was to 
make them in house, however the solution was not considered until after the solution, 
discussed in Chapter 4 was found. 
 
 
Figure 3.8 Flow cells with conical shaped membrane to prevent NSB to Perspex 
 
A further consideration came in the way of syringe filters (Fisher, UK) using the ELIFA 
protocol.  The syringe filters/ELIFA assay did have the advantage of being fast but the 
syringe filter membrane was pressure sealed inside the plastic filter and could not be 
retrieved.  This led to problems with recording the results as over time the stop solution 
(sulphuric acid) degraded the membrane within the filter casing.  This meant that the 
membrane could not be photographed as the purple discolouration from the antigen-
antibody binding was lost with the application of the stop solution.  Additionally, the 
syringe filter membranes were not encased in a clear colourless plastic.  The colour of 
the plastic casing of the syringe filters denoted the pore size of the membrane.  The 
membrane was already difficult to photograph due to the degradation from the stop 
solution but the coloured plastic filter also hampered photographing and interpreting of 
the membrane, as when wet the membrane took up some of the colour of the plastic.   
 
At this point the Mini-ELIFA (Chapter 4) filters were purchased and tried with the 
ELIFA protocol.  These filters had the potential advantage of being auto-clavable, so no 
cleaning between assays was required, they were extremely cheap to buy, no peristaltic 
pump would be required which would reduce running costs and eliminate the 
interference of restricted tubing and the membrane could be retrieved for documenting.   
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3.7.6 ELIFA Synopsis 
The principle behind the ELIFA suggests that this method has many advantages over 
the ELISA system.  The most significant advantage is the sensitivity.  The ELIFA 
system involves the concentration of ligand and analyte on the non-porous membrane 
surface.  This allows low concentrations of ligand to be measured accurately producing 
a sensitive assay.  However, as the assay was not successful the sensitivity could not be 
established.  If more time and money was expended to explore the potential of the 
ELIFA system then it may yield better results provided that the problems highlighted 
were addressed. 
 
The laboriousness of the ELIFA assay due to the problems with NSB did hinder the 
progress of the assay.  However, solutions to over come this problem and the successes 
that followed are documented in Chapter 4. 
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Chapter 4 -Mini-ELIFA 
 
4.1 Introduction  
The mini-ELIFA is an adaptation of the ELIFA method and is a further technique for 
the measurement of lysozyme.  This method was devised to capitalise on the positive 
aspects of the ELISA, such as the effective binding of the antigen & antibodies; and to 
eradicate some of the problems experienced with the ELIFA, such as the NSB and to 
improve on the assay time, LOD and ease of use.  One major problem with the ELIFA 
was non specific binding of protein to the Perspex flow cells.  This problem was tackled 
by exchanging the Perspex flow cells for Swinnex filters (Figure 4.1) which were auto-
clavable and were thought might eliminate the problem.  
 
Figure 4.1 Swinnex Syringe Filter; Consisting of an inlet and outlet which are screwed 
together securing a membrane disc. 
 
4.2 Filter Construction 
The Swinnex filter construction is much simpler and quicker than the ELIFA flow cells.  
A pre-cut disc of membrane is inserted along with the rubber washer into the female 
inlet (Figure 4.1).  The outlet and inlet are then screwed together and sat on to a 
universal collection tube.  Syringes (1ml & 5ml) connected via the inlet, were used to 
inject the analyte samples, antibodies, wash solution and substrate through the 
membrane.  Discolouration on the membrane was directly proportional to the amount of 
analyte in the sample.   
 
4.3 Preliminary Experiments -Bacteria 
Initially the mini-ELIFA was tried with bacterial samples.  This was to broaden the 
focus of sepsis diagnosis.  Instead of measuring a chemical secreted in response to 
infection, such as lysozyme, this test would measure the actual presence of the bacteria 
Male (Outlet) Female (Inlet)
Washer Membrane 
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causing the sepsis.  Escherichia coli (E. coli) was chosen due to its prevalence in 
urinary tract infections.  Once established with bacteria, the mini-ELIFA would then be 
tried with lysozyme samples. 
 
4.3.1 Urinary Tract Infections (UTI) 
Eighty percent of all UTI are caused by E. coli due to its abundance in faecal flora.  
Other bacteria which cause UTI’s include Proteus mirabilis, Pseudomonas aeruginosa 
and Streptococcus faecalis (Andrews et al., 2002).  When a patient complains of urinary 
tract infection symptoms (frequent micturition, painful voiding and haematuria) a mid 
stream urine sample is taken and a urine analysis dipstick for nitrites is used.  Gram 
negative bacteria reduce dietary nitrate into nitrite of which the dipstick detects.  
However, they are known to produce false positives and do not detect Gram positive 
bacterial strains (Kumar & Clark, 1990). 
   
Urinary microscopy is the usual follow up test along with bacterial cultures of the urine 
sample and sensitivity testing for the appropriate antibiotics.  These follow up tests 
however, take up to 2 days, by which time the infection is established and the patient is 
undergoing treatment with non-specific antibiotics.  The aim with the mini-ELIFA is to 
produce a fast, easy to use bedside test which identifies the causative bacteria so 
immediate use of specific antibiotics can be used for treatment. 
 
4.4 Potential Advantages of Mini-ELIFA 
The remit of the mini-ELIFA was to improve sensitivity, reduce assay time so results 
could be obtained at the patient’s bedside and produce a test which was easier to use.  
The mini-ELIFA is built on the same basic principle as the ELIFA, in that the analyte in 
the sample and antibodies are forced to bind on to the surface of the membrane because 
the diffusion rate is limited by the suction through the membrane.  This has the potential 
advantage of utilising all available analyte producing a highly sensitive assay. 
A further potential advantage is the speed of the assay.  The mini-ELIFA does not use a 
peristaltic pump to produce suction through the membrane.  Instead syringes are used to 
drive the reagents through the membrane.  The basic principle and effects are the same 
as when the peristaltic pump was used with the ELIFA, but the assay time is shorter. 
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The main problem with the ELIFA was the NSB on to the Perspex flow cell.  The mini-
ELIFA do not require any pre-treatment prior to autoclaving, therefore this should 
produce reusable filters for this assay. 
 
4.5 Applications 
A second ELIFA system was proposed by Nogrady et al. (1998) for the measurement of 
Bacillus macerans.  The concentration was estimated using an “enzyme-linked 
immunofilter assay”.  The total assay took <1 hour to complete.  Thiele et al., (1992) 
also used the basic principle of ELIFA for their assay for monoclonal capture and 
biotinylated monoclonal detection of Coxiella (C.) burnetii.  Their assay was quoted as 
being fast and highly sensitive with a minimum dose of 2500 C. burnetii particles. 
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4.6 Materials & Methods -Mini-ELIFA 
4.6.1 Bacteria Mini-ELIFA 
The wash buffer with Tween and casein (WBTC), washing step solution, antibodies, 
TMB and sulphuric acid were all made to the same concentration as those used in the 
ELIFA method outlined Appendix G.  
 
The membranes used in the mini-ELIFA were not the Hybond N membrane used in the 
ELIFA.  This is because a pre-cut membrane specially designed for the Swinnex filters 
could be purchased.  This eliminated the potential problem of compressing the 
membrane during the cutting procedure, which could result in a membrane with fewer 
pores. 
 
4.6.1.1 Bacteria Preparation 
Liquid broth and agar were made as stated in Appendix G.  All agar and liquid broth 
were autoclaved before use.  Concentrations of the E. coli JM83 K12 solution were 
prepared.  These included neat, (8.04x108 cells/ml) 1/100, 1/1000 and a control (no E. coli). 
 
4.6.1.2 Filter Construction & Analyte Immobilisation 
Syringe disc filters (0.45µm) from Fisher, (Leicester, UK) were purchased to filter the 
E.coli.  Swinnex filter holders by Millipore (UK) along with Supor membrane, 0.45µm, 
13mm diameter was purchased from Pall, (Hampshire, UK).  Both 2ml and 5ml BD 
Plastipak syringes were used along with 0.8mm x 16mm lancets from Fisher.  The 
syringe disc filters were placed over a 10ml universal tube to collect the filtrate.  
Aliquots (0.5ml) of each dilution of E. coli was passed through the syringe disc filter 
using a 50ml syringe.  A fresh syringe was used for each suspension. 
 
4.6.1.3 Antibody Application 
The step above was followed by 0.2ml primary antibody (1:6000 in WBTC), 0.2ml 
secondary antibody (1:4000 in WBCT) and then a 0.6ml washing step solution.  Anti-
E.coli antibodies (primary) were purchased from Dako B0357 (Cambridge, UK), along 
with a secondary antibody E. coli HRP P0361 (Dako).   
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The filter holder with membrane, was then removed from the universal (Solution 1) and 
a fresh universal was placed underneath the filter (Solution 2). 
 
4.6.1.4 Substrate Application & Quantification of Results 
TMB was pumped through the filter (150µl) and allowed to react for 6 minutes.  The 
reaction was stopped by passing 50µl sulphuric acid (1M) through the filter.  The 
Optical Density (OD) of the solution collected in the universal was measured at 450nm 
and a digital photograph taken of the filters. 
 
4.6.2 Lysozyme Mini-ELIFA 
The WBTC, washing step solution, antibodies, TMB concentrate and sulphuric acid 
were all made to the same concentration as those used in the ELIFA method outlined in 
Appendix G.  The basic method in the lysozyme mini-ELIFA is the same as the ELIFA 
method. 
 
4.6.2.1 Filter Construction 
Swinnex filter holders by Millipore (UK) along with Supor membrane, 0.45µm, 13mm 
diameter was purchased from Pall, (Hampshire, UK).  Both 1ml and 5ml BD Plastipak 
syringes (Fisher) were used.  The Swinnex syringe filters were fitted together by 
inserting a rubber washer and disc of Supor membrane inside the male outlet.  The 
female inlet was then screwed tightly.  The filter was placed over a 15ml universal tube 
to collect the filtrate.   
 
4.6.2.2 Lysozyme Coating 
Purified Lysozyme (Sigma-Aldrich Ltd, UK) from human milk was dissolved in 
Coating buffer (Appendix G).  The lysozyme was stored at -20°C.  0.5ml of each 
Lysozyme dilution (0.01-75µg/ml) was passed through the syringe disc filter using a 
1ml syringe.  A fresh syringe was used for each dilution. 
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4.6.2.3 Antibody Application 
The DAKO Antibodies (Ely, Cambridge, UK) used were rabbit anti-human lysozyme 
immunoglobulin 7.1mg/ml (Primary) and horseradish peroxidase (HRP) conjugated 
goat anti-rabbit immunoglobulin 0.3mg/ml. Both antibodies were diluted in WBTC, to 
1:6000 and 1:4000 for the primary and secondary respectively. 
 
The lysozyme coating was followed immediately by 0.2ml primary antibody (1:6000 in 
WBTC), 0.2ml secondary antibody (1:4000 in WBTC), and then 0.6ml washing 
solution.  The filter holder with membrane, was then removed from the universal 
(Solution 1) and a fresh universal was placed underneath the filter (Solution 2). 
 
4.6.2.4 Colour Reaction 
Undiluted TMB was pushed through the filter (150µl) and allowed to react for 6 
minutes.  The reaction was stopped by passing 50µl 1M sulphuric acid through the 
filter.  The Optical Density of Solution 2, collected in the universal was measured at 
450nm and a digital photograph taken of the upper side of the filters. 
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4.7 Bacteria Mini-ELIFA Results 
The results below (Plate 4.1) show photographs of the membranes used in the bacteria 
Mini-ELIFA.  A photograph of the membrane and the optical density (OD) of the 
filtrate was the method chosen for documenting the results from these experiments. 
 
Plate 4.1 Bacteria Mini ELIFA Raw results, Plate 4.1 show the membrane 
discolouration and optical density of filtrate for several bacteria samples and control 
(distilled water, (DW)).  The concentration for each E. coli sample is shown above each 
membrane and the OD for each sample is shown underneath each membrane. 
Plate 4.1 Photographs of Membrane 
 
 
 
 
 
 
 
 
 
 
OD 
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4.7.1 Membrane Descriptions from Plate 4.1 & Optical Density of Filtrate 
Table 4.1 below shows the optical densities of all filtrates and describes the membrane 
staining for all E. coli dilutions. 
 
Table 4.1 Optical Density of E. coli Filtrates & Descriptions of Membranes 
Conc. of 
Bacteria 
Control 
OD 
Sample 
OD 
Description 
Neat 1.472 0.801 The Neat (8.04x108cells/ml) bacteria sample showed 
considerable binding on the membrane.  A small 
amount of discolouration is seen on the control 
membrane as highlighted.  The OD of the filtrates 
showed a higher reading for the control than the 
sample. 
1/2 2.428 1.723 The ½ dilution shows considerable binding and 
discolouration across the entire membrane.  No 
binding can be seen on the control.  The control 
filtrate had a higher OD compared to the sample. 
1/3 3.123 1.655 The 1/3 again showed considerable binding across the 
entire membrane.  When comparing membrane ½ 
with 1/3, there is a distinct difference in the staining, 
with the higher dilution producing a darker stain.  
The OD of the control was greater than the sample. 
1/4 1.346 1.800 The binding of the 1/4 sample membrane is less 
discoloured than ½ and 1/3 but is distinct from the 
control.  The control membrane had a small amount 
of binding which is highlighted.  The control OD was 
lower than the sample. 
1/5 2.071 2.310 Discolouration is present on the sample 1/5 membrane 
but is less distinct when compared to higher dilutions 
(½ and 1/3).  A small amount of binding is present on 
the control membrane as highlighted above.  The 
sample OD was greater than the control OD. 
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1/6 1.808 1.730 Heavy discolouration is present on 1/6 membrane.  
The control membrane has a small amount of binding 
present as highlighted.  The OD of the control was 
lower for the control compared to the sample. 
1/7 2.805 1.559 Discolouration across the entire membrane is seen on 
1/7.  A small amount of discolouration is seen on the 
control membrane as highlighted above.  The control 
OD of the filtrate was far greater than the sample. 
1/8 2.317 2.652 A distinctly paler discolouration is seen on the 1/8 
membrane, when compared to 1/7. The control filtrate 
OD was less than the sample OD. 
1/9 2.658 2.010 Discolouration was seen on the 1/9 membrane.  When 
compared to 1/8, 1/9 was actually darker in colour.  
The control filtrate OD was far greater than the 
sample. 
1/10 2.082 1.622 Discolouration was seen across the entire membrane 
of 1/10, and was to a less extent when compared to 1/8 
and 1/9.  The control membrane did have some 
binding present as highlighted above.  The control 
filtrate OD was far greater than the sample.  
 
4.8 Bacteria Mini-ELIFA Analysis 
4.8.1 Optical Density of E. coli Filtrates 
Solution 2, collected during the TMB administration, was used to measure the optical 
density (Table 4.1).  The control OD should have been greater than the OD of the 
sample.  A probable reason why this was not so may have been that the bacteria and 
antibodies were trapped on the surface of the membrane, causing the membrane 
discolouration.  The sample filtrate did not contain these bound bacteria and antibodies 
and so did not produce a distinguishable colour change compared to the control filtrates.  
The control filtrate OD was high in most cases because there was residual binding of the 
antibodies and TMB taking place.  With the majority of concentrations the OD was 
greater for the control compared to the sample.  This shows that the membrane was 
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doing its job and trapping all bacteria present in the sample; allowing ample binding of 
the 2 antibodies and TMB. 
 
It was also expected that a calibration curve of filtrate optical densities could be 
produced from the control results, showing an increase in OD with increasing 
concentration of bacteria.  However, the results did not show this pattern.  No 
correlation between filtrate OD and concentration was present. 
 
4.8.2 Membrane Staining 
The stained membranes are a more reliable indication of bacterial presence compared to 
the OD of the filtrate.  The discolouration of the membranes (Plate 4.1) was caused by 
the entrapment of bacteria on the surface of the membrane.  This would then react with 
the primary and secondary antibodies and also the TMB, causing the purple staining.  
There was very little binding on the control membranes.  This meant a clear distinction 
between the sample and control could be made.  The darkness of the staining increased 
with increasing E. coli concentration.  All distinctions could be made with the naked 
eye in a matter of seconds, making assay analysis relatively effortless for the interpreter. 
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4.9 Lysozyme Mini-ELIFA Results 
The results below (Plate 4.2) show photographs of the membranes used in the lysozyme 
Mini-ELIFA.  A photograph of the membrane and the optical density (OD) of the 
filtrate was the method chosen for documenting the results from these experiments. 
 
Plate 4.2 Lysozyme Mini-ELIFA raw results; OD of filtrates is shown. 
Plate 4.2 Photographs of Stained Membrane & Descriptions 
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4.9.1 Membrane Descriptions from Plate 4.2 
The table below describes all the membranes used in the Mini-ELIFA, and lists the OD. 
 
Table 4.2 Lysozyme Membrane Descriptions & OD for the Mini-ELIFA 
Lysozyme 
Conc. 
Control 
OD 
Sample 
OD 
Membrane Description 
0.01µg/ml 0.434 0.408 The sample and control membrane show no 
discolouration, and very little difference between the 
OD of the filtrate for 0.1µg/ml.   
0.02µg/ml 0391 0.375 The sample and control membrane show no 
discolouration, and very little difference between the 
OD of the filtrate for 0.2µg/ml.   
0.03µg/ml 0.899 0.590 The sample membrane shows a small area of 
discolouration.  The discolouration is highlighted on 
the membrane but is very faint in appearance.  No 
discolouration was seen on the control and the 
control filtrate OD was greater than the sample. 
0.04µg/ml 0.785 0.378 A small amount of discolouration is seen on the 
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0.04µg/ml sample membrane, which is highlighted 
above.  The control filtrate OD was greater than the 
sample. 
0.05µg/ml 0.558 1.040 A small amount of binding is seen on the sample 
membrane and is darker in colour to the staining on 
0.04µg/ml.  The sample filtrate OD was far greater 
than the control. 
0.1µg/ml 0.440 0.236 No discolouration was seen on either membrane, and 
both filtrate OD’s were particularly low. 
0.15µg/ml 0.730 0.500 No discolouration was seen on either of the 
membranes.  The control filtrate OD was much 
greater than the sample. 
0.2µg/ml 0.489 0.409 A small amount of discolouration was seen on the 
sample membrane as highlighted above.  No 
discolouration was seen on the control membrane.  
The control filtrate OD was greater than the sample 
filtrate. 
0.25µg/ml 0.724 0.720 A small amount of binding was seen on the sample 
membrane, as highlighted above, to a greater extent 
compared to any other LZ dilution.  The control 
filtrate OD was slightly higher than the sample. 
0.3µg/ml 0.208(i) 0.443 A small amount of binding was seen on the sample 
membrane.  The sample filtrate OD was greater than 
the control. 
0.5µg/ml 0.208(i) 0.317 No discolouration of the sample membrane above 
was seen.  The control membrane (Plate 4.22) also 
showed no discolouration but had a lower filtrate OD 
than the sample. 
0.6µg/ml 0.208(i) 0.712 No discoloration was seen on the sample membrane 
above.  The control (Plate 4.22) had a much lower 
filtrate OD compared to the sample. 
0.7µg/ml 0.229(ii) 0.402 No discoloration was present on the sample and 
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control membranes.  The control filtrate OD was 
much lower than the sample. 
0.8µg/ml 0.229(ii) 0.414 Distinctive discolouration is present on the sample 
membrane, as highlighted above.  The control filtrate 
OD was much lower than the sample. 
0.9µg/ml 0.229(ii) 0.243 Discolouration is present on the sample membrane as 
highlighted above.  The discolouration is not as 
distinct as the 0.8µg/ml LZ dilution.  The control 
filtrate from Plate 4.25 had a very similar filtrate OD. 
1.0µg/ml 0.229(ii) 0.306 Distinct membrane discolouration is present on the 
sample membrane, to the same extent as Plate 4.26.  
The control OD from Plate 4.25 was less than the 
sample filtrate OD.   
2.0µg/ml 0.229(ii) 0.340 Discolouration was present on the sample membrane, 
but not to the same extent as Plate 4.26 and 4.28.  
The control filtrate OD was much less than the 
sample filtrate OD. 
3.0µg/ml 0.229(ii) 0.430 Discolouration was present on the sample membrane, 
but was very faint.  The filtrate OD from the sample 
was much greater than the control. 
4.0µg/ml 0.229(ii) 0.101 Discolouration was present on the sample membrane, 
but was very faint.  The filtrate from the sample had 
an OD less than any others seen, and was much 
lower than the control. 
5.0µg/ml 0.229(ii) 0.527 Binding was clearly present on the final sample 
membrane.  But again was very faint compared to 
Plates 4.26 and 4.28.The control filtrate OD was 
much less than the sample filtrate OD. 
*Samples 0.3-0.6µg/ml used the same control indicated (i). 
Samples 0.7-5.0µg/ml used the same control indicated (ii). 
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4.10 Lysozyme Mini-ELIFA Analysis 
4.10.1 Optical Density of Filtrate 
The membranes should have trapped the lysozyme-1oantibody-2oantibody-TMB 
complex causing a stain on the membrane.  The sample filtrates should not have 
contained this complex and should have had a lower optical density then the control.  
The control was expected to have the 1oantibody-2oantibody-TMB complex and with 
some residual binding taking place this would result in a higher OD compared to the 
sample.   
 
Samples from 0.01-0.25µg/ml, in the majority of cases, did have a control OD which 
was greater than the sample.  However, where the higher concentrations were tried the 
control was always (apart from 4.0µg/ml) lower than the sample OD.  The only 
reasonable conclusion from this half of the results (0.3-5.0µg/ml) was that the filtrate of 
the sample contained the lysozyme-1oantibody-2oantibody-TMB complex. 
 
The previous problem of non-specific binding to the Swinnex filters did not seem tore-
occur.  The filters were autoclaved as per the instructions from the manufacturers, no 
harsh acids, nor biological washing liquids were used, so the integrity of the plastic 
filters was never in question.  This washing procedure was also used with the bacterial 
mini-ELIFA, with success.  The dilutions of the antibodies and the lysozyme were the 
same as those in the ELIFA.  Therefore the antibodies should have reacted with the 
lysozyme.  The sensitivity issue therefore leads to the conclusion that the lysozyme was 
not successfully trapped by the membrane, or was trapped and rendered un-reactive in 
some way, leading to a lack of binding.  
 
4.10.2 Membrane Staining 
The membranes above (Plate 4.2) show very little actual bound lysozyme.  In 
comparison to the bacterial mini-ELIFA membranes this assay lacks sensitivity. The 
membranes did show a small amount of binding indicated by purple discolouration, but 
only from the higher lysozyme dilutions, >0.8µg/ml.  The membrane had a standard 
0.45µm pore size which is recommended for proteins greater than 10kDa.  Therefore 
this membrane should have effectively trapped the lysozyme without any problems. 
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This discolouration was seen more regularly on the higher lysozyme dilutions but the 
extent of the discolouration was not in correlation with the dilution itself.  This meant 
that when comparing a high dilution e.g. 3µg/ml with 0.3µg/ml there was binding in 
both cases, but no more binding was seen on one membrane compared to the other.  
This assay is therefore not capable of quantifying the amount of lysozyme in the 
sample. However, it may indicate that the washing procedure was too vigorous for the 
assay, as it was washing too much of the lysozyme away.  This situation could be 
improved if the membrane was seeded with a monoclonal antibody which would adhere 
to the lysozyme and hold it firmly to the membrane during the washing phase, as with a 
Non-Competitive Indirect ELISA (Figure 2.1).  This could produce an assay with a 
much clearer result and still have the advantage of a fast assay giving a yes/no answer. 
 
As it stands this assay is clearly not sensitive enough to give a definite positive or 
negative answer as to whether lysozyme is present in the sample, due to the faintness of 
the discolouration on the membranes.  All control membranes did not show any binding, 
but the reliability is always in question due to the absence of discolouration where 
lysozyme was present.  Even with some high lysozyme dilutions, (0.5-0.7µg/ml) 
discolouration was not seen. 
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4.11 Discussion  
This section discusses the results in Section 4.7 and 4.9. 
 
4.11.1 Bacteria Mini-ELIFA 
The bacteria mini-ELIFA was a very successful assay.  The remit for the mini-ELIFA 
was to produce an assay which could qualitatively reveal whether bacteria were present 
in a buffered sample.  The membrane discolouration was a clear and accurate 
representation of bacterial presence and in the majority of cases showed the amount of 
bacteria present; i.e. dark staining where there was a high concentration of bacteria and 
no staining for controls.  The membrane staining could also be read with the naked eye 
without training, making analysis of the results very fast. 
 
An assay that is very similar to the bacteria mini-ELIFA is reported by Paffard et al. 
(1997).  Their assay for whole bacterial cells uses an antibody bound bacteria, trapped 
by an immunofilter, and detected by a secondary antibody and third enzyme-conjugated 
antibody in a chemiluminescent assay.  This assay took under 55 minutes and values 
were determined using the reflectance of developed x-ray films placed over 
chemiluminescent membranes.  This method of quantifying results may be a technique 
that could be incorporated in future work on the mini-ELIFA to produce results showing 
actual amounts of bacteria in patient samples. 
 
A good method for measuring the reaction which was occurring on the surface of the 
membrane, (between the bacteria and antibodies) would have been to take an OD 
measurement of this fluid.  A method to test the residual fluid on the surface of the 
membrane was not discovered, simply because it was in such small volumes.  The 
“back flush” used in the ELIFA would have been the way to harness this solution and 
measure its OD, but again it was in such small volumes that not enough could be 
harnessed for even a diluted sample.  Whether the bacteria-1oantibody-2oantibody-TMB 
complex would have released from the membrane during this back-flushing would also 
have come into question; but could have been further investigated if more time was 
invested. 
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Even though the bacteria mini-ELIFA was a success it could not be used on its own for 
diagnosing sepsis.  Only 30-35% of septic patients present with positive bacterial 
cultures (Wheeler & Bernard, 1999).  Therefore, the place for this assay would be in 
conjunction with existing diagnostic procedures, i.e. signs and symptoms.  The assay 
maybe used in bacterial identification and quantification for UTI, for example in GP 
surgeries.  The benefit of using this assay would be its speed of execution.  In less than 
10 minutes the assay can be preformed from scratch giving a result at the patient’s bed 
side. 
 
4.11.2 Lysozyme Mini-ELIFA 
The lysozyme mini-ELIFA was not as successful as the bacteria mini-ELIFA.  Again 
the remit of these experiments was to devise an assay which was fast, cost effective and 
produced an assay which could be qualitatively assessed to reveal lysozyme content in a 
sample.  The assay was successful to a certain extent, but it lacked sensitivity.  Some 
membranes from Plate 4.2 do show some discolouration indicating lysozyme presence, 
but this was only clear for high lysozyme concentrations (0.2-5µgml) and even then 
they were not distinct discolorations.  The assay was also a success in that where 
discolorations did occur; no staining was seen on any of the control membranes.  An 
assay developed by Shields et al. (1991) also found that binding proteins to a nitro-
cellulous membrane in an ELIFA format resulted in a reduced sensitivity.  Their study 
concluded that conformational changes took place during adsorption to the membrane 
causing limited binding and consequently an assay lacking in sensitivity.  A possible 
method which could have been employed if more time was allowed would have been to 
use a capture antibody, seeded onto the surface of the membrane which actively 
captured the lysozyme from the sample.  This may have increased the sensitivity of the 
assay ensuring that all lysozyme from the sample was harvested and immobilised for 2o 
antibody binding. 
 
4.11.3 Advantages of Mini-ELIFA 
The mini-ELIFA was developed to eliminate the problems faced with the ELIFA work. 
The total time for the mini-ELIFA was ~9 minutes.  Preparation time only amounted to 
30 minutes as most of the equipment used was disposed of after use.  This is a far faster 
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assay compared to the ELIFA or the ELISA.  This assay fulfils the initial remit of the 
work; to produce a yes/no answer of whether bacteria or lysozyme is present in a 
biological sample in real time.   
 
The ELIFA was also limited to the amount of samples and controls that could be carried 
out due to the peristaltic pump only having 4 channels.  This meant that a maximum of 
3 samples and 1 control could be processed at any one time.  As the mini-ELIFA did not 
have the limitations of a pump, disposable syringes were used to drive the 
immunochemicals through the membrane; upwards of 11 samples and 1 control (due to 
the number of Swinnex filters purchased) could be processed per run. 
 
The ELIFA had the disadvantage of being single use only.  This was due to the 
problems encountered with the flow cells irremovable protein build up.  The solution to 
this problem was the Swinnex filters.  These have the advantage of being auto-clavable 
so protein could never build up and would never interfere with subsequent uses. 
 
As the filters were cleanable and the only disposable material was the membrane this 
assay was very economical to run.  After the initial costs of the filters the overall cost 
per sample was around £1.30.  This is a considerable difference when compared to the 
ELIFA’s cost. 
 
4.11.4 Mini-ELIFA Synopsis 
The bacteria and lysozyme mini-ELIFA has many advantages over the ELISA and 
ELIFA systems.  The mini-ELIFA is cheap to run, rapid, high throughput due to the 
speed of the assay and the results can be read with the naked eye and by an untrained 
operator.  These attributes are highly sort after in a kit which is to be used in a hospital 
situation, or in the case of the bacteria mini-ELIFA in the home or GP surgery situation 
to test for urinary tract infections. 
 
For future work, the assays both need to be tested with clinical samples and the issues 
with the lysozyme mini-ELIFA need to be addressed to produce a more sensitive test.  
Additional membrane comparisons are detailed in Appendix F. 
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Chapter 5 –Lysozyme Biosensor 
 
5.1 Introduction  
Immunosensors offer an alternative to currently existing immunoassays, as a method for 
measuring lysozyme.  Immunosensors are analytical devices incorporating a biological 
element that is either intimately associated with, or integrated within a physicochemical 
transducer (Homola et al., 1999).  They work on the same principles as an 
immunoassay, where the measurement is not necessarily of the analyte itself but of the 
analyte occupying a receptor.  There are 2 forms of immunosensors, the non-
competitive, and the competitive (covered in more detail in Section 2.2).  In the non-
competitive sensor an analyte signal is produced when binding sites are occupied.  
However, in the competitive immunosensor an analyte signal is produced when binding 
sites are unoccupied due to competition between signal producing molecules and the 
test analyte.  Immunosensors are compact versions of immunoassays which can offer 
greater ease of use.   
 
5.1.1 History of Surface Plasmon Resonance (SPR) 
The phenomenon of surface plasmon resonance was first described at the beginning of 
the 20th century.  But it was not until the late 1960’s that optical excitation of surface 
plasmons was demonstrated by Kretschmann (1968) using a method of attenuated total 
reflection.  In the late 1970’s, SPR was shown to be effective for the monitoring of 
processes on metal surfaces and thin films.  Nylander & Liedburg demonstrated its use 
for gas detection (Liedberg et al., 1983).  Otto, Kretschmann and Raether, Agerwal and 
Swalen brought understanding and showed the versatility of the techniques, 
(www.BIAcore.com).  The first SPR biosensor on the market was developed by the 
Swedish company, BIAcore AB, in 1990.  In later years this has been further defined in 
terms of speed, throughput and accuracy and followed by the introduction of a number 
of instruments by other companies. 
 
5.1.2 Surface Plasmon Resonance  
SPR has become a recognised optical method for the measurement of molecular 
interactions (Rich & Myska, 2000).  This technique gives researchers the chance to 
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explore protein function, identify binding partners as a target and also provides real time 
quantitative data of binding kinetics, affinity, specificity and the concentration of active 
molecules in a sample.  SPR monitors the interactions occurring on a bio specific 
surface, by measuring the changes in refractive index (RI) (Rich & Myska, 2000).  It 
quantifies changes in the solute concentration as a result of any interactions that take 
place.  SPR methods can be used to measure the interactions of proteins, 
oligonucleotides, oligosaccharides, lipids as well as phage, viral particles and cells 
(Rich & Myska, 2000). 
 
The main detection approaches commonly used with SPR include: 
 The measurement of the intensity of the optical wave near the resonance, 
(Liedburg et al., 1995). 
 The measurement of the resonant momentum of the optical wave inducing angle 
and wavelength interrogation of SPR, (Jorgensen & Yee, 1993). 
 
5.1.3 Principle  
SPR measures changes in the refractive index at the external surface of a metal film.  
An increased concentration of sample being passed across the surface causes an increase 
in refractive index and also a change in the refractive angle (Liedburg et al., 1995).  
Figure 5.1 shows this change in refractive index due to the change in surface chemistry. 
 
 
 
 
 
 
Figure 5.1 Changes in the Incident Light Angle.  Diagram shows the change in 
refractive index; when an analyte is passed across the sensor surface the RI changes 
from (1) to (2).  
 
An SPR instrument consists of an optical system, usually a prism; a transducing 
medium, which incorporated the optical system and the biochemical domains; an 
electronic system which supports the optoelectronic components of the sensor and 
processes the data, (Homola et al., 1999). 
1
2 
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Along with the refractive index, SPR also provides concentration, purity information 
and can identify the product.  Many of these techniques rely on the prior knowledge of 
the analytes critical angle for comparison; e.g. as antigens bind to antibodies on the 
metal surface the refractive index at the sensor surface will change and affect the SPR 
coupling conditions of the incident light entering the SP mode.  Increases in the protein 
concentration will create a refractive index change that is proportional to the mass 
loading; e.g. increases in protein by 1ng/mm2 causes a change in the refractive index of 
1x10-3RIU (Refractive Index Units) and an SPR coupling change of 0.10o.  With SPR 
the minimum detectable surface protein concentration is 50pg/mm2, (Earp & Dessy, 
1996). 
 
5.1.4 Optical Sensors 
5.1.4.1. Optical Phenomenon & Wave-Guides 
A wave-guide is a physical medium which light can be guided through.  When a beam 
of light of higher refractive index comes into contact with an interface of a lower 
refractive index, at an angle of incidence that is above a critical angle, the light is totally 
reflected and moves out into a high refractive index medium.  At total internal reflection 
the total amount of light that enters the wave-guide leaves the wave-guide because it has 
been totally confined.  In Figure 5.2, for the light to pass through the wave-guide, the 
wave-guide (N1) must have a higher refractive index than the surrounding area (N2).  
When this takes place Total Internal Reflection (TIR) occurs, (Figure 5.2).  Snell’s law 
says that a TIR can occur at the interface between any two surfaces as long as the 
critical angle of reflection is met.  The critical angle is the minimum angle of incidence 
of a particular interface.  Figure 5.4 shows how total internal reflection can occur when 
the incident light is equal to or greater than the critical angle, and will be discussed 
further later.   
 
 
Figure 5.2 Simplified Interpretation of a Wave Guide.  Diagram shows total internal 
reflection, because the light passing through N1 has a higher refractive index than N2. 
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Also during TIR an evanescent field is created.  The reflected beam loses energy as it 
leaves the interface.  This energy loss is in the form of an electrical field intensity called 
the Evanescent Field Wave.  When the TIR interface (surface) is coated with a metallic 
layer the evanescent wave penetrates the metal layer and excites the electromagnetic 
surface plasmon waves.  If the interface is coated with a non-metallic layer such as gold 
the plasmon waves will become polarized which creates an enhanced evanescent wave, 
(Figure 5.3). 
 
Figure 5.3 Simplified Interpretation of Kretschmanns Prism Arrangement; A- shows the 
incident light to be less than the critical angle, therefore TIR is not created, B- shows 
total internal reflection because the incident light is greater than or equal to the critical 
angle. 
 
5.1.5 Kretschmann’s Prism Arrangement 
Kretschmann’s Prism Arrangement  (Figure 5.4) is defined as a structure where light is 
coupled into a surface plasmon mode, which exists on a solid metal film (Kretschmann 
et al., 1968).  This is the sensor surface onto which a biological sample is placed.  The 
film can either be coated directly onto the surface of the prism or coated onto a glass 
slide and brought into contact with the prism using refractive index matching fluid.  A 
prism is used to increase the wave vector, which is a mathematical expression 
describing the propagation of light.  A surface plasmon mode is an oscillation of 
electrons on the surface of a solid conductor.   
 
This solid conductor can be in the form of the gold or silver thin metal films.  The 
support film is then coated on to a glass slide and optically coupled to a wave-guide.   
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Figure 5.4 Kretschmann Prism Arrangement, showing the polarised light entering the 
prism and due to the binding event taking place on the surface at the bio-system level 
(sensor surface) the refractive index of the reflected light is altered. 
 
Coating gold onto glass can prove difficult as it has poor adhesion properties.  
Chromium can be used to overcome this problem (BIAcore; Sensor Surface Handbook, 
2003).  Many other materials can be used to support the surface plasmon.  However, the 
main criterion for a good support material is the dielectric permittivity has to be 
negative.  The dielectric permittivity is a measurable physical parameter which detects 
the optical properties of materials. 
 
The dielectric material surrounds both sides of the metal film containing the surface 
plasmon.  One of these dielectric materials will be the wave-guide media and the other 
the analyte sample.  The interface between the metal and dielectric material is where the 
surface plasmon exists.  Through this interface will be an electric field current created 
by the light as well as the surface plasmon mode.  The surface plasmon mode will be 
attached to electrons oscillating within this field of electricity that is within the metal 
layer.  Light that is polarized with respect to the metal surface is launched into the prism 
and coupled to the surface plasmon mode within the metal film.  Changes in the amount 
of light reaching the photo-detector, indicates a sensor output.  Only p-polarised light 
can be coupled into the plasmon mode due to its electric field vector orientation.  Some 
light is also partially reflected off the metal to an optical photo-detector.  The dielectric 
permittivity in contact with the metal surface can alter the surface plasmon the dielectric 
permittivity is equal to the square of the refractive index of the material (Liedburg et al,. 
1998).  When a change occurs at the bio-system layer a change also occurs in the 
refractive index of the metal layer.  If these values change, the coupling efficiency of 
the light in the plasmon mode also changes.  The response time for the results is close to 
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instantaneous.  The SPR device measures the angle of incidence light (Earp & Dessy, 
1996). 
 
5.2 BIAcore  
Pharmacia Biosensing started out life in 1982 as a new company within Pharmacia.  
Researchers from the original company worked along side Linkòping University 
physicists and biochemists to develop a unique bioanalytical instrument which analysed 
interactions between biomolecules.  The aim was to replace the current ELISA 
technique with an optical sensor to achieve high levels of sensitivity and specificity.  
Pharmacia Biosensor launched its first biosensing system the BIAcore in 1990.  The 
BIAcore is a fully automated biosensor; it performs sample handling, immobilisation, 
SPR analysis, and regeneration of the sensor surface, (Liedburg et al., 1995).  BIAcore 
components will be discussed in depth in Section 5.5. 
 
5.2.1 Other Biosensing Instruments 
In the late 1990’s Texas Instruments (Dallas, Texas) launched its own SPR device TI-
SPR-1 commonly known as the Spreeta (Appendix L).  This SPR device offers a 
miniature optical bench and uses semiconductor manufacturing techniques.  SPR 
excitation is initiated by a light-emitting diode mounted inside the light-absorbing 
plastic casing along with the light polarizer.  The sensing surface is a gold layer on the 
external of the plastic casing.  The light is then directed onto the sensing surface and 
reflected via an internal mirror onto a photodiode array within the sensor chip.  This 
system has the advantage of being portable for field analysis and low purchase and 
running costs, making it an attractive device for researchers (Earp & Dessy, 1996).   
Several other SPR instruments are available on the market, these include Autolab Esprit 
and Springle low cost SPR detection units (www.ecochemie.nl).  Also Reichertai 
(www.reichertai.com) and Yamagata DKK (www.dkktoa.net) also produce SPR 
instrumentation. 
 
5.3 Immobilisation Techniques 
Firstly in any immobilisation technique, the sensor surface is activated by a sequence of 
reagents, to prepare the surface for the ligand solution injection.  Free ligands that do 
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not bind are deactivated by injection of a suitable agent and to avoid saturation pre-
concentration of the bound ligand is implemented.  Electrostatic attraction between 
negative charges on the surface of the chip and the positive charges on the ligand allow 
the measurement of pre-concentration and also allows successful immobilisation of 
solutions with very dilute ligand concentrations. 
 
5.3.1 Ligand Immobilisation  
Using BIAcore CM sensor chips the following immobilisation chemistries are useable: 
 Amine coupling using reactive esters. 
 Thiol-disulphide exchange. 
 Biotinylated ligand binding to immobilised streptavidin. 
 Hydrazine activated surface used to couple aldehyde. 
 
5.3.1.1 Amine Coupling 
In amine coupling the carboxymethyl groups are modified due to an introduction of N-
hydroxysuccinimide (NHS) and N-ethyl-N (dimethyl-aminopropyl)-carbidimide (EDC), 
resulting in N-hydroxysuccinimide esters (BIAcore; Sensor Surface Handbook, 2003).  
These esters can then form covalent bonds between the ligand and the surface.  The 
method favours ligands with uncharged amino groups and by high pH.  This is generally 
the first coupling method to be tried.  Where other methods are preferred, situations can 
include acidic ligands with a low pH during their pre-concentration phase, which cause 
the amino groups to protonate and reduces the coupling efficiency.  The other situation 
when non-amine coupling is preferred is where ligands possess very reactive amino or 
nucleophilic groups which may lose their biological activity during immobilisation. 
 
5.3.1.2 Streptavidin-biotin Coupling 
Avidin from bird egg albumin and streptavidin from Streptomyces cultures, are proteins 
which have binding sites with high affinities for biotin.  The biotin itself can be 
physically attached to biological molecules for this purpose.  Where biotinylated ligands 
are to be immobilised on the sensor chip an avidin or streptavidin is firstly immobilised 
on the sensor chip.  The avidin-biotin affinity is extremely high therefore binds the 
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ligand to the chip well (Tombelli, 2001). Changes in pH, chaotrophs or manipulations 
via multiple washing will not disturb this bond.   
Avidin has 4 binding sites per molecule.  This can be a major problem because it 
attracts non specific binding of other molecules due to the presence of the sugars in its 
structure (N-actetylglucosamine) and its isoelectric point being so high (pI~10).  
Streptavidin on the other hand has 4 binding sites but no carbohydrates in its structure.  
The pI is 5-6 and has low non specific binding.  When streptavidin binds with biotin it 
goes through several processes including hydrophobic and van der Waals interactions 
(weak non-chemical bonds of attraction) as well as extended hydrogen bonding 
network, (Freitag et al., 1997).  These plus a deep cleft in which the biotin binds inside 
the protein ensures a high affinity between protein and biotin.  Biotin is a small 
molecule so when it reacts with streptavidin it only uses the biocyclin ring.  The 
carboxylic group can therefore be modified and conjugated to many macromolecules 
without altering the overall size, characteristics, and biological activity (Gitlin et al., 
1990). 
 
The streptavidin-binding coupling method is an alternative technique for binding 
ligands to amine and thiol methods, and should be used when the other methods are not 
suitable.  This method has the advantage of being able to be performed above the 
isoelectric point of the ligand and does not rely on electrostatic pre-concentration at the 
sensor chip. Another advantage is that biotinylated probes can be stored at -20oC 
without loss of activity for longer periods than compared to radioactive probes, 
(Tombelli, 2001).  Ligands where streptavidin coupling is useful include: nucleic acids; 
polysaccharides and glycoconjugates; acid sensitive proteins; peptides and other small 
ligands where amine and thiol groups are absent; and where the ligand is to be bound to 
a streptavidin-biotin receptor the ligand always has to be modified to be biotinylated.  
This essentially means that the method is longer than the amine or thiol methods and not 
only this but also optimisation of these steps has to be included too. 
 
5.4 Aptamers & Aptasensors 
Aptamers are a new development in the field of artificial receptor technology.  Before 
the development of aptamers, the most popular group of molecules for molecular 
Chapter 5 106
recognition were antibodies.  Antibodies have been around for more than half a century 
and have subsequently had a huge involvement in diagnostic assays and become 
essential in routine clinical tests. Conventionally, ligands for non-nucleic acid targets 
have incorporated antibodies for analysis of proteins.  But recently work has involved 
aptamers due to their high affinity to bind to target proteins (Liss et al., 2002).  
Aptamers differ from antibodies but they mimic antibody properties.  The demand for 
diagnostic assays to assist in management of current and up-and-coming diseases is 
growing.  Aptamers have the potential to fulfill the recognition requirements in future 
assays (Jayasena, 1999).   
 
5.4.1 History of Aptamers  
In 1990, Joyce (La Jolla, USA), Szostak (Boston, USA) and Gold (Bolder, USA), 
simultaneously and independently reported the development of an in vitro selection and 
amplification technique, which brought about the discovery of specific nucleic acid 
sequences which are capable of binding to non-nucleic acid targets with high affinity 
and specificity that is often superior to those of antibodies (Joyce, 1989; Ellington & 
Szostak, 1990; Tuerk & Gold, 1990).  The technique was termed SELEX; the 
Systematic Evaluation of Ligands by EXponential enrichment.  SELEX is the technique 
used to isolate functional nucleic acids by screening vast libraries of oligonucleotides by 
in vitro selection and amplification to produce artificial receptors, i.e. aptamers as well 
as catalytic nucleic acids such as ribozymes and aptazymes (Luzi et al., 2003).  The 
process results in oligonucleotides referred to as “aptamers”; “aptus” from the Latin 
word meaning “to fit” (Jayasena, 1999).  The progress of research on aptamers has 
grown over the last 10 years into an extensive range with claims for increased abilities 
over antibodies in terms of selectivity, specificity and affinity.  Exploitation of aptamers 
in the coming years is to be expected. 
 
5.4.2 Definition of an Aptamer 
Aptamers are defined as, “artificial nucleic acid ligands generated against amino acids, 
drugs, proteins and other biological molecules” (O’Sullivan, 2002).  Aptamers are an 
emerging class of molecules that pose novel approaches for new analytes.  Aptamers 
have the capacity to recognise and bind to virtually any class of target molecule with 
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high affinity and specificity (Jayasena, 1999).  These include small organic molecules to 
supramolecular structures and organisms, because aptamers are capable of folding into 
3D structures to become receptors for a huge array of targets (Gold, 1995).  Aptamers 
can also react with protein targets, which do not react with nucleotides as part of their 
original function.  They also have the advantage of being generated against a wide range 
of targets, namely, amino acids, drugs, and proteins (Luzi et al., 2003).  The target 
diversity for aptamers is quoted as being somewhere in the range of 101-105 times 
greater than the largest phage display populations that have been generated.  As well as 
being 104-108 times greater than the number of antibodies in the human immune system, 
(Chambers, 2002). 
   
5.4.3 Systematic Evaluation of Ligands by EXponential Enrichment (SELEX) 
The SELEX (Figure 5.5) process begins with the synthesis of a single stranded library 
of oligonucleotides.  Each oligonucleotide consists of a 5’ and 3’ region of defined 
sequence and in-between a central region of random sequence.  The library therefore 
comprises of many oligonucleotides with unique sequences.  The starting library 
(Figure 5.5 (1)) contains 1014-1015 individual oligonucleotides and is usually screened 
within a couple of days, giving a high probability for selecting an aptamer for the 
analyte of interest.  
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Figure 5.5 SELEX Process.  Adapted from Luzi et al., 2003.  Diagram showing SELEX 
from the starting DNA library, through PCR, strand separation, transcription, biding, 
elution of bound nucleotides, amplification and ending, after several cycles with the 
isolation of an aptamer. 
 
The process then either creates a single stranded DNA pool which is amplified through 
PCR to produce a double stranded DNA pool (2).  This is either transcribed for strand 
separated for DNA selection (3a) or RNA selection (3b).  This starting library is then 
incubated with the analyte of interest (4).  All non-specific or nucleotides which have a 
low binding affinity are removed by a washing phase (5).  All nucleotides which do 
bind to the RNA/ssDNA are eluted (6) and amplified by RT-PCR (for RNA libraries) 
and PCR (for DNA libraries) (7), (Luzi et al., 2003).   
 
The enriched pool of either RNA or ssDNA is then transcribed in vitro and used for the 
next amplification cycle.  The total number of cycles required is dependent on the 
activity of the interactions between the target and aptamer.  This usually takes between 
8-15 cycles before an oligonucleotide population that binds to the target the best is 
selected as the successful aptamer (8).  In the initial cycles a tiny percentage of 0.1-
0.5% of individual sequences bind.  These sequences are then separated from the rest of 
the unbound nucleotides, by affinity chromatography or some other filter binding 
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technique.  The Beckman Biomek 2000 performs an automated SELEX process, 
producing an aptamer for a given target in just 2 days (Luzi et al., 2003).  
 
5.4.4 Applications 
Aptamers can mimic antibodies in many applications; they can substitute for antibodies 
in ELISA, immunobead assay, cell sorting, fluorescence microscopy, western blotting, 
and affinity layers for biosensors (Liss et al., 2002).  Where aptamers can be used in 
place of antibodies in ELISA assays, they are referred to as Enzyme Linked 
Oligonucleotide Assays (ELONA).  The ELONA technique was patented in 1997 by 
Nexstar (now Gilead Sciences, California).  Various formats can be employed: 
 The aptamer can be used as the capture molecule and the antibody as the receptor.   
 The aptamer can be used as the capture molecule and the labelled antibody binds to 
the aptamer-analyte immunocomplex as a reporter molecule.  
 The aptamer is the capture molecule and the labelled aptamer against the aptamer-
analyte complex is the reporter molecule.   
Another application is the use of aptamers as molecular beacons in aptasensing.  
Molecular beacons contain two structural components, a loop, and a stem (Yamamoto 
& Kumar, 2000).  The loop is the probe and the stem has two arms of complementary 
sequences, one florophore and the other a quencher.  When the florophore and the 
quencher are in close proximity no signal is created.  But when a target molecule is 
encountered the probe binds.  The probe-target hybrid is stronger than the binding of the 
probe and the stem, therefore it releases the probe and increases the proximity of the 
quencher and the florophore; resulting in fluorescence.  An example of this is 
Yamamoto & Kumar (2000) who immobilised a molecular beacon aptamer that 
fluoresces in the presence of TAT-1 protein derived from HIV-1 and HIV-2, 
(O’Sullivan, 2002). 
 
5.4.5 Regeneration, Reusing the Aptamer 
An antibody coated chip when regenerated (with 0.2M glycine-HCl pH 2.2) can result 
in the complete release of the antibody and the analyte (Liss et al., 2002).  This provides 
a chip that is free from ligands, but if repeated experiments are to be carried out then 
immobilisation has to be applied after every use.  However, an aptamer-coated sensor 
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chip can in principle be regenerated for further testing.  For example experiments by 
Liss et al., (2002) involved a chip coated with an aptamer that was rinsed with 50mM 
EDTA.  The rinsing dissolved the analyte, leaving the aptamer intact on the chip.  
Aptamers unfold in the presence of EDTA and then reassemble into their 3D formation 
in the presence of metal ions, producing a chip that is ready for use with further antigen. 
 
5.4.6 Comparison of Antibodies & Aptamers 
5.4.6.1 Limitations of Antibodies 
The generation of antibodies is normally begun in an animal.  Certain molecules such as 
toxins are not well tolerated in animals therefore it is difficult to generate antibodies 
against them.  Additionally, antibodies against molecules which are naturally less 
immunogenic are difficult to produce.  The isolation and manufacture of monoclonal 
antibodies is both an arduous and often a costly process.  This is especially true for rare 
antibodies, requiring screening of large numbers of colonies.  Antibody production also 
poses the possibility of accidental loss or death of a cell line.  Usually multiple stocks of 
frozen antibody-producing cells are stored at multiple sites to avoid this.  Where high 
yields of monoclonal antibodies are required, they are typically grown in the peritoneal 
cavity of animals.  It poses its own inconveniences as it can be difficult to grow some 
hybridomas in vivo. 
Generally, the production of hybridomas is limited to rat and mouse; this limits the use 
of antibodies in therapeutic applications.  Heterophilic antibodies (human antibodies 
that recognise antibodies from non-human origin) have the potential to bind a capture 
antibody with a non-human detector antibody in the absence of an analyte; leading to 
false positive results.  Auto-antibodies and rheumatoid factors also have the potential to 
behave this way and interfere with immunoassays.  Batch to batch variation can hinder 
the performance of antibodies.  This can lead to an immunoassay being re-optimised 
with each new batch of antibodies purchased.  Finally antibodies are subject to 
irreversible denaturation, are sensitive to temperature changes have a limited shelf life 
and kinetic factors of target-antibody interactions cannot be altered easily (Jayasena, 
1999). 
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5.4.6.2 Advantages of Aptamers  
Aptamers have a high specificity.  They can detect subtle differences between targets, 
between methyl or hydroxy groups or D- vs L-enantiomeric configuration of the target. 
This is due to adaptive recognition.  In solution aptamers unfold and refold upon 
association with the target forming a new 3D complex.  An example of this is an anti-
caffeine aptamer which showed 10,000 fold lower affinity for theophylline, a molecule 
which differs from caffeine by just 1 methyl group (Luzi et al. 2003).  The specificity 
results from a phase in the SELEX process called “counter-SELEX”.  During this phase 
sequences that bind two closely related analogues of the target, are eliminated thus 
producing a highly specific oligoma (Jayasena, 1999). 
 
Advantages in aptamer technology can be seen in the field of affinity sensing.  Kon and 
Koff rates can be adapted and controlled according to the nature of the transducer and the 
desired assay time.  Sandwich assays can be employed instead of competitive formats, 
as they are far more successful at detecting small molecules.  Aptamers also have the 
advantage of allowing modification during the immobilization process or when 
labelling with a reporter molecule, without affecting its affinity.  They can additionally 
be subjected to repeated cycles of denaturation and regeneration without affecting their 
reactivity (O’Sullivan, 2002). 
 
An advantage of aptamers over antibodies is their small size.  This means that a dense 
layer of aptamer can be formed increasing the sensitivity.  The receptor layer can be 
highly ordered as the aptamer can be modified with functional groups allowing 
convalent, direct or indirect immobilization.  The arrangement of aptamers onto a chip 
is highly linear and ordered. Aptamers can produce a dense layer that saturate the chip.  
The usable aptamer concentration quoted by Liss et al. (2002) was 10mg/l and the 
usable antibody concentration on the chip was >1mg/l.  This shows that aptamers form a 
dense receptor layer that is far more sensitive than antibody arrangements.   
 
Aptamers are produced in vitro or in machines, therefore no animals are required.  This 
allows the production of aptamers to affine ligands, non-immunogenic or toxic proteins, 
with more flexibility. This also means no or very little batch-to-batch variability is seen.  
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An additional advantage is that the SELEX process is much faster than the typical time 
spent generating a cell-line to produce monoclonal antibodies and purified antibodies.  
Multiple SELEX experiments can also be carried out simultaneously presenting fast, 
high throughput discovery of aptamers (Jayasena, 1999).  
 
Aptamers are more resistant to denaturation and degeneration and have a longer shelf 
life compared to antibodies (Liss et al., 2002).  Experiments by Liss et al. (2002) 
showed this.  They immobilized antibodies onto quartz crystal biosensors and 
regenerated with 0.2M glycine-HCl pH 2.2 solution.  This regeneration did release the 
analyte from the bound antibody but also irreversibly damaged the antibody.  In contrast 
their aptamer quartz crystal biosensor was washed with 50mM EDTA, releasing the 
analyte leaving the aptamer to be completely reusable.   
 
Aptamers can be stored for several weeks without loss of sensitivity when attached to 
the surface of a biosensor. The surface stability of an antibody coated sensor chip is 
vulnerable compared to an aptamer coated sensor chip.  The antibody’s vulnerability 
was shown in an experiment by Liss et al, (2002).  The aptamer coated quartz was 
subjected to 30 minutes 100oC and retained 25% of its sensitivity yet the antibody 
coated quartz crystal lost all activity. 
 
5.4.6.3 Disadvantages of Aptamers; Nuclease Resistance 
For diagnostic and analytical purposes aptamers need to be stable in biological fluids.  
However, nucleic acids are very prone to degradation when associated with enzymes 
such as nucleases.  Unmodified RNA has a half life of 1 minute in serum.  Its half life 
has been increased to 15 hours by modification (O’Sullivan, 2002). 
Approaches which have been adopted to prevent cleavage include: 
 Alteration of nucleotide bases; modifying pyrimidines at the 2’positions 
amino/fluoro groups.  
 Alteration of the phosphodiester backbone; through use of α-thio substituted 
deoxynucleoside triphosphates. 
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 Use of spiegelmers (enantiomeric aptamers); with a chemical mirror image of the 
target, selecting the complementary aptamers and creating a chemical mirror 
image of the SELEX selected aptamer (Sampson, 2003).  
 
5.4.7 Lysozyme Aptamer  
The Lysozyme enzyme is found in a range of body fluids and is released in response to 
bacterial presence to degrade the cell wall and irradicate its presence.  The current work 
has included an ELISA which detects lysozyme in serum and takes ~100minutes to 
obtain results, rivalling commercial and clinical tests.  However, as Section 5.4.6.2 
describes, aptamers have several advantages over antibodies.    Therefore a test which 
incorporates the benefits of aptamers with the knowledge of lysozyme and its usefulness 
in the diagnosis of sepsis, should produce a much improved test challenging current 
diagnostic tests.  
 
The Lysozyme aptamer sequence used was derived from a paper by Cox & Ellington 
(2001).  The template was used to create the RNA anti-lyosyzme aptamer, which was 
then biotinylated at the 5’ and amine coupled to the surface of a sensor chip. 
 
 
5.4.8 Advantages of the Lysozyme Biosensor 
The main advantage of a lysozyme biosensor would be the result being produced in real 
time.  Immediately after the injection the concentration of lysozyme in the sample can 
be calculated.  The ELISA, commercial immunoassay kit, ELIFA, and the mini-ELIFA 
cannot produce results in such a short time. 
 
The lysozyme biosensor described here using the BIAcore 3000 can process 1 sample 
and 1 control per run with 2 replicates of the sample.  This system has huge time saving 
potential above and beyond any immunoassay.  Potential advantages of this system also 
include; 
 Reduced non-specific binding; The CM5 series chips have a negative charge caused 
by the inactivated carboxyl group.  When the ligand is immobilised this negative 
charge can be counter balanced as the ligands are positively charged.  Ionic 
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solutions in the sample can minimise the effects of the positive ligands on the 
surface.   
 Regeneration; The process of removal of non-covalently bound analytes.  The 
ligand cannot normally be removed without destroying the surface of the chip nor 
can it be removed during the regeneration process.   
 Biological Activity of the bound ligand; The activity of the ligand after the 
immobilisation process, must be retained for the chip to be useable.  When the 
ligand is coupled to the matrix and not to the surface, it is basically suspended in a 
gel solution.  The advantages of this is the conditions are said to be more favourable 
as they are freely accessible in a three dimensional matrix.  However, the biological 
activity of the ligand in the matrix may be affected due to the coupling reaction.  
Steric restrictions may be a consequence of large ligands. 
 Reproducibility; when a ligand has been bound to the sensor chip it can be 
repeatedly used for testing.  The sensor chips are usually highly consistent.  The 
experiment of adhering the ligand has also a high consistency between batches with 
a coefficient variation of <10% for CM5 batches of chips. 
 Ligand Modification; A further advantage is that ligands can undergo modifications.  
The ligand structure has disulphide groups introduced by reaction with its amino 
groups and NHS-activated heterobifunctional reagents for example SPDP or SMPT, 
or by reaction with its carboxyl groups with PDEA.  Where acidic proteins are to be 
immobilised, modification of the carboxyl groups are useful as the reaction 
increases the isoelectric point of the protein and consequently supports electrostatic 
pre-concentration on the sensor chip surface. 
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5.5 Materials & Methods –Lysozyme Biosensor 
5.5.1 BIAcore Sensor Surface Chip 
The BIAcore sensor chip is made of a glass slide housed within a plastic support casing 
to provide integrity and alignment within the BIAcore instrument and with the optics 
and flow system.  The visible glass on the chip is 1cm2 with a 50nm layer of gold 
coating.  On top of the gold layer is a linking layer to aid the binding of the 
biomolecules.  The immobilized molecules need to be linked to the compatible linking 
layer of carboxymethylated dextran, by covalent linking.  Use of an unmodified metal 
film would result in a low number of immobilized sites.  
 
A typical sensor chip can be used for >50 measurements without sensitivity loss.  Two 
types of chip are commercially available from BIAcore.  The first is a certificated grade 
chip that has statistical variability in immobilized capability of less than 5% and the 
second type is a research grade chip with a variability of less than 15%; e.g. CM5 and 
SA (Earp & Dessy, 1996). 
 
5.5.2 BIAcore Flow Injection System 
The BIAcore flow injection system is a micro-fluidic system consisting of miniaturised 
sample loops (Earp & Dessy (1996), Liedberg & Johansen (1998)) valves and conduits 
to reduce sample and reagent volumes.  The unit is comprised of 3 plastic plates welded 
together with the channels running between the plates for the samples etc.  The chip is 
then fixed into the flow cell for accurate delivery of the sample.  Each flow cell has a 
dead volume of 60nL. 
 
5.5.3 The Sensorgram 
SPR is a combined oscillation of electrons with respect to the nuclei in the near surface 
region of the metal film.  The oscillation at the surface plasmon is an optical wave 
driven by an external light source.  The wave is both strong and localized along the 
interface between the metal and the medium e.g., the buffer or the liquid sample.  The 
signal that is sensed in an SPR experiment is change in the angle of incidence.  This 
signal is equal to the changes in the refractive index and the mass concentration of the 
biomolecules at the metal film.  The sensorgram is a term created by BIAcore, for the 
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recording of these events in the form of a graph.  When producing a sensorgram for any 
experiment, the first step is to record the background baseline, during continuous flow 
of the running buffer.  The ligand is then injected, resulting in a refractive index shift.  
After rinsing with buffer the analyte is injected and a new baseline is formed and 
recorded.  The SPR signal is determined by the changes in the second and first baseline. 
 
5.5.4 BIAcore Components 
The pump consists of a syringe which measures down to 1µl-ml and a stroke capacity of 
500µl.  Liquid is pumped from a reservoir to a connector block inlet which is directly 
connected to the Integrated µ-Fluidic Cartridge (IFC) (Figure 5.6).  BIA certificated 
buffer (HBS) or a custom made buffer, is used as the running buffer.  Refilling takes 
place at the end of each stroke. 
 
Figure 5.6 Integrated µ-fluidic Cartridge, (adapted from BIAcore Methods Manual, 
www.BIAcore.com).  Diagram shows the delivery of samples to the flow cell of the 
sensor chip, via the channels in the IFC.   
 
The Connector Block is the sample inlet and outlet chamber.  This has two inlets; the 
pump inlet and the injection port for loading the sample.  The sample is injected using a 
standard Gilson pipette (200µl or 1000µl) with the BIAcore X and is automatic loading 
in the BIAcore 3000.  It also has two outlet ports one for the sample out and the other 
for the flow cell out.  Waste from these runs directly into a waste beaker under the 
connector port in both models. 
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The IFC (Figure 5.6) consists of a series of channels and pneumatic valves controlling 
delivery of liquids to the sensor chip.  The chip is in direct contact with the connector 
block and the inlet and outlet ports are in parallel.  The IFC and the flow cell together, 
form two flow cells in the BIAcore X and 4 in the BIAcore 3000, which can be used for 
multichannel analysis of samples.  Serial flow can enable two or more of the same 
samples to be tested at the same time on two different surfaces or for in line reference 
measurements or used to determine different analytes.  Two basic operating modes exist 
in the IFC due to pneumatic values.  The load allows buffer to flow through the flow 
cells bypassing the sample loops.  The injection allows buffer to be prepared through 
the sample loop and to the flow cells.  The IFC operates in load mode at all other times 
when a sample is not being injected. 
 
Sensor chips commonly used in the BIAcore X and 3000 are CM5 (Figure 5.7), which 
are carboxymethylated dextran coated.  Biomolecules can be adhered to this surface 
with general chemical methods (Section 5.4).  Other sensorchips include SA (Figure 
5.7), which has a dextran matrix and a streptavidin covalently immobilised for use with 
high affinity capturing of biotinylated ligands.  This allows rapid immobilization of 
biotinylated ligands and due to the strength of biotin-streptavidin bonds permits harsh 
regeneration without the loss of reproducibility. 
 
Figure 5.7 Drawing of the Sensor chip surface (adapted from www.BIAcore.com).  (a) 
Sensor Chip CM5, showing carboxymethylated dextran matrix. (b) Sensor Chip SA, 
showing the Streptavidin bound to the carboxymethylated dextran matrix.  
 
NTA chips have a nickel-chelating mechanism for the capturing of poly-his tagged 
recombinant products.  And HPA chips are used for the analysis of membrane related 
interactions due to their hydrophobic surface which allows the creation of lipid 
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monolayers on the surface of the chip.  A sensor chip can be used 50-100 times for 
repeated measurement.  It can be docked in the processing unit for up to 1 week.  The 
shelf life of a chip however, depends on the immobilised ligand. 
 
The flow cell is contained within the optical system.  The outside wall of the flow cell 
consists of glass which is pressed up against a glass prism in the optical unit.  The 
silicone opto-interface between the chip and the prism is matched in refractive index 
and means a good optical coupling between the prism and removable sensor chip is 
achieved.  Light is forced through the prism via a light emitting diode; this hits the 
sensor chip in a wedge shaped beam to give a wide range of incident light.  The 
reflected light from the sensor chip is then monitored by an array of light sensitive 
diodes that are linear to the range of incident light rays.  The SPR angle can be 
monitored accurately in real time without the movement of the light source, chip, or 
detector.  Surface plasmon resonance measurements are sensitive to temperature 
changes.  The temperature is monitored via Peltier elements which ensure a constant 
temperature change.  The air temperature when the BIAcore is operating, must not 
deviate 10oC above or below the operating temperature range of the BIAcore system.   
 
A microcomputer controls the operations of the processing unit within the BIAcore.  It’s 
job is to record and process raw data from the detection unit.  The microcomputer is 
then controlled by a PC within the lab; all data can then be tabulated or printed as 
sensorgrams, (BIAcore; Sensor Surface Handbook, 2003). 
 
5.5.5 BIAcore 3000 Maintenance 
Training was provided by Università degli Studi di Firenze (Italy).  A Kinetic and 
Affinity Analysis Level 1 training course was provided by BIAcore UK. 
 
Throughout all experiments, and all conditioning of sensor chips and maintenance of the 
Biacore machine the flow rate was 5µl per minute.  Before and after each experiment a 
Desorb was run (in accordance with IBST/SOP RQ1037).  The BIAcore was a busy 
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instrument with several users therefore a desorb was run at the start of each users turn 
both for machine maintenance and to ensure a constant environment was retained.  
BIAdesorb solution 1 (0.5% (w/v) sodium dodecyl sulphate) and solution 2 (50mM 
glycine pH 9.5) (BIAcore, Sweden) were used.  All buffers were filtered using 0.2µm 
syringe filers and degassed for 10 minutes before use.  All buffers were made from fresh 
stock each day and the stocks made fresh monthly. When changing buffers the Prime 
tool was used followed by the Flush tool to completely remove any of the previous 
buffer that was remaining.  This sequence was repeated if the refractive index signal 
was unstable or if air bubbles were disrupting the signal. 
 
5.5.6 General Reagents 
All buffer recipes can be found in Appendix G.  
 
During the preconditioning of the SA sensors and the immobilization of Streptavidin on 
the CM5 chips HBS-EP buffer (BIAcore, Sweden) was used as the running buffer.  To 
immobilize Streptavidin onto CM5 chips the surface was activated with an amine 
coupling kit (Appendix G).  Streptavidin was purchased from Sigma-Aldrich Ltd, from 
Streptomyces avidinii.  A solution of Ethanolamine (98% purity) (Biacore, Sweden) was 
prepared to deactivate any unbound NHS-esters. 
The SA sensor chips were preconditioned with a preconditioning solution (Appendix 
G).  This preconditioning solution was injected three times for one minute each time. 
The biotinylated anti-Lysozyme aptamer was purchased from MWG (UK).  The 
aptamer buffer (Appendix G) was used as the running buffer during the aptamer 
immobilisation.  The negative control was a custom made biotinylated 80mer oligo 
(Sigma-Genosys, UK).  The Poly-T buffer (Appendix G) was used as the running buffer 
during the Poly-T immobilisation, and was used to make Poly-T dilutions.  Biotin 
(Sigma-Aldrich Ltd, UK) was used to block unbound Streptavidin sites on the SA chips 
(Appendix G). 
 
5.5.7 Regeneration Solutions 
Several regeneration solutions were tried to remove analyte bound (Appendix G). 
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5.5.8 Aptamer Preparation 
The anti-lysozyme aptamer was synthesised by MWG.  The aptamer was biotinylated at 
the 5’ and stored in the recommended buffer (Appendix G). 
 
5.5.9 Analyte Preparation 
Human Lysozyme (Sigma-Aldrich Ltd, UK) was dissolved in Aptamer buffer.  The 
lysozyme was stored at -20°C.  On the day of use the lysozyme aliquot was defrosted by 
leaving it on the bench for 30 minutes.  Dilutions were made using the Aptamer buffer. 
 
5.5.10 Serum Preparation 
All serum was centrifuged using Vivaspin centrifugal filters 30kDa (Fisher, UK), at 
1200rpm for 10 minutes, to remove all albumin from the sample.  The residue 
containing the albumin was discarded and the filtrate was then used for all dilutions and 
injection onto the sensor surface. 
 
5.6 Final Lysozyme Biosensor Method 
5.6.1 Sensor Chip Preparation 
The SA sensor chip was docked and HBS-EP buffer was allowed to flow for about 5-10 
minutes to stabilise the signal.  Flow cells were then pre-conditioned separately using 
the preconditioning solution; 3 injections of 5µl at a flow rate of 5µl/min.  Signal 
changes were recorded. 
 
5.6.2 Control Application 
After preconditioning the buffer was changed to the Poly-T buffer and primed for 6 
minutes to remove any residual HBS-EP buffer.  The sensorgram was started and the 
signal allowed to stabilise at a flow rate of 5µl/min.  An injection of 75µl of 0.1µM 
Poly-T was carried out.  The signal was recorded before and after the injection. 
 
5.6.3 Ligand Application 
The poly-T buffer was replaced with Aptamer buffer and the system primed for 6 
minutes.  The sensorgram was restarted and the new running buffer allowed to stabilise 
for several minutes.  During this time the Aptamer was prepared for injection.  The 
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2x10-3pmol aptamer was heated using a Bunsen burner, for 3 minutes at 95oC.  It was 
then removed from the heat and injected 75µl.  The signal was recoded at the start and 
end of the injection. 
 
5.6.4 Analyte Preparation & Use 
The Lysozyme was stored at -20oC until use.  On the day of use the aliquot was 
defrosted at room temperature for 30 minutes then diluted using aptamer buffer.  An 
injection volume of 75µl was used at a flow rate of 5µl/min.  The baseline was recoded 
before and after the injection. 
 
5.6.5 Serum Preparation & Use 
The serum was divided into aliquots of 150µl on the day of collection and stored at -
20oC.  On the day of use an aliquot was defrosted at room temperature.  All serum was 
spin-filtered and the filtrate used for dilution and use in the BIAcore.  The dilution of 
serum samples was made using aptamer buffer.  Lysozyme spiked serum samples were 
used in the development of the method.  Here, a lysozyme negative serum sample was 
used from non hospitalised patients.  A 1/100 dilution of serum was produced in aptamer 
buffer and spiked with various concentrations of lysozyme. 
 
5.6.6 Regeneration Using Heat Changes Protocol 
After the analyte injection had finished the signal was allowed to stabilise for several 
minutes (Cycle 1).  The baseline was then recorded and the sensorgram stopped.  The 
new temperature was set and allowed to reach temperature over several minutes until 
stable.  The sensorgram was then restarted (Cycle 2) and the loss in baseline recorded.  
The sensorgram was again stopped and the temperature reduced back to 25oC.  Once the 
BIAcore temperature was stable, the sensorgram was restarted (Cycle 3) and the 
baseline recorded.  All fluctuations in baseline were recorded. 
   
Chapter 5 122
5.7 Lysozyme Biosensor Method Optimisation Results 
This section presents the development and optimisation of the lysozyme biosensor.  
This included testing aptamer and control concentrations, sample preparation, non-
specific binding using control analytes, and types of regeneration solution.  The 
Response Units (RU) represents an arbitrary measurement used by BIAcore to measure 
changes within the baseline. 
 
5.7.1 Ligand Binding  
Figure 5.8 and Table 5.1 show successful aptamer binding onto an SA sensor chip. 
Table 5.1 shows the different concentrations of aptamer that were tried to reach an 
amount which was stable and also produced a response similar to that achieved with the 
control immobilisation.  The final Aptamer concentration chosen was 2x10-3pM.  
During these trials, the aptamer was immobilised after treatment and without treatment.  
The treatment consisted of heating the aptamer to 95oC for 3 minutes.  The results 
showed that heating the aptamer had a positive effect on binding.   
 
Figure 5.8 Aptamer binding (2x10-3pM); A stable signal after the injection has ended 
showing final bound concentration of aptamer of ~250RU. 
 
 
 
 
 
 
 
Injection start 
Injection end 
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Table 5.1 Selection of aptamer concentrations immobilised on to Carboxymethylated 
dextran sensor chips (CM5) and sensor chips which have a Streptavidin covalently 
bonded to the carboxymethylated dextran (SA); 2x10-3pM on SA used. 
Concentration 
of Aptamer 
Preparation  
(Treated*) 
Sensor Chip Type Volume 
Response 
(RU) 
2x10-6pM Treated CM5 100µl 407.1
2x10-12pM Untreated CM5 100µl 15
2x10-12pM Treated CM5 100µl 55.6
4x10-11pM Treated CM5 100µl 600
2x10-6pM Treated SA, no preconditioning 100µl 719
2x10-6pM Treated SA, preconditioning  75µl 233
2x10-3pM Treated SA, preconditioning  75µl 250
*Treated=Heated to 95oC for 3 minutes 
 
The sensor chips initially used were CM5 (dextran immobilised), but SA (streptavidin 
immobilised) chips were used later to speed up the assay.  The use of SA chips also 
ensured that the immobilisation surface was constant.  With the CM5 chips the surface 
was produced by immobilising streptavidin, and the biotinylated aptamer.  However, the 
streptavidin did not distribute evenly over the surface of the 4 flow cells, producing a 
higher degree of binding onto flow cells 1 and 2 and much less on 3 and 4.  This 
obviously affected the amount of aptamer which could potentially bind.  The SA chips 
eliminated this uncertainty, producing a sensor chip surface which evenly distributed 
with streptavidin. 
 
5.7.2 Control Ligand Binding  
Figure 5.9 shows the immobilisation of the Poly-T ligand.  The graph shows a stable 
immobilisation at the end of the injection.  Table 5.2 shows the concentrations of Poly-
T control that were tried.  The injected volume was set at 75µl purely by mistake, but 
the result showed that the original 100µl volume was far too much ligand to inject.  
Subsequently the volume of aptamer was also changed to 75µl and again the 
immobilisation was much improved.   
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Figure 5.9 Poly-T Binding (1µM) and the stable signal after the injection had ended 
showing final bound concentration of ~245RU. 
 
Table 5.2 Results from the Poly-T immobilisation.  Various concentrations were tried, 
along with two types of sensor chips to achieve a stable immobilisation of the control. 
Concentration of Control  
(Poly-T) 
Sensor Chip Type Volume 
Response 
(RU) 
1µM CM5 100µl 1071
0.1µM CM5 100µl 104
0.1µM SA, preconditioned 75µl 240
 
When the sensor chip was changed for the aptamer immobilisation, the control chip was 
also changed.  Again the immobilisation of the control was more reliable with the SA 
chips, due to the uneven binding of the streptavidin on the CM5 chips. 
 
5.7.3 Non-Specific binding of Poly-T  
Figure 5.10 shows the injection of Poly-T onto a CM5 sensor chip.  The sensor chip was 
not activated with the NHS-EDC solution nor was it immobilised with streptavidin.  
The two injections of Poly-T here show no binding.  After the first injection, the 
baseline increases slightly, but then after the second injection the baseline decreased, 
indicating no binding has taken place.  This therefore shows that Poly-T is not non-
specifically binding to the sensor chip surface and is in fact binding to the streptavidin.   
 
Injection end 
Injection 
start 
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This graph does show some binding due to the buffer at 5000 seconds onwards.  
However, the Poly-T buffer was only used during the immobilisation of the control and 
during serum injections.  As fresh buffer was made on each new day, and because the 
amount of binding was quite small this was ignored. 
 
Figure 5.10 Sensorgram showing two injections of 1µM poly-T.  No binding was 
present with either injection. 
 
5.7.4 Non-Specific Binding Tests with Analytes  
Figure 5.11 shows the injection of lysozyme onto an immobilised SA sensor chip.  Two 
injections of lysozyme were injected onto a sensor chip which had no ligand 
immobilised and had under gone no preconditioning.  The lysozyme had not bound in 
either injection showing that lysozyme does not non-specifically bind to the sensor 
surface. 
 
Injection start 
Injection start 
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Figure 5.11 Test for non-specific binding.  Lysozyme was injected on to an unmodified 
SA sensor chip; no binding was present. 
 
Figure 5.12 below the use of biotin to block any unbound sites on the sensor surface.  
The idea behind this experiment was to prevent non-specific binding of lysozyme and 
any other analyte to these unbound sites.  However, the biotin did not bind, so was not 
applied again in future experiments.   
 
 
Figure 5.12 Sensorgram showing the injection and binding of Poly-T and the injection 
of biotin.  Biotin did not bind as the signal slowly returned to the pre-biotin level. 
 
The use of a negative control was used in Figure 5.13 to prove that lysozyme was 
specific to the anti-lysozyme aptamer.  BSA was used as the negative control because it 
was readily available in the lab.  The BSA did bind to the sensor surface as shown by 
Injection 
start 
Injection 
start 
Biotin 
Injection 
start 
Poly-T 
injection 
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the dips on the graph; this is not binding but simply a change in the refractive index.  
The BSA also caused the aptamer to change in confirmation in someway so it did not 
bind to the serum injection or the buffered lysozyme injection.  
 
 
Figure 5.13 Application of a negative control.  BSA showed some binding and 
interfered with subsequent binding of serum samples and buffered lysozyme injections. 
 
Myoglobin from equine heart was the second negative control to be used as shown in 
Figure 5.14.  This analyte was chosen because it had a similar molecular weight to 
lysozyme.  The dotted lines on the graph illustrates how the baseline has increased 
slightly after the injection, indicating that the myoglobin has bound to both the aptamer 
and poly-T flow cells.  An explanation of why this may have occurred is due to the 
charges of the molecules.  If lysozyme and myoglobin have the same charge then both 
would be attracted and bound to the poly-T and the aptamer.   
 
-ve control 
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Figure 5.14 Injection of second negative control Myoglobin from Equine Heart.  The 
dotted line shows increase in baseline indicating binding. 
 
5.7.5 Regeneration 
Table 5.3 shows the solutions that were used to regenerate the sensor chip.  During 
regeneration the ideal situation is where the ligand is freed of all analyte and is left in an 
active state to bind to further injections of analyte.   The only regeneration solution 
which came close to achieving this ideal situation was the ethanol and sodium 
hydroxide solution.  All others either increased the baseline indicating binding of the 
regeneration solution or decreased the baseline destroying the ligands. 
 
Table 5.3 Table shows the Results from the Regeneration Scouting; table lists the 
regeneration solutions tried, along with concentrations, volumes and the responses. 
Regeneration 
Solution 
Concentration & Volume of 
Regeneration Solution 
Response 
Hydrochloric 
Acid  
1,5, 10 & 20mM
5-2µl
HCl bound to sensor surface and 
increased baseline. 
No regeneration achieved 
Ethanol & 
Sodium 
Hydroxide 
25-100% (25mM)
5-40µl
Baseline decreased.  A degree of 
regeneration success was achieved 
but was unpredictable.  Some 
results varied as the solution was 
unstable after preparation (see table 
Chapter 5 129
5.4). 
Sodium Citrate 0.1 & 1M
10 & 50µl
Signal increased.  Sodium citrate 
bound to the sensor surface. 
Sodium 
Hydroxide 
1mM &1M
5µl
The baseline decreased, destroying 
bound ligand.  No regeneration 
achieved. 
Sodium Chloride 1 & 10mM
5µl
No regeneration was achieved.  
Binding took place on the aptamer 
flow cell and the signal decreased 
on the control flow cell. 
Magnesium 
Chloride 
1M
10µl
No regeneration achieved.  Binding 
took place on the aptamer 
immobilised flow cell and the signal 
decreased on the control. 
 
The ethanol and sodium hydroxide was tried in various percentage concentrations and 
several volumes were injected.  The volume and percentage concentration was 
dependent on the amount of analyte binding; if a lot of analyte had bound then a 
stronger and larger concentration was injected.  A degree of regeneration success was 
achieved with this solution.  However, the search for a regeneration solution/process 
which produced better results was still required. 
 
Table 5.4 shows the instability of the ethanol and sodium hydroxide regeneration 
solution.  The “fresh 100%” indicated a solution made fresh on the day of use and 
without dilution.  An “old 25%” solution indicates a solution not made fresh on the day 
of use and diluted ¼.  Even though the solution was stored over night in a sealed 
container and stored at 4oC, the ethanol was still evaporating, making the effects of the 
regeneration solution unpredictable.  In some cases the regeneration would not only take 
off the analyte but also remove bound ligand.  This begs the question of whether it was 
better to regenerate to a point where a small amount of analyte was still bound to the 
ligand, or whether it was better to remove a small amount of the ligand to ensure all 
analyte was completely removed.  As it was felt that removing ligand may cause more 
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damage to ligand that remained bound, a decision was taken to regenerate using this 
solution to a point where some (>10RU) was still bound.  This ensured that free ligand 
still bound, was not deactivated. 
 
Table 5.4 Table showing the Instability of the Regeneration Solution Ethanol & Sodium 
Hydroxide (EtOH+NaOH) 
Percentage 
Concentration  of 
25mM EtOH+NaOH 
Baseline reading at the 
Mid Injection of 
Regeneration Solution 
Baseline Reading at the 
End Injection of 
Regeneration Solution 
Fresh 100% (no dilution) 234 137
Fresh 50% 1156 230
Fresh 25% 1481 264
Old 25% 1248 38
 
Table 5.4 above shows an experiment carried out to determine the effects of day-old and 
freshly prepared ethanol and sodium hydroxide solution.  The results showed that the 
day-old solution had very little regeneration effect compared to solutions made fresh on 
the day.  This suggests that the ethanol was evaporating overnight and reducing the 
effectiveness of the solution. 
 
The freshly made solutions of ethanol and sodium hydroxide produced unexpected 
results.  As the concentration of ethanol and sodium hydroxide reduced the effect, on 
reducing the baseline was stronger.  The results suggest that the regeneration solutions 
used were unreliable at regenerating a sensing surface and produce random effects 
regardless of concentration.  This is the main reason why the search for appropriate 
regeneration conditions continued. 
 
5.7.6 Thermo-Regeneration  
The experiment from Table 5.5 shows the sensor chip was prepared in the usual way 
with preconditioning of 3x 1 minute injections of 50mM Sodium Hydroxide + 1M 
Sodium Chloride, and then injection of both aptamer and control.  A concentration of 
0.1µg/ml lysozyme was injected and the temperature was increased by a known amount 
and the decrease in bound analyte recorded.  The temperature was then reset at 25oC and 
Chapter 5 131
further ligand and analyte was injected.  This cycle was repeated several times until the 
temperature of the BIAcore had reached its upper limit (40oC).  The experiment showed 
that as the internal BIAcore temperature increased, the amount of bound analyte 
removed also increased.  This was the most effective regeneration regime used.  Not 
only was analyte removed, but the ligands remained attached and active.  There was 
also a high degree of control over the amount of regeneration.  The temperature could 
be tailored to how much regeneration was required simply by using the data shown in 
Figure 5.15 below and determining the temperature the BIAcore needed to be set at to 
achieve adequate regeneration.   
 
Table 5.5 Table showing the results from the thermo-regeneration method.  The baseline 
decreased with increasing temperature showing the sensor surface was being cleaned of 
immobilised analyte.   
 
 
The problem of how much regeneration to expose the ligand to was still present.  
Whether to leave a certain amount of analyte bound or to remove a small amount of 
ligand ensuring the analyte was completely removed was still a matter for consideration.  
Again the amount of analyte left bound was >10RU, this was sufficient to ensure that all 
remaining free ligand was active. 
Baseline Before 
Temp Change 
Baseline After 
Temp Change 
Difference in Baselines Temp 
Change (ºC) 
FC1 FC2 FC1 FC2 FC1 FC2 
25→25.2 27172 27331 27172 27329 0 -2
25→25.3 27172 27331 27165 27322 -7 -10
25→25.4 27172 27331 27128 27285 -44 -46
25→25.5 27184 27215 27119 27151 -65 -64
25→26 27170 27106 27033 26972 -137 -134
25→30 27146 27395 26444 26684 -703 -711
25→35 27102 27558 25708 26067 -1394 -1490
25→40 27108 27539 24961 25381 -2147 -2158
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Figure 5.15 Graph showing the degree of regeneration achieved when the BIAcore 
temperature was increased. 
 
5.7.7 Serum Preparation  
Table 5.6 shows the results from various dilutions of the same concentration of serum 
spiked lysozyme.  The dilution of 1/100 was chosen for all future serum samples as this 
was the lowest dilution producing viable results. 
 
Table 5.6 Results showing dilution scouting to determine the dilution to be used for all 
Serum samples. 
Response Units Lysozyme Dilution 
(0.2µg/ml) FC3 FC4 
Description 
1/400  -4.2 -2.0 No binding on either FCs 
1/200 -3.8 -4.5 No binding on either FCs 
1/100 1.1 10 Binding on both FCs 
1/50 1.0 18.5 Binding Increased in FC4 
1/25 
-1.2 29.6
Further binding increase on 
FC4, no binding on FC3. 
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5.8 Lysozyme Biosensor Results 
This section describes the results gained from testing the biosensor.  Tests included 
standard lysozyme in buffer, spiked lysozyme in serum, clinical serum samples and 
regeneration using the thermo-regeneration technique. 
 
5.8.1 Lysozyme in Buffer  
Figure 5.16 shows the results gained from a variety of lysozyme injections.  The results 
show no binding of the lysozyme on the control (Poly-T) ligand.  All results for the 
control ligand were negative showing lysozyme to be specific to the anti-lysozyme 
aptamer.  The results for the aptamer show an increase in the amount of binding as the 
concentration of lysozyme increases.  This is true up until the final injection of 0.5µg/ml 
lysozyme at which point the binding decreased and presumably the ligand is saturated 
with lysozyme.  It should be noted that no regeneration was carried out in-between each 
lysozyme injection.  The lysozyme concentrations were simply repeatedly injected until 
the limit was reached at 0.5µg/ml. 
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Figure 5.16 Response Units (RU) from the control and Aptamer surface, for various 
concentrations of Lysozyme in Buffer 
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5.8.2 Calibration Curve Construction 
The experiment for Figure 5.17 was carried out due to the unreliability of the Poly-T 
control; in some experiments lysozyme bound to the Poly-T.  In this experiment the 
Poly-T was not immobilised.  Instead the sensor chip was preconditioned as usual using 
the 3x 1 minute injections of the preconditioning solution (Appendix G).  It was then 
used without a ligand present. 
 
The low concentrations of lysozyme (0.05-0.25µg/ml) did not bind to the blank control 
surface, but the final concentrations of 0.3-0.5µg/ml did.  This could have been due to 
small amounts of the lysozyme from previous injections binding and changing the 
charge of the surface so it became attractive to subsequent lysozyme injections and thus 
causing the binding of lysozyme at the high concentrations.  The lysozyme binding on 
the aptamer showed a consistent pattern.  As the lysozyme concentration increased so 
did the amount of lysozyme bound.  The only exception was with 0.25µg/ml and the 
final lysozyme concentration 0.5µg/ml.  As found with the previously (Figure 5.16), the 
limit of ligand binding was reached at 0.5µg/ml. 
This experiment also incorporated the thermo-regeneration regime.  Figure 5.17 shows 
that the regeneration is working and the ligand is being freed from analyte for 
subsequent analyte binding.  This is also why the lysozyme was binding to such a 
greater extent than compared to Figure 5.16. 
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Figure 5.17 Calibration Curve of Various Buffered Lysozyme Concentrations injected 
onto both an Aptamer immobilised flow cell and a blank flow cell acting as control. 
 
5.8.3 Thermo-Regeneration Using Lysozyme-Spiked Serum Samples  
Table 5.7 shows the results from the spiked serum samples.  Again with this experiment 
the Poly-T was attracted to the serum and produced high RU’s with all dilutions of 
lysozyme tried.  This can both be attributed to the unreliability of the control and also 
the stickiness of the serum.  Even though the serum was centrifuged to remove the 
albumin, it still contained unknown contaminants, possibly bacteria, or remnants of 
bacterial cells, which were attracted to the ligands.  These unknown contaminants made 
regeneration via temperature change more difficult, requiring a higher temperature, but 
still manageable.  
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Table 5.7 The Response of Lysozyme Spiked Serum Samples regenerated via 
temperature change 
SLZ 
Conc. 
LZ Bound 
(RU) 
Temp Increase 
for 
Regeneration 
RU loss due to 
Temp Increase 
Difference in 
Start & End 
Baselines (RU)
0.05µg/ml  FC1     15 
FC2     27 
25.2oC
25.4oC  
5.2
8.2
55.1
55.8
-1.6
+8.5
0.1µg/ml FC1     51 
FC2     46 
25.2oC
25.3oC 
25.4oC  
 
11.8
13.0
27.6
27.8
59.2
58.3
-4.5
-7.3
0.2µg/ml FC1     28 
FC2     31 
25.3oC
25.4oC  
5.7
8.2
45.6
43.2
+7.3
+7.4
*Values in Red are obtained from FC1; values in Blue are obtained from FC2. 
 
The lysozyme binding was again affected by the regeneration.  After 0.05µg/ml was 
regenerated, 8.5RU was still left bound.  As less than 10RU remained bound it was 
thought that this was small enough to not effect any subsequent injections.  However, 
the remaining bound analyte did have the effect of increasing the RU for the 0.1µg/ml 
injection.   
 
5.8.4 Validation Study  
This validation study (Table 5.8) was carried out to test the quality of samples after they 
had been spin filtered.  Before injection into the BIAcore each serum sample was spin 
filtered using Vivaspin centrifugal filters which removed all molecules larger than 
30kDa.  Before centrifuging, each sample was spiked with 0.25µg/ml lysozyme.  In 
theory the lysozyme should remain in the sample after centrifugation as its molecular 
weight is 15kDa and the albumen in the serum (MW 60kDa) should be removed. Once 
spun, the samples were then diluted and assayed with the ELISA protocol and also 
injected into the BIAcore.  The lysozyme content was then recorded. 
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Table 5.8 Validation study; results were compared from two spiked serum samples 
assayed with the ELISA and then injected into the BIAcore. 
BIAcore Response Units 
Sample ID 
FC1 (Control) FC2 (Aptamer) 
ELISA (µg/ml) 
VN1 4.3 34.8 0
VN2 14.4 37.9  0
 
The results from the BIAcore experiment seemed promising.  Lysozyme was seemingly 
detected in both samples and there was a difference between anti-lysozyme aptamer 
detection and poly-T control detection.  However, when the samples were assayed via 
the ELISA protocol, a system which has a proven record of good lysozyme detection, 
no lysozyme could be detected in either sample.  This experiment suggested that using 
the centrifugal preparation method with serum samples, resulted in total removed of all 
lysozyme in the sample.  All previous results using this technique are therefore brought 
into question.  The removal of lysozyme maybe due to its attraction to albumen or other 
molecules in the serum, such as bacteria, drugs and plasma proteins.  If the lysozyme 
binds to any of these molecules, and is then trapped on the membrane and disallowed 
through the pores, the lysozyme will be removed from the sample. 
 
5.8.5 Serum Sample Trial  
Figure 5.18 shows the effects of injection of a non-centrifuged spiked serum sample.  
The serum sample was spiked with 0.05µg/ml lysozyme.  The sample produced a huge 
response, with FC1 3101.9RU and FC2 2458.7RU.  As such a small amount of 
lysozyme was used to inoculate this sample the huge response can only be attributed to 
the albumin, bacteria and unknown contaminants of the serum.  Regardless of the 
increase in internal BIAcore temperature, the ligand could not be regenerated. 
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Figure 5.18 Graph showing the loss in baseline due to temperature regeneration method 
using an un-spun lysozyme spiked serum sample. 
 
This experiment showed the importance of the centrifugal process in the serum sample 
preparation.  It additionally showed that the serum could pass through the micro-tubing 
of the microfluidic system.  As previous experiments had shown, a compromise 
between not centrifuging the sample at all and centrifuging using the spin filters needed 
to be found, before adequate lysozyme detection could be achieved using this method.  
The solution may simply lie in using a spin filter with a greater pore size. 
 
5.8.6 Clinical Samples  
For the final experiment (Figure 5.19) to test the Lysozyme Biosensor, 10 clinical 
samples were randomly chosen from those assayed using the ELISA protocol.  The 
samples were chosen because of their high lysozyme content, as shown by the ELISA.  
The BIAcore results were produced from serum samples which were diluted 1/100 and 
compared to those shown in Figure 5.17.  Figure 5.19 shows that there is no correlation 
between the samples processed using the Lysozyme Biosensor and those from the 
ELISA. 
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Figure 5.19 Clinical Samples; the figure shows the lysozyme content of a set of serum 
samples donated from of a selection of ill patients all with known high lysozyme levels.  
The samples were assayed using the ELISA system and the Lysozyme-Biosensor 
method. 
 
Eight of the samples (D4, D22, D52, D55, D46, N26, A15, & A17) yielded results that 
were lower than the results gained from the ELISA.  These results do tally with the 
results from the Validation Study, which showed samples that were centrifuged using 
spin filters contained no lysozyme.  The clinical samples used with the lysozyme 
biosensor could be influenced by bacterial presence in the samples.  The conclusion 
therefore is that another method needs to be sought after to prevent the loss of lysozyme 
when serum samples are being prepared for use in the BIAcore. 
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5.9 Discussion 
This section discusses the results from sections 5.7 and 5.8.  Further detailed analysis is 
collated in Appendix M. 
 
5.9.1 Ligand & Analyte Binding 
The final concentration of anti-lysozyme aptamer which was used for clinical testing 
was 2x10-3pM.  This was shown to be stable after injection as well as being active. 
Preconditioning of the SA sensor chip helped make the aptamer stable and the binding 
of the aptamer reproducible.  The pre-treatment of the aptamer at 95oC for 3 minutes 
also assisted in the binding of the aptamer securely.  The aptamer preparation was 
prescribed in the paper by Liss et al. (2002).  The theory behind the heating of the 
aptamer before injection was to unfold the structure.  The aptamer was then chilled on 
ice after heating to preserve the intra-molecular folding and then immediately injected.   
The binding of the control ligand was achieved with 0.1µM concentration.  This 
concentration was the same as the IgE control used in Appendix B.  The control binding 
and aptamer ligand binding were tailored to the same RU values.  This was to ensure an 
equivalent test was carried out, with the same ligand coverage on the chip surface. 
 
5.9.2 Non-Specific Binding 
Non-specific binding was tested using several different methods.  Poly-T was injected 
onto an unmodified CM5 sensor chip.  The poly-T did not bind showing that it was not 
non-specifically binding to the surface, but in fact binding via the streptavidin-biotin 
bond.  Streptavidin is a homotetrameric protein with a single biotin binding site in each 
subunit.  It is to be expected that the biotinylated ligand binds to the streptavidin 
because of the exclusively strong bond between the two.  The dissociation constant of a 
streptavidin and biotin complex is estimated at 4x10-14M (Qureshi et al., 2001). 
 
Lysozyme was injected onto a blank SA sensor chip.  This was to test for non-specific 
binding of the analyte.  Again no binding was seen showing the binding of lysozyme to 
the ligand was specific to the aptamer.  This was to be expected as the lysozyme was 
specific only to the anti-lysozyme aptamer.  The aptamer buffer may have also helped 
as non-specific binding is limited by the salt content in the running buffer. 
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The problem of non-specific binding of the lysozyme on the control ligand surface was 
tackled by immobilising biotin on to the free streptavidin molecules.  This idea was 
taken from a paper by Schneider et al. (2000), where biotin was used to control the 
surface chemistry of an optical sensor chip for the detection of human chorionic 
gonadotropin (hCG).  In theory, the biotin should have bound to the free streptavidin 
rather than the ligand (poly-T) and thus eliminated any non-specific binding of 
lysozyme.  However, no biotin bound and therefore a solution to this problem was not 
found.  An explanation of why the biotin did not bind could have been that instead of it 
working as an allosteric activator and binding to the allosteric (other) site on the 
streptavidin, it worked as an allosteric inhibitor in that it decreased the activity of the 
streptavidin (Huang et al., 2002).   
 
5.9.3 Negative Control Analytes 
The molecular charges of the ligand and analyte have an important bearing on their 
binding ability.  This is also true for the negative control analytes which were used to 
test the ligand.  Bovine serum albumin (BSA) was chosen due to its availability in the 
laboratory.  On injection, the BSA coated the surface of the sensor chip and destroyed 
the ligand completely.  There are two explanations for this, either the charge of the BSA 
was opposite to that of the ligand and an attraction was formed, or the BSA could have 
been too sticky and viscous and simply covered the surface.  The more likely effect is 
the charge of the molecules.  An article by Krieger (2003) explains that molecules with 
the same charge can “snuggle up” if the ions in solution are oppositely charged.  These 
oppositely charged ions nullify the repulsion between the larger molecules which have 
the same charge.   
 
The second negative control analyte to be tried was myoglobin from equine heart.  This 
was chosen because of its similar molecular weight to lysozyme. However, the 
myoglobin again coated the surface of the sensor chip.  As such a weak solution was 
prepared and filtered rigorously, the myoglobin’s coverage onto the chip was put down 
to charge attraction.  As explained above the ions in solution could have acted to nullify 
the repulsion of the myoglobin and caused an attraction to the surface of the sensor. 
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5.9.4 Biosensor Regeneration 
The initial search for a regeneration solution began with examples from the work on the 
IgE biosensor (Appendix B).  These solutions were tested first as they were known to 
have an affect on the IgE aptamer.  There was little information in the literature that was 
directly relevant since sources such as the “Biacore Sensor Surface Handbook” (2003) 
lacks information on aptamer regenerations due to their novelty.  Ideally regeneration 
should simply remove the bound analyte from the ligand leaving the ligand intact, 
undistorted and reusable.  The analyte should be removed and the original pre-analyte-
injection baseline should be reached.  In cases where the ligand is lost during 
regeneration it can be assumed that the surface modification of the senor chip has also 
been damaged and the life of the chip is effectively ended.  The nature of and strength 
of association and dissociation of the analyte and ligand binding can determine whether 
regeneration will work properly. 
 
The Hydrochloric acid and Ethanol & sodium hydroxide solution did not have an affect 
on the aptamer ligand.  The hydrochloric acid did not decrease the baseline and the 
ethanol & sodium hydroxide was very unstable.  The “Biacore Sensor Surface 
Handbook” (2003) also suggested sodium hydroxide, sodium chloride and magnesium 
chloride as potential regeneration solutions, but again none had the desired effects.  
Many of the regeneration solutions were tried because they were known to reduce or 
increase the pH on the surface of the sensor chip; such as hydrochloric acid and sodium 
hydroxide.  Others were tested because they increased the ionic strength on the sensor 
surface; such as magnesium chloride and sodium chloride.  As none had favourable 
effects other regeneration resolutions were sort after.   
 
The question as to whether to regenerate to a point of some ligand loss or to leave some 
analyte bound was apparent with all regenerations.  The theoretical Rmax equation 
showed that the anti-lysozyme aptamer binding capacity was 149RU.  The maximum 
analyte capacity was never reached by any of the lysozyme concentrations shown in 
sections 5.8.1-4.  Not even the highest dilutions of lysozyme or where lysozyme was 
repeatedly injected and not regenerated produced a response that reached the Rmax.  This 
according to the BIAcore “Sensor Surface Handbook” (2003) is normal.  Rmax is simply 
Chapter 5 143
an estimation of the maximum amount of binding possible; and is rarely obtainable due 
to ligand accessibility, dissociation of ligand after immobilisation and regenerations 
with harsh solutions.  Therefore a decision was made to leave some analyte bound when 
regenerations could not be fully achieved.  A limit of analyte bound was arbitrarily set 
at 10RU.  Leaving 10RU of analyte bound ensured that the ligand remained intact and 
active. 
 
5.9.5 New Regeneration Regime 
As the stability and ultimately the effectiveness of the regeneration solution ethanol & 
sodium hydroxide was deemed unreliable, a new regeneration regime was sought after.  
The idea for the thermo-regeneration came from a consideration of the aptamer 
confirmation change during a temperature increase, which is known to be useful to help 
immobilise the aptamer.  It follows then that the aptamer’s confirmation could be 
changed to release analyte. 
 
The thermo-regeneration was both inexpensive to perform and most importantly did not 
harm the ligand.  The only limitation of this regeneration is the time it takes to perform.  
The BIAcore 3000 can only increase the internal temperature by 5oC per hour.  
Therefore, when processing large numbers of clinical samples, the regeneration time 
may have to be taken into consideration or the instrument redesigned.  A solution to this 
lengthy regeneration process might be to transfer the method over to a newer BIAcore 
system.  The BIAcore T100, allows 384 samples to be analysed per run.  Incorporating 
the lysozyme biosensor method, with the thermo-regeneration and the T100 would 
justify the lengthy regeneration time. 
 
A further limitation with the thermo-regeneration was with the fine-tuning.  Whether to 
regenerate to a point of ligand loss or to a point of some analyte remaining was still a 
problem even with this regeneration regime.  The same pragmatic solution was applied 
to this regime and a limit of 10RU of analyte remaining was adopted.  This allowed the 
ligand to remain intact and as the Rmax was never reached, for the analyte to continue 
binding. 
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5.9.6 Serum Dilution 
A range of serum dilutions were tried but 1/100 was chosen because of its positive 
binding response.  Published work has described serum dilutions as low as 1/40 
(Jongerius-Gortemaker et al., 2002).  Even though other published methods use 
different serum dilutions, the method here responded better to the 1/100 dilution.  This is 
perhaps due to the spin filters used, which other published methods have omitted. 
 
5.9.7 Lysozyme in Buffer Calibration Curve  
The lysozyme calibration curve (Figure 5.16) showed specificity of the lysozyme to the 
aptamer as no binding was seen on the control ligand.  The amount of lysozyme binding 
increased with increasing concentration, up until the final dilution (0.5µg/ml).  With this 
dilution and subsequent higher dilutions binding decreased.  Regeneration was not 
carried out in between each lysozyme concentration when building this calibration 
curve.  The ligand was simply being saturated over time and saturation was reached at 
0.5µg/ml.  There is the possibility that some active ligand sites were blocked, but the 
Rmax was reached as the following explains. 
 
The Rmax determines the capacity of the ligand.  Here the Rmax is 149RU.  However, this 
is a rough estimate of the ligand capacity; the exact Rmax is unattainable due to the 
nature of this work, as the ligand and analyte are not under complete control possibly 
due to active sites on the ligand being blocked or allosteric effects taking place. By 
taking the figures from Figure 5.16 and adding them a saturation of 154RU is 
calculated.  This shows that the Rmax has been reached and explains why no further 
binding takes place after 0.4µg/ml. 
 
5.9.8 Thermo-Regeneration Using Lysozyme-Spiked Serum Samples 
The regeneration in this experiment using serum samples (Table 5.7) was far more 
difficult compared to the regeneration of buffered lysozyme as shown in Figure 5.19. 
This work showed that the preparation of the serum samples was not adequate for the 
detection of lysozyme.  Bacteria, remnants of bacteria or unknown factors were still 
present and attracted to both ligands.  This resulted in the regeneration behaving very 
differently to other trials, in that higher temperatures were required.   
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A method which may improve the lysozyme measurement from serum was proposed by 
Hansen & Andersen (1973).  Their work tested the quality of lysozyme from blood 
plasma and found that solublisation with n-butanol was the best method for releasing 
lysozyme for the measurement.  One millilitre of n-butanol was added to the plasma and 
mixed vigorously for 30 minutes.  The suspension was then centrifuged for 10 minutes 
at 3000g and the sample was then ready for use.  Hansen & Andersen (1973) suggest 
that during the spinning of serum samples, without this pre-treatment there is 
destruction and fracturing of the cells which release lysozyme.  This suggests that 
lysozyme itself may also be inactivated or destroyed.  This method could be used with 
the lysozyme biosensor method and may increase the lysozyme content of the serum 
samples, leading to a more accurate measurement. 
 
5.9.9 Validation Study 
This study was carried out to establish whether there was any lysozyme present in the 
spiked serum samples.  Two samples were assayed using the ELISA and also injected 
into the BIAcore for measurement.  This study showed that no lysozyme was present 
after centrifugation.  Possible reasons for this might include the lysozyme being broken 
down during this process, leading to sedimentation and ultimately no detection.  A 
further reason might be that the bacteria, drugs and other plasma proteins in the sample 
may be breaking down and the fragments are then being separated into the working 
serum portion and being injected into the BIAcore and interfering with the ligand.  
Either of these reasons are plausible.  The “Biacore Sensor Surface Handbook” (2003) 
recommends the use of salt in the running buffer to reduce non-specific electrostatic 
interactions; however, the aptamer buffer did contain salt and this did not solve the 
problem.   
 
A limitation of the ELISA was that the anti-lysozyme aptamer was not used in this 
method.  Future work may include the development of an aptamer based ELISA known 
as an Enzyme Linked Oligonucleotide Assay (ELONA).  Serum samples in the ELISA 
were not subjected to spin filtering so any bacteria, drugs etc in the samples were shown 
not to be interfering with the ELISA results.  Further work needs to be carried out to 
explore this aptamer based ELISA system. 
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The answer to the Lysozyme biosensor problem may lie not actually in filtering the 
serum further but in treating the serum sample prior to injection into the lysozyme 
biosensor.  The “Biacore Sensor Surface Handbook” (2003) recommends “ligand 
mimics”, which actively compete with the analyte in the serum for ligand on the sensor 
surface.  This may limit the need for rigorous filtering of the serum and may therefore 
preserve the lysozyme in the serum. 
 
5.9.10 Un-spun Serum Sample Trial 
Figure 5.18 shows the response from injection of an un-spun serum sample.  A serum 
sample was spiked with a known amount of lysozyme and immediately injected into the 
BIAcore.  No centrifugation was carried out on this sample, so the response was purely 
due to the lysozyme and the other contaminants of the serum sample.  The result was 
that the sensor could not be regenerated.  As we know from previous experiments, a 
centrifuged spiked lysozyme sample can be regenerated and a buffered lysozyme 
sample can also be regenerated.  This leads to the conclusion that the contaminants of 
the serum sample which are not being removed by the centrifugation are interfering 
with and binding to the ligand.  This shows that the preparation method for the serum 
samples is not sufficient for injection into the BIAcore.  A further method for the 
preparation of serum needs to be investigated. 
 
5.9.11 Serum Sample Trial 
Despite the problems with spiked serum samples, an initial experiment was carried out 
using 10 clinical samples, which were injected onto the lysozyme biosensor.  The 
majority of the results produced from the BIAcore revealed lower amounts of lysozyme 
in the samples than those produced by the ELISA (Pearson r2=0.0145).  The conclusion 
here still stands, due to time constraints this was not addressed, but a new preparation 
method for the serum, which removes contaminants such as albumin and bacteria, but 
leaves lysozyme intact, needs to be established before this system can be used as part of 
routine clinical detection of lysozyme.   
 
 
 
Chapter 5 147
5.9.12 Lysozyme Biosensor Synopsis 
The lysozyme biosensor has huge potential, but not enough time was available to 
explore this further.  Once established, the biosensor would require very little training 
by an operator.  A further advantage would be if the method was transferred to the T100 
BIAcore, which could process more than 300 samples per run. 
The only downfall of the BIAcore method is the initial cost of the system and the 
expense of the sensor chips which would be beyond the scope of a hospital.  A way to 
overcome this problem is to use an inexpensive system such as the Spreeta (Texas 
Instruments, USA), which has small initial costs, is inexpensive to run and analyse 
samples.  The lysozyme biosensor method could potentially be transferred over to the 
Spreeta (Appendix L) and would still produce a real-time detection system.  However, 
there would be some loss of sensitivity with these simpler instruments.  The only way 
the BIAcore system would be cost effective for a hospital is if it were to be used to 
analyse more than one clinical parameter. 
 
Currently the lysozyme biosensor gives good results for lysozyme in buffer, where it 
can be successfully regenerated.  Pearson r2=0.5729 for lysozyme in buffer and clinical 
samples r2=0.0145.  Further development is needed on the serum preparation method.  
Serum contains proteins such as albumen and globulins with a MW66kDa.  Serum from 
septic patients, also contain bacteria and prescription drugs which also have a high MW.  
Therefore spin filters (30kDa pore) should remove all albumen and bacteria from the 
serum, leaving free lysozyme to be detected.  But this was not the case.  Remnants of 
bacteria, drugs, plasma proteins, sedimentation of disturbed lysozyme, lysozyme 
sticking to albumen could all prevent suitable filtering and explain why lysozyme was 
not found in serum.  The serum samples for the ELISA and BIAcore were all prepared 
in the same way, in that they were all centrifuged at the hospital and frozen for delivery.  
No spin filtering took place.  A serum sample which undertook no spin filtering was 
injected into the BIAcore but coated the surface of the chip.  A spin-filtered serum 
sample was also injected into the BIAcore, but no lysozyme could be detected.  
Therefore a method for removing these interfering particles, which leaves the lysozyme 
free and detectable, is needed.   
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A simple test to illuminate the problem of bacteria with the lysozyme would be to 
culture a spun and an unspun serum sample.  This would elucidate one of the possible 
causes of lysozyme loss.  Ideas for lysozyme extraction will be discussed in the Future 
Work section.  This may then allow the lysozyme biosensor to detect lysozyme in serum 
samples and create a test with huge possibilities for future diagnosis of sepsis. 
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Mild Sepsis Severe Sepsis
0 1 2 3
•Plasma bilirubin level in absence of jaundice >25µmol/l
•Plasma albumin 31-35g/l
•Platelet count 100-150x109/l
•Leukocyte count 12-30x109/l
•Positive blood culture
•Haemoglobin level in absence of bleeding 7-10g/dl
•Plasma albumin 25-30g/l
•Platelets <100x109/l
•Leukocyte count <30x109/l
•Haemoglobin <7g/dl
•Plasma albumin <25g/l
•Leukocyte count <2.5x109/l
•1x Positive blood culture + 
•cardiac murmur and/or tender enlarged spleen
•2x Positive blood culture over 24hrs
•1xPositive blood culture + invasive procedure
Laboratory Data
Mild Sepsis Severe Sepsis
0 1 2 3
Pyrexia
36-37.4ºC 37.5-38.4ºC 38.5-39ºC >39/<36ºC
Mild Sepsis Severe Sepsis
0 1 2 3
Secondary Effects of 
Sepsis
Max daily temp >37ºC +1      If 2+ temps peak above 38.4ºC in 1 day +1
APPENDIX A -Sepsis Grading
Adapted from Elebut & Stoner, 1983
•Metabolic 
acidosis-
compensated
•Metabolic acidosis-
uncompensated
•Jaundice (in absence of 
hepatobiliary disease)
•Renal failure
•Gross disturbance of mental orientation
•Level of consciousness
•Septicaemia
•Bleeding diathesis
•Wound infection with 
discharge/enterocutaneous fistula, requires light 
dressing changed daily
•Localised peritonitis
•Clinical or x-ray signs of chest infection, 
without cough
•Wound infection with discharge, 
requires dressing changing more than 
once/day, requires suction
•Clinical or x-ray signs of chest 
infection with productive cough, 
(sputum)
•Generalised peritonitis
•Full clinical manifestation of 
lobar/bronchopneumonia
•Deep seated infection eg. Abscess, 
pelvic abscess, empyema thoraxis
•Acute/chronic osteomylitis
Mild Sepsis Severe Sepsis
2 4 6
Local Effects of Tissue 
Infection
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APPENDIX B - IgE BIAcore Protocol & Discussion of Results 
 
Objective 
This part of the project took place at the Universita Degli Studi Di Firenze in Italy.  The 
main objective of this work was to produce a model system using Immunoglobulin E as 
the target using the BIAcore X.  The working system would then be considered for 
future use for the determination of lysozyme using the BIAcore 3000 at Cranfield 
University.  At the time of this work, the BIAcore X was malfunctioning so the IgE 
Spreeta work was carried out first, therefore several of the buffers used for the Spreeta 
work were also used in the BIAcore X method.  These can be found in Appendix L. 
 
Materials & Methods  
Many of the materials used for the Spreeta experiments (Appendix L) were also used for 
the BIAcore IgE biosensor.  Changes are shown below. 
 
Sensor Chips 
The Sensor chips used with the BIAcore experiments were CM5 (Research Grade) 
(Biacore, Sweden).  These sensor chips were immobilized with Dextrin. 
 
Control Ligand 
The non specific DNA used for the control sensor chip with the Biacore was poly-
T_57_B purchased from MWG (the IgE aptamer has 45 base pairs so the poly-T was a 
good comparison).  No heat-treatment was required for the preparation of this. 
 
Buffers 
A buffer recommended for use with the BIAcore was used, this was HSP-EP buffer 
with added detergents (Tween 20).  Spreeta buffer was also used with these 
experiments. 
 
BIAcore X 
The BIAcore flow rate for all injections was set at 5µl/min. 
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Before use the BIAcore was cleaned for 72hours with reverse osmosis water in 
continuous flow.  The water was then changed for degassed Spreeta buffer.  The 
cleaning sensor chip was undocked and refrigerated. 
 
Sensor Chip Docking 
After initial preparations were carried out the CM5 sensor chip was inserted into the 
BIAcore X and primed for 3 minutes. 
Continuous flow of the buffer was carried out for a further 12 hours. 
 
CM5 Activation 
The CM5 sensor chip was activated using a NHS+EDAC solution.  A volume of 55µl 
was injected at a flow rate of 5µl/min. 
 
Streptavidin Immobilization 
Streptavidin was prepared (200ppm) as of Appendix G and 50µl injected.  A blocking 
solution of ethanolamine was used (35µl), to block unbound sites on the chip. 
 
Control Ligand Immobilisation 
On flow cell 1 a non specific DNA molecule was used.  This flow cell became the 
control.  The non specific DNA was poly-T (57 bases); this was injected for 20 minutes, 
(100µl) onto flow cell 1 only. 
 
Aptamer Ligand Immobilisation 
On flow cell 2 the anti-IgE aptamer was immobilized.  Pre-treatment was carried out as 
with the Spreeta (Appendix L) and a 200ppm dilution was injected over 20minutes, 
(100µl). 
 
Analyte Injection 
All IgE antigen dilutions were prepared in the Spreeta buffer (Appendix L).  The 
running buffer of the BIAcore X was the BIAcore Specific buffer HBS-EP, but was 
changed to the Spreeta buffer during the analyte injections. 
 
Appendix B 
Control Analyte 
IgG was used as a control analyte and were prepared in the Spreeta buffer. 
After injection of IgE & G sample, buffer was allowed to flow for several minutes to 
stabilize the signal. 
 
Regeneration 
The regeneration buffers included 1mM hydrochloric acid, 5mM hydrochloric acid, 
10mM hydrochloric acid, and NaOH+EtOH 50%. 
 
BIAcore IgE Results 
Figure B1 shows the association between IgE and aptamer at various concentrations.  
Some concentrations could only be tested once due to the limited supply of the IgE 
antigen.  However, the results from 30ppm-50ppm were in proportion with all other 
concentrations, even though they were only trialed once. 
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Graph 5 Shows Concentrat ion  versus  RU for Bia core Results
 
Figure B1 Shows the concentration of IgE and the respective RU value obtained. 
 
Running Buffer 
Initially the running buffer and the buffer used to make dilutions of IgE and G was not 
the same.  All IgE and G dilutions were made using the spreeta buffer and the running 
buffer was the BIAcore specific HBS-EP.  No signal could be seen with this, so the 
running buffer was changed to the spreeta buffer.  The baseline increased but stabilized 
quickly and produced positive results. 
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Control Analyte 
Double negative controls were carried out as seen in the raw data (Table 2) using IgG 
and flow cell 1 with the non specific poly-T immobilisation.  Binding was only seen on 
flow cell 2 with IgG once, giving a value of 5.9 RU.  However, the IgG 20ppm was 
trailed twice more shown on 21/07/04 giving negative results both times (Table 2).  An 
IgG 50ppm was also injected onto flow cell 2 also showing no binding. 
 
IgE Binding 
Insignificant binding of IgE was seen on flow cell 1 (control).  Where binding was seen 
it could be attributed to the IgE being from an old aliquot.   
The IgE was purchased at the start of the experiments.  All aliquots of this were made 
on the same day using fresh spreeta buffer and all were frozen at –20oC at the same 
time.  However, specific dilutions were made at various times during the experiments.  
A new sample would therefore be the first dilution made from a fresh aliquot from the 
freezer and all dilutions there after would be considered old.  Where an old sample is 
noted on the raw biacore results a significant decrease was seen in the binding of the 
IgE and aptamer results.  This led to significantly large error bars on Figure B1, for 
10ppm especially.  
 
The only conclusion to be drawn from this is that the IgE is very unstable in the spreeta 
buffer.  We can hypothesis that when the initial aliquots of IgE were made the freezing 
process stopped the denaturation of the IgE.  However, upon defrosting denaturation 
began, thus resulting in low RU results as the aliquots aged.  This meant that the 
concentrations of IgE were not reproducible unless fresh aliquots were used with every 
dilution. 
 
This hypothesis is given credibility by the high dissociation rate as seen in Figure B2.  
Figure B2 shows the dissociation rate in seconds when the sample injection stops.  The 
dissociation rate shows a decrease constant for all concentrations, with an R2 value of 
0.9778.  Compared to the results seen in the paper by Liss et al. (2002) this dissociation 
is ~100 times faster than that seen in their experiments.  This is perhaps due to the 
degradation of IgE which only temporarily binds to the aptamer then quickly released 
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leaving only a small amount securely bound.  The RU value after the dissociation for 
5ppm was less than 10, meaning that any lower concentrations would probably not have 
been detectable.  Liss et al. (2002) reported a detectable limit of 100µg/l IgE were as the 
detection limit here is 5x103µg/l; a considerable difference.  However, their aptamer 
was used in solution and not immobilized to a solid surface, which could explain our 
aptamers disappointing performance when compared to the work by Liss et al. (2002).  
This degeneration of IgE was also seen in the regeneration phase.  Hydrochloric acid 1, 
5 and 10mM were all tried without success.  A harsher solution of sodium chloride and 
ethanol was used to remove the IgE from the aptamer.  If the IgE was broken down into 
fragments of immunoglobulins then some were remaining intact and binding securely, 
which therefore warranted a harsh regeneration solution. 
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Figure B2 shows the dissociation for various IgE concentrations. 
 
Due to this harsh regeneration solution the viability of the sensor chip surface was 
brought into question.  After each regeneration phase the baseline would always be 
lower than the pre-IgE injection baseline.  In conjunction, was the declining signal with 
increased use of the sensor chip.  This may indicate that the regeneration solution is 
degrading or removing aptamers from the surface with increased use; thus limiting the 
life of the sensor. 
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Immobilization Phase 
 Plateau Result 
Post Dissociation 
Result (RU)  
Date Analyte Dilution Cell 1-Control 
Cell 2-
Aptamer 
Cell 1-
Control 
Cell 2-
Aptamer 
Injection 
volume/time, if 
different from  
75µl/15mins 
Comments 
14/07/2004 NHS+EDC 271.9 236.1 35/7 All dilutions made in Spreeta buffer.  Running buffer was HBS-EP  
 Streptavidin 200ppm 4555.2 4093.4 50/10  
 Ethanolamine -37.7 -3.1 35/7  
 Poly-T 25µM 2004.7 -22.1 125/25  
 Aptamer -112.3 1108.4 100/20  
 
IgE Testing Phase 
 Plateau Result 
Post Dissociation 
Result (RU)  
Date Analyte Dilution Cell 1-Control 
Cell 2-
Aptamer 
Cell 1-
Control 
Cell 2-
Aptamer 
Injection 
volume/time, if 
different from  
75µl/15mins 
Comments 
14/07/2004 IgE 0.1ppm -34.6 -35 Dilutions made in Spreeta buffer, running buffer was HBS-EP.  
15/07/2004 IgE 1ppm -12.1 -6.9 Reg. HCl 1mM 4µl 
IgE 1ppm -3 -6 Reg. HCl 1mM 4µl 
IgE 2ppm -1.3 -4.1 Reg. HCl 1mM 4µl 
IgG 2ppm   1 -2.7  Reg. HCl 1mM 4µl 
16/07/2004 IgE 5ppm -2.8 2.4 Reg. HCl 1mM 4µl 
IgE 5ppm -1.7 -1.5 Reg. HCl 1mM 4µl 
 IgE 10ppm   -0.7 1.3 Reg. HCl 1mM 4µl 
 IgE 20ppm  -6 6 Reg. HCl 1mM 4µl 
20
pp
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 IgG 20ppm     9.3 5.9  Reg. HCl 1mM 4µl, 5mM 4µl, NaOH+EtOH 4µl 
 IgE 10ppm 31.5 32.7 6.9 5.6  Reg. HCl 1mM 4µl, NaOH+EtOH 50% 4µl 
19/07/2004 IgE 20ppm 34.9 340.5 -0.7 57.8  Reg. HCl 5mM 4µl, 10mM 4µl, NaOH+EtOH 50% 4µl 
 IgE 30ppm 50405.3 405.3 -5.9 65.9 Reg. HCl 10mM 4µl, NaOH+EtOH 50% 4µl 
 IgE 40ppm 7.4 467.4 -3.1 94.5 Reg.NaOH+EtOH 50% 4µl 
50
pp
 IgE 20ppm 32.5 309.1 0.6 60.5 Reg.NaOH+EtOH 50% 4µl 
20/07/2004 IgE 10ppm 13.4 12.2 -0.2 -1.1 Old IgE used. Reg.5mM HCl 4µl, NaOH+EtOH 50% 4µl 
 IgG 40ppm     0.9 -4.2    
 IgG 50ppm     10.3 -2.3   Old IgG used. Reg.NaOH+EtOH 50% 4µl 
 IgG 50ppm     -12.6 -10.5   Old IgG used. Reg.NaOH+EtOH 50% 4µl 
10
pp
 IgE 10ppm 10.1 202.6 14.8 33.2 70/14 New IgE used. Reg.NaOH+EtOH 50% 4µl 
 IgE 10ppm -2.3 171.8 -13.9 18.8 70/14 New IgE used. Reg.NaOH+EtOH 50% 4µl 
 IgE 5ppm -10.5 86.8 -4.3 10.6 70/14 New IgE used. Reg.NaOH+EtOH 50% 4µl 
 IgE 5ppm -10.6 68.9 -0.8 8 70/14 New IgE used. Reg.NaOH+EtOH 50% 4µl 
 IgE 10ppm 24.1 105.9 -0.7 7.5 70/14 Reg.NaOH+EtOH 50% 4µl 
5p
p
 IgE 20ppm -8.1 254.9 4.5 56.2 70/14 Reg.NaOH+EtOH 50% 4µl 
 IgE 5ppm -7.1 59.9 -3.7 14.4 70/14 Reg.NaOH+EtOH 50% 4µl 
21/07/2004 IgE 10ppm 63.6 73.8 7.8 7.5 70/14 Reg.NaOH+EtOH 50% 4µl 
 IgG 20ppm     -1.6 -6.2 70/14  / 
 IgG 20ppm     0.6 -7.5 70/14  / 
50
pp 
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APPENDIX D – Collection of Normal Blood Samples 
Analysis of Serum Samples from Healthy Donors to Establish a Reference Range for Lysozyme 
 
Aim of Study -This study will be used to determine normal serum lysozyme levels.  These can then be 
used as a reference range for clinical samples provided by the Great Western Hospital.  This study will 
also validate the ELISA test currently used for blood samples. 
 
Background -My project is involved with the development of a diagnostic test for lysozyme which can 
be used to indicate intra abdominal sepsis.  There is currently no standard reference range for lysozyme 
which is universal across hospitals.  This study will be used to determine the normal level for lysozyme in 
healthy individuals, to be used as a guide for clinical samples provided by the Great Western Hospital.   
 
Samples Required -Human blood samples from healthy individuals are required.  20 volunteers will be 
recruited and blood samples taken by the campus nurse.  
 
Exceptions -Samples will only be taken from those people who deem them selves well enough, who have 
no known infections or have had recent surgery.  
 
Protocol 
1. Volunteers will be recruited from within the Institute of Bioscience and Technology via verbal 
invitation. 
2. An explanation of the study will be given and the volunteer will receive an information sheet and 
consent form to sign.  
3. No personal information will be taken from the volunteers.  Each sample taken will be given a 
unique lab number. 
4. A blood sample of >10ml will be taken by the campus nurse. 
5. The sample will be centrifuged and the serum extracted and stored at -20oC.  When all samples 
have been collected an ELISA will be carried out and the lysozyme level determined.  
6. When the test is complete the volunteers will not be given the lysozyme level results. 
7. All information collected from the samples will be stored in a locked filing cabinet and the 
samples put in long term storage at -80oC. 
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You are being invited to take part in a research study.  Before you sign up it is important that you 
understand why the research is being carried out and what will be expected of you. 
 
Consumers for Ethics Research (CERES) publish a leaflet entitled Medical Research and You.  A copy of 
this may be obtained from CERES PO BOX 1365, London N16 0BW if you require any further 
information regarding medical research. 
 
Purpose of the Study -The purpose of this study is to establish a normal level of lysozyme in serum.  
Lysozyme is an enzyme in blood, released during infection.  It is therefore a good indicator for Intra-
abdominal Abscess.  Intra-abdominal abscess causes multiple organ failure in severe cases with a 
mortality rate exceeding 90%.  The current tests for lysozyme both lack reliability and sensitivity and are 
therefore not relied on in hospitals.  Signs, symptoms, and white blood cell counts are used instead which 
are not conclusive.  A need for a clinical test which provides a definite response for the diagnosis of 
sepsis is required.  However, in order to do this a target needs to be set.  This involves establishing the 
normal lysozyme range in disease free volunteers. 
 
Do I have to take Part? -If you do decide to take part you will be asked to sign a consent form with the 
understanding that you are free to withdraw from participating at any point.  You should not take part in 
this study if you have had had a surgical procedure or an infection recently. 
 
What will be Required From You? -A 10ml blood sample will be taken by the medical centre nurse. 
 
Possible Risks -You may suffer from discomfort while the blood is being taken and slight bruising in the 
region where the blood was taken from.  If you are harmed during the procedure due to negligence then 
you may have grounds for legal action. 
 
At the End of the Study -All samples will be destroyed at the end of the project and no information 
regarding results will be relayed to the volunteers. 
 
Confidentiality -All personal information including any results gained will remain confidential.  No 
results will be given you any volunteer. 
 
Study Reviewers -The Cranfield Biomedical Ethics Committee has deemed this study fit for execution. 
 
Contact for More Information -If you have any further questions, please contact: 
n.j.lawton.s02@cranfield.ac.uk or s.morgan@cranfield.ac.uk 
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Volunteer Consent Form: 
 
Analysis of Serum Samples from Healthy Donors to Establish a Reference Range for Lysozyme 
 
 
Please initial all boxes: 
 
1. I confirm that I have read and understood the information sheet for the above study and have  
had the opportunity to ask questions. 
2. I understand that my participation is voluntary and that I am free to withdraw at any time. 
3. I understand that I should not take part in the study if I have had a recent infection or surgery. 
4. I agree to take part in the above study. 
 
 
Name of Volunteer 
 
Signature         Date 
 
Name of Campus Nurse 
 
Signature         Date 
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Sample 
No. M/F Age Date LZ µg/ml 
Com. 
Kit 
ng/ml 
Hb Platelets WBC Neut % 
Lym 
% ESR CRP Diagnosis 
Diag. 
Ref. 
A29 M 51 - 5.58 0.0179 9.2 116 6.6 31 66  38 Leukaemia, cellulites, cerotic   A 
A33 M 51 - 5.2 0.0148        Leukaemia, cellulites, cerotic   A 
A34 M 51 - 5.5 0.0183        Leukaemia, cellulites, cerotic   A 
D34 M 66 28/11 4.8 0 8.6 16 0.8 8.7 83.4  33 Leukaemia, no sepsis A 
D35 F 64 29/11 6.8 0 10.4 1248 28.2 87 5  132 Leukaemia, no sepsis, died A 
D4 M 90 30/11 10.3 0.55 8.3 778 89.7 15 14  26.1 Leukaemia, septic, died A 
D57 M 43 5/12 9.4 0 5.7 261 9 84 7  20 Chronic myeloid Leukaemia, non sepsis 
A 
N12 M 58 30/11 3.7 0.2 11.2 195 1.9 39 37   Leukaemia, non-Hodgkin’s lymphoma A 
A11 M 79 13/9/04 8 0.0183 10.1 31 0.6 51 45  122 Died neutropenic, lymphopenic, pneumonic, leukaemia 
Ab 
A13 F 89 - 5.5 0.0183 12.4 373 10 60.6 26.8  70 Pneumonia B 
A15 M 95 - 9.2 0.0195 9.2 292 14.9 81 7.9   Pneumonia, septicaemia, died B 
A17 F 66 12/9/04 8 0.0195 12.1 209 9.9 65.5 18.4  105 Pneumonia, died B 
A2 M 67 11/9/04 3.9 0.0148 7.2 650 17.7 95 2.6   Pneumonia B 
A21 F 75 - 5.7 0.0195 7.2 26 1.5 61 34  62 Pneumonia, died B 
A23 M 95 - 6.3 0.0195        Pneumonia, septicaemia, died B 
A30 F 76 - 7.2 0.015 9.4 433 8.9 54 29  100 Septic pneumonia B 
A31 M 84 - 7.8 0.0195 9 443 14.8 92 5.9  194 Pneumonia, pseudo +ve, died B 
A32 F 75 - 5.7 0.0195        Pneumonia, died B 
A36 F 59 - 5.6 0.0195 8 621 11.7 74 16  153 Peripheral vascular disease, pneumonia, +ve dipthroid, died 
B 
A5 M 67 11/9/04 5.2 0.018 7.2 650 17.7 95 2.6   Pneumonia, septicaemia B 
C15 F 68 3/11 5.6 0 11.8 295 12.5 77 8.8  63.9 Died, stroke, pneumonia, bilary tumour B 
C20 F 72 8/11 4.5 0.25 11.7 422 11 76.5 13 51 71 Recovery from pneumonia, non septic B 
D1 F 90 4/12 5.6 0 10.6 336 7.6 86.1 7.7   Fractured neck of femur, pneumonia, died 
B 
D13 F 75 26/11 8.2 0 9.6 57 4.8 11.8 18.3  240 Pneumonia, died B 
D23 F 61 1/12 6.4 0 10.9 276 11.8 86 6.8   Infected hip, pneumonia B 
D28 F 61 6/12 7.5 0 6 144 11.9 91 4.3  55 Infected hip, pneumonia B 
D51 F 61 28/11 9.8 0 5 91 10 90 9   Infected hip, pneumonia B 
APPENDIX E –Blood Count Data 
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D55 F 75 27/11 20 0.5 8.6 33 4.6 22.6 20  240 Pneumonia, died B 
D58 F 87 6/12 12 0 6.4 163 9.7 81 12  41 Pneumonia, pulmonary embolism=septic. 
B 
D9 F 61 30/11 4 0 10.3 186 10 60 8   Infected hip, pneumonia B 
E13 M 98 11/1 7.1 0.22 13 141 7.9 72 14  106.4 pneumonia B 
F4 M 83 10/2 1.5 0.13 6.5 360 12.7 83 9.3   Pneumonia B 
N25 M 81 30/11 8 0.37 11.8 219 8.4 61 25   pneumonia B 
C6 F 61 5/11 8 0 8.3 203 7.1 61 29   Wound infection, staph +ve, pneumonia, septicaemia, CRF 
Bde 
A25 F 84 8/9/04 5.3 0.0148 11.1 345 4.4 56 36  1 Died, MRSA +ve, fractured neck femur, pneumonia 
Be 
C17 M 87 2/11 6.2 0 9.4 263 19.7 85 7  143.1 Died, chest infection, anaemia, pneumonia 
Be 
E14 F 25 11/1 6.2 0.24 12 267 9.5 75 18   No sepsis, pregnant C 
E27 F 23 11/1 6.9 0.29 13.7 278 9.4 70 21 3  No sepsis, pregnant C 
E7 F 34 11/1 5.5 1.94 11.7 214 5.7 60 31   No sepsis, pregnant C 
F14 F 28 10/2 5.2 0.28        No sepsis, Pregnant C 
A26 F 59 11/1/04 3.4 0.0196 11.3 456 14.4 84 6.5   C. renal failure, died D 
N9 F 80 30/11 5.3 0.42        CRF, no sepsis  D 
F32 F 80 10/2 4.4 0.15 9.5 287 4.9 75 19   +ve blood culture, CRF, myeloma DG 
A1 F 56 - 3.8 0.015 13.4 194 4.1 90.6 8.6  47 Sepsis URTI, UTI E 
A18 M 33 9/9/04 5.8 0.0075 13 271 15 63 21 16 50 Septic arthritis, knee trauma, no sepsis E 
A27 F 90 - 5.7 0.0183 12.4 278 8.8 66 19   Infected hip prosthesis, died E 
A3 M 48 11/9/04 3.8 0.0148 8.5 306 13.4 52 22  104 GM-ve septic, diabetic E 
A35 M 48 8/9/04 5.58 0.015 11.6 87 13.7 89 11   GM-ve septic, diabetic E 
A4 M 48 9/9/04 3.1 0.017 11.6 87 13.7 89 11   GM-ve septic, diabetic E 
A6 M 55 13/9/04 5.6 0.015 14.9 254 11.3 77 14   +ve lactose fermenting, coli forms in urine 
E 
A7 M 78 - 6.32 0.0168 9.8 367 6.6 58.7 24.3  48 Pretibial abscess Ostiomylitis 
E 
A8 F 48 10/9/04 3.5 0.015 13.4 261 10.0 66 27.7  20 Groin abscess, diabetic +ve culture E 
A9 F 66 14/9/04 5.5 0.0195 6.7 162 14.9 85 6.3  80.1 Died, septic, +ve staph, septicaemia, MRSA 
E 
C12 F 50 2/11 5.2 0 11.8 740 13.4 72 19   Wound infection, MRSA, UTI, sepsis E 
C13 F 77 2/11 4.7 0 7 255 16.4 81 11  348.5 Chemotherapy , UTI sepsis E 
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C2 F 55 4/11 4.5 0 13 239 7 72 17  22.4 Wound infection, β-haemolytic strep +ve, abscess on foot 
E 
C3 F 56 5/11 6 0 13.6 193 18.2 86 6.3 14 229.6 Died, staph in line, infected elbow, septicaemia 
E 
C7 M 42 5/11 4.6 0 14.5 282 11 70 22 4 11 +ve staph culture, septic arthritis E 
D12 F 61 3/12 3.7 0 9.4 383 16.3 87 8.4  48 Infected Hip, septicaemia  E 
D14 F 64 6/12 3.8 0 11 158 6.2 89 1.6  3.7 Sepsis, pneumonia, died E 
D15 M 40 5/12 5.6 0 9.2 462 11.8 76 14  44.8 Inflammation of testes, +ve coli form E 
D18 F 75 6/12 5.7 0 8.3 218 16.7 17 12  127 Coli forms in sputum, heart failure, chest infection, died 
E 
D20 F 88 2/12 5.6 0 10.8 520 8.1 73 16  131 UTI, coli forms in urine, died E 
D21 F 75 20/11 7.2 0 7.4 209 12.5 68 14  66 Coli forms in sputum, heart failure, chest infection, died 
E 
D22 M 64 5/12 9.2 0 13 165 30 81 7  63 Wound & chest infection, septic E 
D29 F 77 4/12 8.8 0 10.5 361 17.4 78 12   MRSA, septic E 
D3 F 29 5/12 5.7 0 13.6 242 12.8 79 15   UTI, coli form in urine E 
D30 M 89 6/12 8.9 0 13 415 19 87 5  125 C-difficile infection in bowel E 
D32 F 64 5/12 5.5 0.33 12.2 162 6.1 88 2  307 Sepsis, pneumonia, died E 
D37 F 75 1/12 5.3 0 7.8 241 28.2 75 10.6   Coli forms in sputum, heart failure, chest infection, died 
E 
D41 F 60 26/11 7.5 0 5.2 195 7.9 75 19  13 Cyst abscess E 
D46 F 32 6/12 8.4 0 6.2 384 16.2 70.6 15  11.7 Pelvic inflame disease, UTI E 
D47 M 72 30/11 6.6 0.55 6.2 697 15 82 8.9  93 Staph. in urine, N/S E 
D49 F 58 3/12 7.6 0 6.8 334 12.7 74 14  194.8 Obstructed renal system, UTI E 
D5 M 25 1/12 4.5 0 15.2 198 11.4 58 27   Renal colic, UTI E 
D53 M 64 6/12 13 0 6.5 112 22.7 87 3.5   Wound & chest infection, sepsis E 
D56 M 85 26/11 10.4 0 4.8 59 13 70 11  181 C-difficile, septic E 
D8 M 65 29/11 4.6 0 11.2 397 8.7 77 14  14 Peritoneal abscess E 
E26 F 77 11/1 7.2 0.18 11.8 262 6.5 80 14   THR, UTI, +ve blood cultures E 
F1 M 67 11/2 4.8 0.14 6.8 52 16.5 86 7   Died, septicaemia, sepsis, MRSA, CRF E 
C4 F 54 3/11 5.6 0 12.9 419 8.8 64 22  21.9 Rectal cancer, sepsis, neutropenic Eg 
A28 F 59 - 6.4 0.0168        No sepsis F 
A10 F 76 10/9/04 2.6 0.0199 9.4  8.9 54 29  100 epilepsy F 
A14 F 53 13/9/04 3.7 0.0143        No sepsis F 
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A19 F 83 13/9/04 3.5 0.0179 12.3 154 18.1 89 4.5  205 Heart failure, died F 
A20 M 84 - 3.8 0.0195 8.8 346 18.5 91 6  198 Heart failure, died F 
A22 M 62 7/9/04 6.3 0.0112 13.8 200 5.3 50 34  42 No Sepsis, died F 
A24 M 33 7/9/04 6.4 0.0183 15 369 11.2 54 33   Non septic F 
C10 M 61 5/11 5.5 0 10.3 526 7.1 63 23 32 14.7 Out patient, no sepsis F 
C11 F 41 5/11 4.4 0.22 16.3 321 5.4 61 27.8  2.2 Gall stones, no sepsis F 
C14 F 79 2/11 4.8 0 7.9 699 15.1 74 12  37.2 Asthmatic, anaemic, no sepsis F 
C18 F 45 3/11 4.4 0 10.9 52 5.1 57 32   Non septic F 
C21 F 69 2/11 4.8 0 14.8 202 5.9 56 33.8   Non septic F 
C23 M 61 8/11 4.2 0 9.2 31 33.9 59 22  186.3 Head ache, non septic F 
C8 F 74 5/11 4.7 0.13 13.2 306 8.6 87 24   No sepsis F 
D10 M 75 1/12 5.7 0 13.7 266 41 90 3  179 Perforated gall bladder, died F 
D11 M 73 6/12 3.8 0 10.3 130 7 81.8 9.8  17 Diabetic, leg ulcer, non septic F 
D16 M 87 28/11 5 0 9.8 387 8 62 23  57 Non septic F 
D17 M 87 2/12 4.6 0 9.8 384 7.2 64 20   Non septic F 
D26 M 32 6/12 6.4 0 11.8 295 7 60 28 18 4 Non septic F 
D27 M 87 26/11 6.8 0 8.3 289 8.5 71 16.2  57 Non septic F 
D33 F 75 3/12 4.6 0 9.6 249 25 71 15   Heart failure, died F 
D36 F 17 26/11 5.5 0 8.5 458 10 67 24   Over dose, no sepsis F 
D38 M 78 5/12 6 0 12 350 10 81 9  101 Non sepsis, died F 
D42 F 30 28/11 7.4 0 5.5 345 10 62 27  0.5 Non septic F 
D44 F 58 2/12 8.2 0 6.8 360 14.7 83 11   anaemia F 
D45 F 58 6/12 8.7 0 7 457 10 62 21   anaemia F 
D48 F 66 6/12 8.4 0 6.2 267 6.8 50.9 37  36.4 Chrones disease, N/S F 
D50 M 84 26/11 9.2 1.1 8.6 432 24.5 80 6.1  115 MI, died F 
D7 F 80 29/11 3.1 0 15.4 159 40.4 96 3   Trauma, no infection, died F 
E1 F 79 11/1 5.7 1.28 11.5  12.1     No sepsis F 
E10 M 51 11/1 6.4 0        No sepsis, diabetic F 
E11 M 35 11/1 5.2 0        No sepsis F 
E12 F 56 11/1 6.6 0 13.9 253 6 69 18   No sepsis F 
E15 F 80 10/1 5.7 0.38        No sepsis, varicose ulcer F 
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E16 F 36 11/1 6.3 0.24        No sepsis, diabetic F 
E17 F 49 11/1 5.3 0.3 11 196 5.1 84 10  6.3 No sepsis, chrone’s disease F 
E19 M 75 11/1 6.3 0.25        No sepsis F 
E2 F 69 11/1 5.8 1.2        No sepsis F 
E20 F 91 10/1 7.1 0.23 9.3 179 3.5 46 43   No sepsis F 
E21 M 84 11/1 4.6 0.23        No sepsis F 
E22 F 84 10/1 6 0.24        No sepsis, abdo pain F 
E23 F 33 11/1 6.6 0.3 11 356 10 82 12   No sepsis F 
E24 F 37 10/1 6.9 0.24        No sepsis F 
E28 M 82 11/1 7.2 0.3        No sepsis F 
E29 M 48 11/1 6.2 0.3 15 197 7.5 45 40   No sepsis, chest pain F 
E3 M 55 11/1 6 0.82        No sepsis F 
E30 M 72 11/1 6.5 0.25      3 0.5 No sepsis F 
E5 M 43 11/1 6.9 0.92 14.2 358 11.5 60 19   No sepsis F 
E8 F 77 11/1 8 1.47      4 2.4 No sepsis F 
E9 F 40 11/1 6.7 0.56 11.4 184 6.3 74 16   No sepsis F 
F10 F 81 10/2 5.8 0.22 12.7 292 7.5 74 15 11 2.8 +ve blood culture, no sepsis F 
F12 M 65 10/2 5.2 0.3        No sepsis F 
F13 M 72 10/2 7.6 0.35 12.7 201 7.2 76 14   No sepsis F 
F15 M 82 10/2 5.2 0.2 11 245 6 58 24  4 No sepsis F 
F16 M 65 10/2 4.6 0.3 14.5 328 8.8 57 30 5  No sepsis F 
F17 M 61 10/2 5.5 0.3 12.1 241 7.5 62 28   No sepsis F 
F18 F 68 10/2 5.4 0.3        No sepsis F 
F19 F 61 10/2 5.7 0.25 12.7 240 7 65 25   No sepsis F 
F2 M 55 10/2 5 0.3 15.4 207 7 52 35   Diabetic, no sepsis F 
F21 M 73 10/2 6.2 0.16        Diabetic, no sepsis F 
F23 F 66 10/2 6.3 0.25        No sepsis F 
F24 M 33 10/2 5.6 0.15        Diabetic, no sepsis F 
F25 M 65 10/2 6.5 0.22 14.2 254 7 52 34   No sepsis, chron's disease F 
F26 F 70 10/2 6.2 0.29 12.4 298 6.8 63 27   no sepsis F 
F27 M 49 11/2 6.2 0.2 11.1 347 7.5 38 45   Chest pain, no sepsis F 
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F28 F 64 10/2 5.7 0.17 10.6 265 9.3 74 17   THR, no sepsis F 
F29 F 52 10/2 5.7 0.22        No sepsis F 
F3 M 34 10/2 4.7 0.12        No sepsis F 
F30 M 54 10/2 5.68 0.23        No sepsis F 
F31 M 72 10/2 6.4 0.24        Diabetic, No sepsis F 
F33 M 33 10/2 6.1 0.23 14.5 255 6.8 77 14 9  No sepsis F 
F34 M 56 10/2 5.9 0.25 12.7 295 5.6 61 26   No sepsis F 
F35 F 50 10/2 5.7 0.22        No sepsis F 
F36 F 54 10/2 5.7 0.24        Diabetic, No sepsis F 
F37 M 57 10/2 5.9 0.3 14.5 195 5.9 61 27   No sepsis F 
F38 M 42 9/2 5.7 0.29        Diabetic, No sepsis F 
F39 F 66 10/2 6.6 0.22        No sepsis F 
F40 F 53 10/2 6.1 0.25 12.8 259 6.5 72 16  18.6 No sepsis F 
F5 F 54 10/2 5.4 0.12        No sepsis F 
F6 F 68 10/2 4.9 0.18        No sepsis F 
F7 M 40 10/2 5.2 0.1        No sepsis F 
F8 F 62 10/2 5.1 0.24        No sepsis F 
F9 M 78 11/2 1.4 0.12 9.7 84 5.3 70.9 12.4  17 Non septic, died F 
N1 M 60 30/11 4 0.42 13.9 208 5.8 62 26   Non septic F 
N11 M 30 30/11 4.5 0.22 15.8 219 12.7 69 20 12  Seizures, no sepsis F 
N13 F 65 30/11 4.5 0.42 12.4 267 8.8 50 39   Gynaecological, non sepsis F 
N14 M 70 30/11 3.4 0.22 13.9 201 8.5 48 35  3.3 Non septic F 
N15 M 69 1/12 4.2 0.2        Non septic F 
N16 F 51 30/11 4.6 0.29        Non septic F 
N18 M 70 30/11 4.7 0.2        Non septic F 
N19 M 69 30/11 5.5 0.22        Non septic F 
N2 F 41 30/11 5 0.28        Non septic, high cholesterol F 
N20 F 79 1/12 6.2 0.35        gout F 
N21 M 60 30/11 6.9 0.3 13 326 10 62 27 33 12.4 Divaticulitis, inflammation of the colon, non sepsis 
F 
N23 M 57 30/11 7.7 0.42 15.1 242 5.8 55 35   GP referral , Non septic F 
N26 M 71 30/11 8 0.15 9.8 308 3.6 74.3 17  16.9 Chest complaint, Vegas syndrome, no F 
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sepsis 
N27 M 69 30/11 7.5 0.25        Non septic F 
N28 M 63 30/11 6.6 0.2        Non septic F 
N29 M 51 30/11 8.2 0.16 15.5 243 5.7 53 35   GP referral, normal F 
N3 F 47 30/11 3.9 0.29 12.7 233 4.5 65 17  6.1 Liver disease F 
N30 F 43 30/11 7.1 0.16 13.1 421 12.4 64 20 8 1.5 Non septic F 
N4 F 70 30/11 4.5 0.2 14.4 198 5.5 56 31 3  Non septic F 
N5 F 62 30/11 4.6 0.03 13.9 164 7.8 71 21   Non septic F 
N6 F 30 30/11 5.4 0.35 11.8 134 10.3 76 14.7  69 Non septic F 
N7 M 35 30/11 5.2 0.69        Non septic, GP referral F 
N8 F 91 30/11 5.2 0.36        died F 
V1 F 26 Dec 04 3.7 0.15        Healthy F 
V2 M 25 Dec 04 2 0.15        Healthy F 
V3 F 42 Dec 04 3.8 0.16        Healthy F 
V4 F 28 Dec 04 4.6 0.15        Healthy F 
V5 F 26 Dec 04 5.8 0.18        Healthy F 
V6 M 27 Dec 04 5.7 0.15        Healthy F 
VN1 M 27 Aug 05 3.7         Healthy F 
VN2 F 26 Aug 05 4.4         Healthy F 
VN3 F 29 Aug 05 3.8         Healthy F 
VN4 M 31 Aug 05 5.4         Healthy F 
VN5 F 40 Aug 05 5.4         Healthy F 
VN6 F 45 Aug 05 5.4         Healthy F 
VN7 F 40 Aug 05 3.8         Healthy F 
VN8 M 37 Aug 05 3.7         Healthy F 
D6 F 51 - 5.2 0        Appendicitis, Non septic, abdo pain Fh 
E4 F 33 11/1 5.4 1.26 12.3 391 13.2 79 15   No sepsis, pregnant FC 
N24 F 32 30/11 7.4 0.24 11.9 231 8.3 60 30.3 7  pregnant FC 
C9 F 81 4/11 4.5 0.18 12.5 343 8.6 43 29   Renal cancer removal, pre-op G 
D19 M 82 26/11 4.6 0 10.9 337 19.6 89 3  9 Bladder tumour G 
F11 F 68 10/2 5.2 0.12 13.3 420 12.9 81 14 48  Breast cancer, No sepsis G 
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F20 M 75 10/2 6.2 0.25 11.1 434 5.2 62 25   Tumour, chemo, No sepsis G 
N10 M 71 30/11 6.3 0.4 11.8 175 4.7 60 24   Chemotherapy, colon tumour, no sepsis 
G 
N17 M 53 30/11 4.6 0.25 14 178 10 90 6.7   Lymphoma patient G 
N22 M 50 30/11 7.4 0.13 13 201 4.3 66 20 5  Lymphoma, Hodgkin’s disease, no sepsis 
G 
D52 F 64 2/12 9.6 0 4.4 358 8.7 76 14 40 9 Pancreatic tumour, stroke, chest infection, died 
Ge 
A12 F 13 10/9/04 5.2 0.0183        NS abdo pain H 
C1 F 45 7/11 5.2 0 13.9 271 9.7 86 7  119.2 Abdo pain H 
C16 M 30 4/11 4.6 0 13.4 219 4.9 49 35  6.9 Abdo pain H 
C5 F 20 4/11 5.3 0 13.4 381 12.3 75 15   Ovarian cyst, abdo pain H 
D25 M 22 5/12 6.8 0 13 203 5 6 23  41 Abdo pain H 
D31 F 48 28/11 5.8 0 10.6 348 5 65 21   N/S abdo pain H 
D39 F 44 6/12 5.7 0 11 501 16.9 83 9.2  175 N/S abdo pain H 
D40 F 43 3/12 5.4 0 5.2 494 27.3 89 4.4   N/S abdo pain H 
D43 F 58 4/12 7.4 0.15 7 428 8 64 20  107 Abdo pain H 
D54 F 78 23/11 9.8 0 4.9 292 5 49 35   N/S abdo pain, GP results H 
E18 M 53 11/1 6.5 0.2 13 237 12 87 7  0.3 Abdo pain, No sepsis H 
E25 F 26 11/1 6.5 0.24 13.2 397 9.8 60 29  9.8 No sepsis, abdo pain H 
E6 F 63 11/1 5.6 0.98 14.1 236 7.1 57 33 69 23 Abdo pain, No sepsis H 
F22 F 43 10/2 6.9 0.25 12.7 333 9.8 55 35 16 5 Abdo pain H 
A16 F 46 11/9/04 7.7 0.015 12.9 294 19.2 92 5  47 Perf. Appendix I 
C19 M 16 4/11 4.6 0.35 13.7 296 16.7 79 7.4  258.6 Gangrenous appendix I 
C22 F 42 5/11 5.3 0 8.9 233 9.8 47 48  38.4 Wound infection, staphylococcus +ve, appendectomy 
I 
D2 M 17 3/12 5 0 16.2 241 17.4 76 11  66 Acute gangrenous appendix I 
D24 F 45 29/11 6.6 0 13 312 17 79 8  258 Appendectomy, +ve wound culture I 
*Diagnosis Reference =A-leukaemia, B-pneumonia, C-pregnant, D-CRF, E-septicaemia, MRSA, UTI, URTI,  
F-no sepsis, C. difficile, G-tumour, H-abdo pain, I-appendicitis 
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Appendix F Concentration Comparison Assays 
 
Membrane Descriptions from Plate F1 
The discolouration on ½ was far greater than on sample 1/3, as expected.  The OD of ½ 
was also higher than the filtrate of 1/3.  Neither control membrane shown as 
discolouration, and both filtrate OD’s were greater than their respective samples.  The 
control OD’s were very different to each other. 
The discolouration on 1/5 is slightly lighter then on 1/6 membrane.  The control 
membrane for 1/6 has a small amount of binding present as highlighted.  The control 
filtrate OD for was higher than the 1/6 filtrate OD.  However, the OD of the control for 
1/5 was not greater than 1/5. 
 
Plates F1 Comparison of membrane discolouration for several bacteria samples, 
showing.  The OD for each sample is underneath the membrane.  The concentration of 
each sample is above each membrane. 
 Plate F1 Photograph of Membrane 
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The discolouration on 1/3 is clearly darker than the ¼ membrane.  No discolouration was 
seen on either the controls, and only the 1/3 control OD was greater than the sample. 
There is a slight difference between the discolouration on 1/9 and 1/10 with 1/10 being 
slightly darker.  The control for 1/10 also showed a small amount of binding as 
highlighted above.  Both control filtrate OD’s were greater than the sample OD. 
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APPENDIX G -Solution Recipe Index 
 
 
Table G1 -ELISA Solutions   
Coating Buffer Tris (Hydroximethyl) aminomethone (Fisher, UK) 25mM pH8 
dissolved in Reverse Osmosis (RO) water.   
Wash Buffer 0.1% BSA, 0.05% Tween 20 solution in Tris pH8 25mM.   
Blocking Agent 250µl of a 1% Bovine Serum Albumin (BSA grade V, Sigma-
Aldrich Ltd, UK) and Tris pH 8 25mM 
TMB cocktail 1:1 dilution of TMB (3,3’,5,’ – Tetramthylbenzidine),  (Sigma-
Aldrich, UK) containing chromogen & hydrogen peroxide with Tris 
pH8 25mM 
 
Table G2 -ELIFA Solutions 
Wash Solution Tris pH7.5 25mM, 0.1% BSA and 0.05% Tween 20  
Blocking Agent 1% Casein in Tris pH7.5 25mM 
Coating Buffer Tris (Hydroximethyl) aminomethone (Fisher, UK) 25mM pH8 
dissolved in Reverse Osmosis (RO) water.   
WBTC Tris pH7.5 25mM, 0.1% casein, 0.05% Tween 20 and 1% BSA.   
 
Table G3 -Mini-ELIFA Solutions 
Wash Solution Tris pH7.5 25mM, 0.1% BSA and 0.05% Tween 20  
Blocking Agent 1% Casein in Tris pH7.5 25mM 
Coating Buffer Tris (Hydroximethyl) aminomethone (Fisher, UK) 25mM pH8 
dissolved in Reverse Osmosis (RO) water.   
WBTC Tris pH7.5 25mM, 0.1% casein, 0.05% Tween 20 and 1% BSA.   
Liquid Broth 0.1% Bacto Tryptone (The microbiological Supply Company, UK), 
0.05% Bacto Yeast Extract (Oxoid, UK) and 0.05% Sodium 
Chloride (Fisher, UK) in 1 litre reverse osmosis (RO) water. 
Agar 15g/litre of agar (The microbiological Supply Company, UK) added 
to Liquid Broth 
E. coli JM83 K12 derivative was used from the laboratory stock.   
A loop of E. coli from the laboratory stock was incubated and 
shaken in 50ml LB broth for 24 hours at 37°C.  Cotton wool was 
placed inside the neck of the conical flask and silver foil and 
autoclave tape were used to seal the flask during incubation.  The 
contents of the conical flask were then transferred to a centrifuge 
tube and spun for 10 minutes at 14000g-force.  The supernatant was 
poured off and disposed of and replaced by an equal volume of 
PBS.  The tube was vortexed to mix and resuspend the pellet. 
 
Table G4 -BIAcore Solutions 
Aptamer buffer Tris 20mM pH 7.5, 10mM Sodium Chloride and 5mM Magnesium 
Chloride (Sigma-Aldrich Ltd, UK).   
Poly-T Buffer 10mM Tris pH 7.5 and 1mM Ethylenediamiretracetic Acid 99% 
(EDTA) (Sigma-Aldrich Ltd, UK).   
Anti-lysozyme Tris 20mM pH 7.5, 100mM NaCl and 5mM MgCl2 (Fisher, UK).   
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aptamer buffer 
Amine Coupling 
Kit  
N-hydroxysuccinimide (≥97% purity) and 1-Ethyl-3-(3-
Dimethylamin propyl) Carbondiimide (Biacore, UK) 
Streptomyces 
avidinii  
Stock solution of Streptavidin avidinii diluted in acetate buffer 
10mM pH5 
Ethanolamine 1M pH8.6 (Biacore, UK) 
Preconditioning 
Solution 
50mM Sodium Hydroxide and 1M Sodium Chloride (Fisher, UK) 
Regeneration 
Solutions 
0.1-1M Sodium Citrate (Sigma-Aldrich Ltd, UK); 1, 5 and 10mM 
Hydrochloric Acid (Fisher, UK); 1M Magnesium Chloride (Sigma-
Aldrich Ltd, UK) and a 50% solution of 2.5% Ethanol with 25mM 
Sodium Hydroxide (Fisher, UK) 
Biotin 1mM 10µl dilution on Poly-T buffer 
 
 
 
APPENDIX H –Commercial Kit Instructions
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Appendix I - Additional ELISA Clinical Data Analysis 
This section details the suggestive relationship between the patient’s condition and the 
results from the blood analysis provided by the Great Western Hospital and the 
lysozyme analysis from the ELISA.  The results from the commercial kit are also shown 
on each graph, however, no correlation could be found for any value. 
 
Clinical Sample Results -Abdominal Pain & Appendicitis 
Figure I1 shows the haemoglobin levels of patients suffering from abdominal pain.  The 
graph shows the haemoglobin levels increasing with increasing lysozyme.  Compared to 
the reference range, the lysozyme levels are high for this group of patients but the 
haemoglobin levels are within range (Appendix J).   
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Figure I1 Comparison of Lysozyme and Haemoglobin levels in patients with abdominal 
pain; graph showing lysozyme levels lowering with lower haemoglobin. 
 
Figure I2 shows the neutrophil levels of these patients against lysozyme levels.  The 
neutrophil levels are decreasing as the lysozyme levels increase.  The neutrophil levels 
for this group are at the top end of the reference range, where as the lysozyme levels 
range from normal to higher than normal.   
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Figure I2 Comparison of lysozyme and neutrophil levels in patients with abdominal 
pain; graph indicates neutrophil levels decreasing with lysozyme concentration. 
 
Figure I3 shows the lymphocyte levels.  The lymphocyte levels for the abdominal pain 
patients varied enormously, increasing with increasing lysozyme levels.  The white 
blood cell counts of Figure I4 also covered the entire reference range from 4-11x109/µl.  
The white blood cells appeared to decrease with increasing levels of lysozyme. 
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Figure I3 Comparison of lysozyme and lymphocytes in patients with abdominal pain; 
graph indicates lymphocyte levels increasing with lysozyme increase. 
 
For the appendicitis patients the only correlation in the results which could be found 
was between lymphocytes and lysozyme.  The lymphocytes appeared to decrease as 
lysozyme increased.  During the aftermath of surgery the body goes through a stressful 
period and many changes in the leukocyte family occur.  This happens due to the stress 
of surgery which impairs the lymphocyte function causing a defect on antigen 
recognition, proliferation response and a decrease in antibody production.  
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The lysozyme levels from Figure I5 are higher than the normal reference range; this is 
due to lysozyme release from neutrophils at the infection site.   
 
No correlation could be seen when comparing the haemoglobin levels with lysozyme in 
the appendicitis patients.   
 
The white blood cells counts from Figure I4 are raised in some causes and this may be 
an indication of the start of a more serious infection.   
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Figure I4 Comparison of lysozyme and white blood cells in patients with abdominal 
pain; figure indicates decreasing white blood cells with increasing lysozyme levels 
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Figure I5 Comparison of lysozyme and lymphocytes in patients with appendicitis; 
Figure I5 indicates decreasing lymphocytes with increasing lysozyme levels. 
 
Clinical Sample Results –Chronic Renal Failure  
Chronic renal failure is the progressive deterioration of renal function, leading to 
complete renal failure.  Figure I6 shows the decreased haemoglobin levels from the 
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chronic renal failure patients sampled.  Sixty to eighty percent of renal failure patients 
suffer from anaemia (lack of haemoglobin) (www.medlineplus.com, 2005).  This graph 
illustrates the symptoms of this disease. 
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Figure I6 Comparison of lysozyme and haemoglobin in patients with chronic renal 
failure; Figure shows decreasing haemoglobin levels with increasing lysozyme levels.  
 
Figure I7 shows the platelets levels in the chronic renal patients.  Normally in chronic 
renal failure platelet levels are decreased. 
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Figure I7 Comparison of lysozyme and platelets in patients with chronic renal failure; 
graph shows decreasing platelet levels with increasing lysozyme levels. 
 
The lysozyme levels in these patients are raised due to the kidneys lack of ability to 
excrete waste products.  Also during chronic renal failure the renal mass can reduce 
drastically and this can also increase the serum lysozyme levels, (Davis, 1971). 
 
Very often infections are a result of renal failure for this reason and the increase in 
lymphocytes in Figure I8 shows this.   
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Figure I8 Comparison of lysozyme and lymphocytes in patients with chronic renal 
failure; graph shows increasing lymphocyte levels with increasing lysozyme levels. 
 
Acute renal failure precedes the chronic stage of the disease.  This stage is not as severe 
and the neutrophil counts of these patients are generally raised.  In the chronic form of 
the disease the neutrophil counts are depressed due to the stress of the disease on the 
immune system.  Figure I9 shows the depression of the neutrophil count as the 
secondary infection is succeeding, due to the development of chronic renal failure in 
these patients. 
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Figure I9 Comparison of lysozyme and neutrophils in patients with chronic renal 
failure, Figure shows decreasing neutrophil levels with increasing lysozyme levels. 
 
 
Clinical Sample Results – Leukaemia  
Leukaemia is a form of cancer involving the lymphocytes of the bone marrow 
(www.cancer.org, 2005).  Leukaemia is known to cause to be associated with anaemia.  
Figure I10 shows a decreased haemoglobin levels in these patients and an increased 
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lysozyme level.  Lysozyme levels are increased in leukaemic patients due to the high 
WBC count and increased turnover which is indicated in Figure I11, (Davis, 1971). 
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Figure I10 Comparison of lysozyme and haemoglobin in patients with leukaemia; 
Figure indicates decreasing haemoglobin levels with increasing lysozyme levels. 
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Figure I11 Comparison of lysozyme and lymphocytes in patients with leukaemia; graph 
shows decreasing lymphocytes levels with increasing lysozyme levels. 
 
Figure I12 shows normal levels of platelets in the leukaemia patients which are not 
expected.  Due to the increased prevalence of anaemia the platelet levels should have 
been decreased; however Figure I12 does not show this. 
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Figure I12 Comparison of lysozyme and platelets in patients with leukaemia; graph 
indicates increasing platelets levels with increasing lysozyme levels. 
 
The neutrophil count of these patients is shown in Figure I13.  Myeloid leukaemia is 
cancer of the granulocyte white blood cells, (e.g. neutrophils) and lymphocyte 
leukaemia is cancer affecting the lymphocytes of the body.  The clinical information 
provided, in most cases did not specify which type of leukaemia these patients were 
suffering from.  Therefore it can only be assumed from the results that most patients 
were suffering from lymphocytic leukaemia as the lymphocytes in this sample group 
were lower than normal values.  The neutrophils were higher as seen in Figure I13.   
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Figure I13 Comparison of lysozyme and neutrophils in patients with leukaemia; graph 
indicates increasing neutrophils levels with increasing lysozyme levels. 
 
The white blood cell count is a total count of all leukocytes, including neutrophils, 
monocytes, lymphocytes, and eosinophils.  In Figure I14 the graph shows the white cell 
count to be vastly increased due to the leukaemia.  Leukaemia like many cancers 
involves uncontrollable cell growth.   
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Figure I14 Comparison of lysozyme and white blood cells in patients with leukaemia; 
graph indicates increasing white blood cells levels with increasing lysozyme levels. 
 
Clinical Sample Results – Pneumonia  
Pneumonia is the inflammation of the lung tissue caused by infection.  Figure I15 shows 
the platelet counts from the pneumonia patients.  This graph shows the decrease in 
platelets as lysozyme is released.   
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Figure I15 Comparison of lysozyme and platelets in patients with pneumonia; Figure 
shows decreasing platelets levels with increasing lysozyme levels.  
 
Figure I16 shows the C-reactive protein levels in the pneumonia patients.  Levels of 
CRP are usually increased in pneumonia patients as CRP is released by the liver in 
response to inflammation.  Therefore as lysozyme is released and more neutrophils are 
present at the site of infection the higher the CRP level will become.  Figure I16 shows 
this increase in CRP with increasing lysozyme. 
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Figure I16 Comparison of lysozyme and C-reactive protein in patients with pneumonia; 
graph shows increasing C-reactive protein levels with increasing lysozyme levels. 
 
Clinical Sample Results – Pregnant  
During pregnancy it is normal to have a slightly low platelet count due to the body 
producing more blood plasma which makes the platelets more dilute.  Figure I17 shows 
a normal amount of platelets in the patient’s samples.  As the graph shows a fall in 
platelets as lysozyme is released it indicates that these patients are suffering from some 
kind of infection.   
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Figure I17 Comparison of lysozyme and platelets in patients who are pregnant; shows 
decreasing platelets levels with increasing lysozyme levels.    
 
Figure I18 shows the increased neutrophil count along with a decrease in neutrophils 
when lysozyme increases.  During pregnancy leukocytosis occurs; this is the increase of 
neutrophils with a slight increase in lymphocytes.   
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Figure I18 Comparison of lysozyme and neutrophils in patients who are pregnant; graph 
shows decreasing neutrophils levels with increasing lysozyme levels. 
 
Clinical Sample Results – Tumours  
Anaemia is very common in cancer patients.  It was not certain whether the patients in 
this study had malignant tumours but the low haemoglobin levels in Figure I19 suggest 
anaemia in these patients.  Anaemia can be a result of bleeding or a lack of red blood 
cells being produced in the bone marrow.  Either reason could be linked to the patients 
underlining condition. 
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Figure I19 Comparison of lysozyme and haemoglobin in patients with tumours; graph 
shows decreasing haemoglobin levels with increasing lysozyme levels. 
 
Figure I20 shows the white cell count of the patients with tumours.  As many of these 
patients had suspected cancerous tumours it would be expected that their white cell 
count be depressed.  During chemotherapy to treat malignant tumours the white blood 
cells numbers fall and sepsis is very likely due to the body’s lack of defence.  Figure I20 
shows normal white blood cell counts for these patients but it also shows the white cell 
count decreasing as lysozyme increases.  The lysozyme levels in these patients are 
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increased either due to infection or increased white blood cell turnover.  As mentioned 
previously, the white blood cell count measures the collective amount of neutrophils, 
band cells, T-lymphocytes, B-lymphocytes, monocytes, eosinophils, and basophils 
(www.medlineplus.com, 2005).  Therefore, as the lysozyme levels are increased it 
suggests that some of the patients in this group may also have infections or that the 
patients cells are being destroyed and the lysozyme is freed from the cells. 
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Figure I20 Comparison of lysozyme and white blood cells in patients with tumours; 
graph shows decreasing white blood cells levels with increasing lysozyme levels.   
 
Clinical Sample Results – Age & Sex Distribution 
Groups Sample Number Sex Ratio 
M:F 
Mean age  
(years) 
Age range 
(years) 
Controls 14 5:9 32 25-45 
Tumours 10 1:1 67.8 50-82 
Bacteraemia 42 8:13 62.1 25-90 
Pregnant 6 0:6 29.2 23-34 
Non Septic 109 54:55 60 17-91 
Pneumonia 28 5:9 76.1 59-98 
Leukaemia 9 8:1 61 43-90 
Deceased 37 12:25 75.5 56-95 
CRF 4 0:4 60 59-80 
Appendicitis 5 2:3 33 16-46 
Abdo Pain 15 1:4 42 13-78 
Totals 279 23:33 54 13-98 
 
The groups of patients studied were well matched for age and sex.  Lysozyme levels 
were compared between male and female patients who were non septic to determine if 
there were sex related differences.  No correlations between lysozyme and sex could be 
established. 
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Clinical Sample Results – Sex Related Variation of Lysozyme Concentrations in all 
Non-Septic Patients 
 
 Mean Age  
(years) 
Range  
(years) 
Mean Lysozyme Standard Deviation 
Male 58.6 25-87 5.6 1.42 
Female 55.6 17-91 5.5 1.28 
 
In non septic patients lysozyme levels did not differ significantly between male and 
females. 
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Appendix J -Reference Ranges 
Table J1 - Ranges used at Swindon’s Great Western Hospital, 2005 
Blood Cell Normal Range 
Haemoglobin Male 13-17.0g.dl
-1 
Female 11.5-16.5g.dl-1 
Platelets 150-400x109/µL 
White Blood Cell Count 4-11 x 109/L 
Neutrophil 2-7.5x109/L 
Lymphocyte 1.0-4x109/L 
C-Reactive Protein (CRP) <6mg/L 
Erythrocyte Sedimentation Rate (ESR)                           0-35mm in 1hr 
 
Table J2 - Cited Lysozyme Reference Range 
Reference Method Patients Condition
Biological 
Fluid 
LZ Range 
(µg/ml)* 
Medlab Analytic Undisclosed Control Serum 3-9
Taylor et al., 1992 Direct Immunoassay Control Serum 0.54±0.15
Giles et al., 1990 Turbidimetric Control Serum 3.38±7.35
Borgen et al., 1977 Turbidimetric Control Serum 2.1
Lysoplate Control Serum 10-25
Turbidimetric Control Serum 4-12Reitamo et al., 1981 
Nephelometirc Control Serum 5-11
Francina et al., 1986 Non-Competitive Avidin-Biotin Assay Control Serum 
0.95-
2.45mg/ml
Maron et al., 1971 Turbidimetric Control Serum 10
Johansson  
et al., 1971 Electrophoresis Control Serum 2.8±0.8
Mörsky, 1983 Turbidimetric Control Serum 0.9-2.1mg/l
Lysoplate Control Serum 22.4±1.4
Turbidimetric Control Serum 4.54±0.36Klass et al., 1971 
Fluorimetric Control Serum 11.1±0.63
Brouwer et al., 1984 Immunoassay Control Serum 0.95-2.45
M 6.4±0.8Burgess, 1973 Undisclosed Control Serum F 5.8±0.5
Hankiewicz  
et al., 1974 Undisclosed Control Serum 9.8±2.9mg/l
Hayes et al., 1972 Turbidimetric Control Serum 3.7±2
Harrison et al., 1971 Turbidimetric Control Serum 5-14
Catovsky et al.,  1971 Turbidimetric Control Serum 27.7±5.6
*M=Males, F=Females 
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Table J3 - Other Reference Ranges for Diseased Patients 
Reference Method Patients Condition 
Biological 
Fluid 
LZ Range 
(µg/ml)* 
Syrjanen et al., 1983 Lysoplate Rheumatoid Arthritis Serum 5.7±3.2
Lysoplate Crohn’s disease Serum 34.5±3.3
Turbidimetric Crohn’s disease Serum 8.79±0.47
Fluorimetric Crohn’s disease Serum 18.4±1.5
Fluorimetric Ulcerative colitis Serum 17.6±2.5
Klass et al., 1971 
Turbidmetirc Ulcerative colitis Serum 7.24±0.28
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APPENDIX K -Expected ELIFA Results 
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Figure K1 - Effect of the volume of lysozyme solution upon signal size. 
ELIFA’s were performed with lysozyme ranging from 0.05 to 20.00 µg ml-1 and three 
different volumes (62.5, 125 and 250 µl) of each concentration were passed through 
nylon membranes.  Controls lacked primary antibody.  The inset enlarges results 
obtained over the lysozyme range 0.05-0.5 µg ml-1.  Results are presented as mean 
values±SD; n=3.  Faedda A, 2003. 
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APPENDIX L - IgE Spreeta Protocol & Discussion of Results 
 
Objectives 
With the ELISA method established the next step was to produce a test which met the 
initial requirements of the project; to produce a test which could be carried out at the 
patient’s bedside.  The Spreeta technology meets this criterion, as it is a portable, 
compact device with the potential for near patient execution.  This part of the project 
took place at the Universitả Degli Studi Di Firenze in Italy.  The work shows a 
technique which has the potential for a near patient test.  If the lysozyme-Biosensor 
assay can be transferred to the spreeta it would produce a cost effective, rapid near 
patient test with huge potential. 
 
Materials & Methods  
General Reagents 
The Spreeta running buffer consisted of 60mM NaHPO4, 40mM NaHPO4, 100mM 
sodium chloride, 1mM Magnesium chloride made up to 1 litre in reverse osmosis water.  
The pH was adjusted with sodium chloride to pH7.4. 
 
Spreeta Preparation & Construction 
The Integrated Flow Cell (IFC) (SPR-EVM-BT, Texas Instruments, USA) was opened 
by loosening the screw and the black nitrile silicon gasket (1/32” thick 1560 type) was 
fitted inside the IFC, (Figure L1).  The Spreeta sensor chip was washed with ethanol 
and a Kimwipe to remove surface debris.  The Spreeta sensor was inserted with the gold 
facing the flow cell.  The lid was closed and the gasket checked to ensure the inlet and 
outlet are still visible.  The lid was screwed tight.  The tubing was attached to the inlet 
and outlet holes and the inlet tube is connected to the peristaltic pump and the outlet to 
the waste container.  The BNC-Ext cable was connected to the two pins on the face of 
the flow cell.  The Interface box is also connected using a 15-pin cable and printed 
circuit board.  This contains the electrons needed to interface between the PC and the 
Spreeta sensor. 
Supelco (Dorset, UK) TFE Teflon tubing 0.5mm IDX 1.5mm OD was connected to the 
inlet and outlet.  The outlet tubing was then connected to solvent flex tubing (ELKAY, 
Ireland) via a peristaltic pump (Gilson, Italy).  The flow rate was set at 30µl/min. 
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Figure L1 - Cross section of the Spreeta Sensor Chip, adapted from Earp & Dessy, 
1996. 
 
System Tests 
A calibration of the sensor with the software in air was carried out and the reference file 
saved.  A calibration in water was also carried out.  Water was pumped through the 
Spreeta until a stabile signal was obtained. 
 
Sensor Chip Preparation 
The thiol solution consisted of 11-mercaptoundecanoic acid 95% (Sigma-Aldrich, UK) 
2mg in 10ml Ethanol.  This was pumped though the Spreeta for 15 minutes then left 
stationary for 1 hour.  Ethanol was pumped past the sensor surface to remove unbound 
thiol until the signal stabilized.  The thiol activation solution consisted of N-
hydroxysuccinimide (≥97% purity) (Sigma-Aldrich, UK), 5.8mg and 1-Ethyl-3-(3-
Dimethylamin propyl) Carbondiimide (Sigma-Aldrich, UK) 38.3mg and water (1ml).  
This solution was left in continuous flow for 5 minutes. 
 
A stock solution of Streptavidin (Sigma-Aldrich, UK) from Streptomyces avidinii 
1000ppm was made and diluted to 200ppm for use in acetate buffer 10mM pH5.   
This was pumped though the Spreeta for ~10 minutes until the volume was depleted.  
 
Blocking Solution 
Ethanolamine (pH 8.6) was used to block unbound sites on the sensor.  A 1M solution 
(98% purity) (Sigma-Aldrich, UK) was pumped passed the sensor surface continuously 
for 20minutes.  After the blocking phase, buffer was pumped through the sensor to 
stabilize the signal. 
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Ligand Immobilisation 
The IgE Aptamer (D17.4ext) (MWG Biotech, IT) was diluted using the Spreeta buffer 
to 200ppm and stored at –20oC until use.  The IgE aptamer was pretreated before the 
immobilization by heating to 95oC for 3 minutes in a water bath.  The Aptamer was 
pumped across the Spreeta sensor for 10mintes in continuous flow and left stationary 
for 50minutes.  Running buffer was pumped through the Spreeta to stabilize the signal 
and to wash unbound aptamer from the sensor surface.  The sensor was then ready for 
testing. 
 
Analyte Preparation 
All IgE antigen (Biogenesis, UK) dilutions were prepared using the Spreeta running 
buffer.  Each IgE antigen dilution pumped through the spreeta for 15 minutes.  Buffer 
was then used to wash the unbound protein from the surface. 
 
Control Antigen 
The control antigen was IgG (Biogenesis, UK) was tested using the same procedure as 
the IgE analyte. 
 
Regeneration of the Sensor 
Various solutions were used to regenerate the sensor.  These included 1mM 
hydrochloric acid, 10mM hydrochloric acid, 50mM EDTA, 6M Urea, and Sodium 
hydroxide 25mM with Ethanol 2.5%.  Each solution was pumped through the Spreeta 
for 1 minute.  Buffer was always applied to stabilize the signal after regeneration.   
 
Results 
Preamble to Results  
This section described all the results gained from the spreeta experiments.  As 
previously mentioned, this work was carried out to demonstrate a method that could be 
used as a model system for future lysozyme detection.  The results here are therefore 
generated using the IgE target. 
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Figure L2 Streptavidin and aptamer immobilisation for various different sensors. 
 
Figure L2 shows the streptavidin and aptamer immobilised on each sensor.  Sensor 1 
had the highest amount of streptavidin immobilised but this did not result in the highest 
amount of aptamer immobilised.  An even amount of streptavidin was achieved on 
sensors 2, 4 and 5 but the aptamer immobilisation was not reproducible. 
 
Analyte Binding  
Figure L3 shows the amount of IgE binding on all sensors including the controls used.  
The control sensors were blank gold surfaces without the ligand bound; therefore no IgE 
should have bound.  On both control surfaces IgE bound.  On the ligand bound spreeta’s 
very similar IgE binding of 1ppm was seen on all sensors tried.  However, 10ppm did 
not to the same consistency, with different levels of binding seen on sensors 1 and 2. 
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Figure L3 Comparison of IgE binding on control sensors and ligand bound sensors. 
 
Analyte & Control Analyte Binding  
Figure L4 shows the levels of binding of IgE and IgG; the control analyte.  The IgE 
levels of binding look promising, as the amount of IgE binding increases with 
increasing IgE concentration.  However, when the control analyte was injected the 
binding patterns were irregular, showing no correlation indicating non-specific binding.   
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Figure L4 Comparison of IgE and IgG binding at various concentrations. 
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Reproducibility Testing  
Figure L5 shows the binding responses of several IgE solutions (5ppm) repeatedly 
injected on to sensor 4.  As the sensor was regenerated between IgE injections the same 
number of ligands should be available for further IgE binding; this should produce a 
graph which shows a reproducible amount of binding.  However, as no pattern of 
binding is seen it can only suggest the analyte is binding none specifically.  If the 
number of binding sites reduced with repeated regenerations then the levels of IgE 
binding should be decreasing with increasing numbers of injections; but this is not 
indicated. 
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Figure L5 Various IgE 5ppm samples injected on to sensor 4. 
 
Discussion  
Preliminary Testing 
Sensor 0 was the first sensor to be used.  The immobilization technique as described in 
Miller et al. (1991) stated that the sensor should be left immersed in the thiol solution 
for 2 days.  After 2 days the plastic coating of the spreeta sensor had degraded and the 
thiol solution had evaporated.  The sensor was inserted into the IFC but no minimum 
value for the baseline could be obtained.  This resulted in the conclusion that the 
organic solvent in the thiol solution had also damaged the gold surface, as well as the 
plastic coating around the sensor.  For the remaining sensors all steps of the 
immobilization procedure were carried out with the sensor inside the IFC.  All solutions 
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were pumped by the peristaltic pump passed the surface of the sensor.  This eliminated 
degradation and over exposure of the gold to the solvents. 
 
Streptavidin Immobilisation 
All 5 sensors (1-5) had the exact same concentration and volume of the thiol, thiol-
activation, and streptavidin used.  However, different running conditions were 
employed.  Figure L2 shows the streptavidin RI is much higher in sensor 1 than any 
other sensor.  In the method of sensor 1, the spreeta was left stationary in the thiol for 
2.5 hours, whereas sensors 2, 3, 4, and 5 all had three hours.  This could explain the 
increase.  A reduced time of 2.5 hours of thiol incubation may be the optimum 
incubation time.  Perhaps after this period the gold is either saturated with thiol or the 
gold begins to degrade as with sensor 0 from over exposure with an organic solvent in 
the thiol mixture.  Another explanation is the pump rate.  In sensor 2, 3, 4, and 5 the 
pump rate was altered to be in conjunction with the IgE BIAcore method Appendix B, 
of 30µl/min (pump number 0.33).  However, the immobilization phase of sensor 1 was 
carried out using pump number 2.4 a much faster speed (~240µl/min).  This could have 
caused the decrease in the streptavidin binding on all other sensors. 
 
A further change was the duration of the streptavidin incubation.  With sensor 1 the 
streptavidin sample was pumped through the spreeta, and then left for 20 minutes 
stationary.  This procedure was the same as that used for all other sensors however, with 
spreeta sensor 1 the signal had not stabilized after 20 minutes.  It was then left a further 
10 minutes stationary.  This would also explain the huge difference in streptavidin 
binding between sensor 1 and sensors 2, 4, and 5 as shown on Figure L2, because the 
longer the incubation time the more binding of the streptavidin will occur until 
saturation. 
 
Aptamer Immobilisation 
All sensors (1, 2, 4, and 5) had the same volume and concentration of aptamer passed 
through the spreeta.  However, differences can be seen on Figure L2 in the aptamer 
immobilization RI value.  Sensor 2 showed the greatest amount of binding of aptamer.  
The method here involved a 20 minute stationary phase with ethanolamine then a 15 
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minute continuous flow of aptamer followed by 60 minutes stationary phase (where the 
pump flow was stopped for 60 minutes and the sensor surface was exposed for the 
duration without a flowing solution).  This method was identical to that used in sensor 
1.  
 
The method for sensor 4 and 5 was different.  Here the ethanolamine was pumped 
through the spreeta for 20 minutes continuously and no stationary phase was used.  
Sensor 4 had a 15minute continuous flow of aptamer then a 60minute stationary phase.  
Sensor 5 had 10 minutes continuous flow and then 50 minutes stationary of aptamer (as 
seen in the raw date results).  Of the two sensors, sensor 4 yielded the lowest aptamer 
binding result.  But overall sensors 4 and 5 had lower results compared to sensors 1 and 
2.  This may be attributed to the continuous flow of the ethanolamine which did not 
effectively bind to the COOH groups of the streptavidin as well as when it was left in 
contact with the sensor in stationary phase as shown in sensor 1 and 2. 
 
A further reason why sensor 4 results may be low could be due to the cooling phase of 
the aptamer after the pre treatment.  The aptamer of all sensors are “unfolded” with 3 
minutes in a water bath at 95oC.  The aptamer is biotinylated and during the 
refrigeration the aptamer forms a secondary structure, which traps the biotinylate inside.  
The thermo-treatment unfolds the aptamer and releases the biotinylate so it can bind to 
the streptavidin.  Therefore if the aptamer after the thermo-treatment was left on ice for 
too long before injecting into the spreeta for the immobilization on the gold, it could 
refold into this secondary structure again and thus not bind properly to the gold, 
resulting in low aptamer binding. 
 
IgE Binding 
Figure L3 shows the results gained for 1ppm and 10ppm IgE for the control sensor.  It 
also shows the same concentrations for other sensors.  As the control had no aptamer 
immobilized, no binding of the IgE antigen was expected.  However, non specific 
binding (NSB) did occur.  This is shown in Figure L4.  IgE where 1ppm was applied to 
sensor 2, 4, and 5 yielding very similar results.  However, these were also similar to the 
1ppm IgE’s on the control sensor, showing that NSB was taking place.  This was further 
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shown where 10ppm IgE was applied to the Spreeta, as the binding increased on the 
control sensor at this concentration.  When comparing the results from sensor 2 10ppm 
with sensor 1 10ppm and the control, the results show that this concentration was not 
reproducible across the sensors. 
 
Figure L4 shows a comparison between IgE and IgG binding.  The overall graph shows 
that NSB is a problem with this immobilization procedure.  As IgG concentration 
decreased the NSB did not decrease as expected.  The NSB does not show a trend and is 
therefore not reproducible because of the nature of the NSB interactions. 
A trend can be seen in the IgE concentrations.  As IgE concentration decreases the RI 
also decreases.  However, as the amount of NSB is high and due to the degree of error 
also being high the reproducibility of the results is very low. 
 
Figure L5 shows all IgE 5ppm results on sensor 4 in the order they were applied to the 
sensor.  Samples 1 and 3 show a reasonable amount of binding, but as the sample 
numbers increase and the use of the sensor increases, the 5ppm RI decreased 
dramatically.  This shows firstly that the binding of IgE is not reproducible.  It also 
shows that the more the sensor is used the less binding of IgE takes place.  This may be 
due to the regeneration phase.  It was noted that with increased use of the sensor the 
number of regeneration phases also increased to reduce the signal back to the baseline; 
this trend did not correlate with the concentration of the sample.  Various regeneration 
solutions were tried in accordance with Liss et al. (2002).  This may indicate that with 
increased exposure to regeneration solutions (sensor 4 used only 10mM HCl) the 
aptamer is denatured thus reducing the IgE binding. 
 
Limitations of Methods 
Air bubbles in the spreeta system disrupt the signal both during the sample injection and 
during running buffer intervals.  Air bubbles were introduced by two methods; via the 
sample itself, via the inlet and outlet tubing not forming a complete seal as well as the 
change of solutions.  Regardless of the method of introduction, air bubbles caused many 
problems in the spreeta data collection.  Several responses were seen when an air bubble 
was introduced into the spreeta.  The signal would either produce peaks within the 
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signal, which would reduce back to the baseline when the bubble had passed through 
the system.  Alternatively the baseline signal would slowly decrease as the air was 
trapped inside the spreeta.  The only way to remove this was to discontinue sensing and 
remove the sensor chip from the Spreeta, thus losing the original baseline.  Performing a 
fast flush by altering the peristaltic pump speed had no bearing on the removal of the air 
bubbles. 
 
A further limitation of the Spreeta technique is the software.  The Spreeta software has 2 
options for viewing the refractive index signal; either a zoomed-in view of a particular 
point in the signal or a rescaled view showing the whole recorded signal in one window.  
The problem here was the signal peaks never remained at their correct proportion.  This 
means a minor peak when zoomed-in to show a single point of the signal measured, 
became a significant peak when the signal view was rescaled to show the entire 
recorded signal.  This was because when the signal window was rescaled to fit all the 
peaks and dips of the baseline into 1 small window, it would be compressed; thus 
making minor peaks into significant ones.  This therefore relies on the operators 
experience and judgment to dictate whether regeneration was needed and whether the 
baseline in fact stable; thus leading to potential errors.  This was a particular problem 
when air bubbles disrupted the signal.  The BIAcore 3000 software does not have this 
problem.  This software produces a graph that is continuously expanding with time 
used.  Here the proportion of the peaks always remains constant. 
 
Another limitation with the Spreeta was the stabilization of the baseline.  At the start of 
a days work, whether reusing a sensor or using a new one, the baseline would take over 
an hour to stabilize.  This dramatically decreased the amount of work that could be done 
in 1 day.  An explanation of why the signal was so erratic at the start of each day can 
only be the lack of continuous flow of buffer overnight.  This may suggest that deposits 
of the Spreeta buffer maybe adhering to the sensor surface, and during the initial run of 
buffer at the start of the day these deposits are washed free, showing an erratic signal.  
A solution to this problem therefore is to leave the Spreeta in a state of continuous flow 
of running buffer. 
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Conclusions 
The full potential of the Spreeta method, was not realised in these limited experiments.  
The time available to work on this piece of kit was very limited.  This meant the method 
was only partially developed and the capability of the equipment not fully explored.  
With more time to focus on this method, optimisation and refinement could have 
produced more promising results both for IgE detection and eventually lysozyme.   
 
The Spreeta has advantages over other methods such as the Biacore 3000.  Its 
portability, inexpensive sensor chips and real time detection should not be over looked 
as a possible future diagnostic instrument for lysozyme. 
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Before After Difference Comments  
Interval RIU 
Standard Dev. 
Interval RIU 
Standard Dev. 
RIU  
Sensor 1 Results  
H2O 080604a 1100 1.334540486 3.77-06  
Thiol 080604a 1800 1.362212 5.95-06 / 1.362862 7.25-06 0.000650391 
Streptavidin 090604a / 1.332752834 8.32824-06 / 1.33450880 6.24636-06 0.001756 
Aptamer 090604a / 1.337744398 6.54735-06 / 1.33782483 6.33167-06 0.0000804 
IgE 10ppm 1st 100604a 400 1.337690507 5.63592-06 1700 1.33791779 6.73931-06 0.000227 
IgE 10ppm 2nd 100604c 300 1.339888184 1.04259-05 1640 1.34014589 1.08024-05 0.000255 
IgG 10ppm 100604b 200 1.340192696 6.59391-06 1500 1.34025489 7.59934-06 0.0000622 
  
Sensor 2 Results  
H2O 170604d 300 1.33282831 5.7398-06  
Thiol 170604d / 1.360005021 6.49978-06 / 1.36091772 6.06148-06 0.000913 
Streptavidin 180604a 2500 1.332961628 4.12236-06 4552 1.33389855 6.70201-06 0.000937 
Aptamer 180604b 7150 1.336829131 6.83416-06 13100 1.336959 6.64-06 0.00013 
IgE 1ppm 210604a 5300 1.336192338 1.93953-06 6400 1.33619863 4.26939-06 0.00000629 
IgE 10ppm 210604b 200 1.336297097 3.81347-06 2000 1.33641166 3.04485-06 0.000115 
IgE 5ppm 1st 220604a 650 1.33646917 4.0527-06 2500 1.33656468 4.32638-06 0.0000955 
IgE 5ppm 2nd 220604b 4200 1.336485451 4.16703-06 6000 1.33651232 7.00693-06 0.000026868 
IgG 1ppm 210604a 600 1.33619904 3.36914-06 2100 1.33624151 1.92108-05 0.00004246 
IgG 5ppm 220604b 300 1.336483873 4.72041-06 2000 1.33651232 4.19748-06 0.0000284 
  
Sensor 3= Control   
IgE 5ppm 010704a 190 1.337612835 4.29872-06 4000 1.3376092 3.2845-06 -0.000003635 
IgE 10ppm 010704c 200 1.337600975 3.80857-06 3500 1.33766582 3.42184-06 0.000064844 
IgE 1ppm 010704c 100 1.337600531 3.50728-06 1500 1.33760666 3.29915-06 0.000006129 
  
Sensor 4 Results  
Thiol 020704b&c 3200 1.358349315 4.6183-06 6500 1.35847775 5.6026-06 0.0004278 
Streptavidin 050704a 320 1.331659328 2.64384-06 2300 1.33258821 5.9297-06 0.000928884 
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Aptamer 050704a 4200 1.335834699 4.48428-06 8000 1.33581208 5.78416-06 0.000022616 
IgE 5ppm 1st 050704b 1390 1.335777238 6.994-06 3600 1.3359131 5.7385-06 0.000140719 
IgE 5ppm 2nd 050704b 7700 1.335916745 3.75013-06 10300 1.33596746 3.31001-06 0.000050719 
IgE 5ppm 3rd 050704c 400 1.335923467 3.83416-06 2400 1.3360388 3.60285-06 0.000115328 
IgE 5ppm 4th 060704a 5200 1.336286256 4.34647-06 8200 1.33631178 4.84709-06 0.000025522 
IgG 5ppm 1st 060704b 300 1.336280218 4.66378-06 1700 1.33629511 4.21854-06 0.000014892 
IgG 5ppm 2nd 060704b 3000 1.36266674 5.10356-06 5500 1.3363015 4.29111-06 0.000034826 
IgG 5ppm 3rd 060704c 540 1.33649559 3.59807-06 1700 1.3365412 5.19323-06 0.000045609 
IgE 1ppm 1st 070704a 8000 1.336692267 4.10104-06 9800 1.33670486 2.89472-06 0.000012597 
IgE 1ppm 2nd 070704a 10800 1.33668269 4.21473-06 12500 1.33668336 4.72579-06 0.00000067very little signal was seen 
IgE 1ppm 3rd 070704b 1600 1.336820994 4.84408-06 5700 1.33675658 3.79686-06 -0.000064415hardly any signal was seen so repeated (4th) 
IgE 1ppm 4th 070704b 5700 1.336756579 3.79686-06 7200 1.33677097 4.54203-06 0.000014388 
IgE 5ppm 1st 070704a 300 1.336767035 3.27052-06 2200 1.33678124 3.81754-06 0.000014205 
IgE 5ppm 2nd 070704a 4000 1.336764859 5.15096-06 5700 1.33679148 3.23245-06 0.000026622 
IgE 5ppm 3rd 080704a no signal seen 
IgE 5ppm 4th 080704a 9600 1.337221233 4.32227-06 11600 1.33723805 4.64445-06 0.000016813 
IgE 10ppm 1st  no buffer run after sample so no results gained 
  
Sensor 5 Results  
Thiol 090704a 1550 1.358698107 3.53553-06 13300 1.35924995 5.08218-06 0.000016813 
Streptavidin 090704b 2000 1.33114825 3.5617-06 2800 1.33209664 5.6137-06 0.00094839 
Aptamer 130704a 2300 1.336974067 6.06415-06 6300 1.33705158 4.80408-06 0.000077512 
IgE 1ppm 1st 130704a 6300 1.337051579 4.80408-06 9700 1.33707209 5.35053-06 0.000020511 
IgE 1ppm 2nd 130704a/b 13300 1.33702903 3.96855-06 1800 1.33699811 4.04928-06 -0.00003091
very little binding seen plus 
an initial dip at start of IgE 
sample 
IgE 1ppm 3rd 130704c 130 1.336978489 4.69078-06 1400 1.33698121 4.43842-06 0.000002722 
IgE 1ppm 4th 130704c 2500 1.336979409 3.696-06 4000 1.33698333 4.16179-06 0.000003916 
IgE 2ppm 1st 140704a 3000 1.337662342 5.08527-06 5700 1.33761564 5.11062-06 -0.000046702 
IgE 2ppm 2nd 140704a 7500 1.337595212 5.71825-06 9400 1.33759346 4.48803-06 -0.00000175 
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Sensor No. 
& Type Aptamer Binding (RU) 
Control 
Binding 
(RU) 
Binding Events Experiment Aims 
1 
CM5 
FC1234 
No thermo-treatment 
used.=very little 
binding  
FC1 241,  
FC2 218,  
FC3 326,  
FC4 364. 
 The RB was HBS-EP at a flow rate of 5µl/min. 
NHS+EDC-11 minutes, 35µl, FC1-4, -4.5, -4.1, -1.6, -3.2 
50µl streptavidin injection, FC1-4, 122, 101, 205, 278 
Followed by 35µl ethanolamine, FC1-4, 243, 212, 234, 372 
Used Ap buffer for activation and AP immobilisation 
2x10-6pMol Ap injected. 
75µg/ml LZ sample tried 
To test the preconditioning 
regime & compare the results 
from IT. 
2 
CM5 
FC1234 
Thermo-treated 950C 
3mins (PCR) 
FC1 157,  
FC2 125,  
FC3 360,  
FC4 211. 
 Chip conditioned as above with NHS+EDC, strep, ethanolamine 
NHS-EDC, FC1-4, -4.2, -3.9, -3, -2.8 
Strep FC1-4, 41, 31, 73, -124 
Ethanolamine FC1-4, 262, 217, 428, 233 
2x10-6pMol Ap injected. 
 
To test the preconditioning 
regime & compare the results 
from IT. 
3 
CM5 
FC1234 
Thermo-treated Ap 
(PCR) 
FC1 977,  
FC2 704,  
FC3 6.4, 
 FC4 -68.  
2nd Ap injected, 
untreated, FC1 964,  
FC2 676,  
FC3 -84, 
 FC4 -176 
3rd Ap injection,  
FC1 85,  
FC2 98,  
FC3 63,  
FC4 80 
 Conditioning carried out using HBS-EP buffer, then buffer changed to Ap buffer. 
NHS-EDC, FC1-4, 378, 263, 24, 158 
Strep FC1-4, 969, 715, 4.8, 59 
Ethanolamine FC1-4, 977, 8.3, 368, 511 
Immobilisation of the strep is uneven across the chip.  Need to do separate immobilisations 
running one FC at a time. 
2x10-6pMol Ap injected. 
75µg/ml lysozyme injected (volume too small for 4 flow cells) FC1 943, FC2 297, FC3 
228, FC4 276 
Regeneration=10mM HCl= Not successful. 
FC1 317.4  RU↓27.2 
FC2 378.3 RU↓-66.3 
FC3 -156.6 RU↓118.5 
FC4 485.8 RU↓-73.1 
 
Test the preconditioning 
regime using HBS-EP buffer 
4 
CM5 
FC1234 
Thermo-treated Ap 
(PCR)  
FC 3+4,  -33, -27 
Thermo-treated Ap 
(PCR) FC2, 0  
Poly-T 
FC1 50, 
2nd 60 
Bought Poly-T control, 80mer 1µM in Poly-T buffer 
NHS-EDC FC1-4, 393, 578, 103, -45 
Strep FC1-4 4128, 4464, 3190, 3067 
Ethanolamine FC1-4, 4120, 4548, 3379, 3291 
Poly-t was injected twice due to such a small amount of binding need to change RB before 
injection. 
Did not change buffer for Ap injection. RB changed for injection onto FC2. PCR machine 
has a cooling phase at end of heating cycle so need to change treatment method.  1µM Ap 
injected. 
75µg/ml LZ injected 75µl x4 volume- no binding 
Immobilisation of Control -
Poly-T 
 
Volume modifications 
5 
CM5 
FC1234 
Treated BH Ap 
FC3+4, 41,-9.2 
Poly-T 
FC1 
174.8-no 
All injected fluids were increased in volume by 4 to cover all 4 FC’s. 
NHS-EDC FC1-4, 694, 1094, 1138, 341 
Strep FC1-4 3975, 4320, 3913, 3690 
Volume modifications for 
combined FC Strep 
Immobilisation 
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binding 
overall 
Ethanolamine FC1-4 -16, -28, 7.7, 62  
Before Poly-T Immobilisation the RB was changed to Ap buffer from HBS-EP- no binding 
overall, need to change RB to poly-t buffer just for immobilisation. 
Ap buffer=RB 1µM Ap injected x4 volume. 
75µl of 75µg/ml LZ x4.5 volume injected. FC1-4 89.2, 135, 134, 146. Regeneration10mM 
HC x3.  no poly-t binding to LZ. Regen. unsuccessful. 
6 
CM5 
FC1234 
BH treated Ap FC2 -
8.3,33.6 
Poly-T 
FC1 0 
binding 
Reverted back to standard method as the 3000 model was explained.  These volumes are the 
standard method for single FC immobilisation. 
NHS-EDC FC1-4, 391, 238, -4.3, -23.7 
Strep FC1-4 680, 624, 180, 163 
Ethanolamine FC1-4  695, 654, 248, 252  
Poly-T 1µM injected while in Poly-t RB. 
1µM Ap injected yielding no result, tried 2µM small amount of binding. 
0.05µg/ml LZ injected. FC1-4 5, 18.5, -1.3, 4 
Regen. 10mM HCl x3 without success. EtOH+NaOH 50% 20µl injected with out success. 
To get the running buffers 
right for each immobilisation. 
7 
CM5 
FC1+2 
BH treated Ap FC2 
1618.5 
Poly-T  
FC1-8.2 
no binding 
Buffers were changed according to the immobilisation. 
NHS-EDC FC1-2, 404, 284 
Strep FC1-2397, 409 
Ethanolamine FC1-2 36.9, 51 
Poly-T 5µM injected 
Ap 5µM injected, slow association but an actual binding event. 
0.1µg/ml LZ injected.  This was diluted in Tris which caused a change in the RI. FC1-2, 
293.8, -59.7. 
0.2µg/ml LZ FC1-2, 38.8, 83.8 
To increase the immobilised 
Ap & control 
7 
CM5 
FC3+4 
BH treated Ap 5µM 
853.2 reducing to 
168.9 
Poly-T 
FC3  
-83.9, 2nd  
-247.5 
NHS-EDC FC3+4 380, 307 
Strep FC3+4 417, 357.5 
Ethanolamine FC3+4 369, 317 
50µM Poly-t injected on to FC3. Poly-T buffer used for RB. 
5µM Aptamer injected.  Not much binding took place, that that did dissociated.  A degree 
of aptamer had bound but the signal refused to stabilise. 
To increase the Poly-T 
binding 
8 
SA 
FC1 
BH treated Ap Fc1 41 
2nd untreated Ap407.1 
 No preconditioning with 3x 1 minute injections of 1M NaCl + 50mM NaOH as this was a 
free chip from a biacore rep and came without instructions. 
Used Ap buffer for RB, injected 1µM Ap.  A binding did take place but then after a few 
hours of the buffer being run the signal was very unstable and the Ap may have dissociated. 
A 2nd 1µM Ap was injected showing a binding signal of 407.1RU but again after running 
the buffer reduced to 218.9RU. 
Trial of an SA sensor chip 
8 
SA 
FC2 
Untreated Ap FC2 
4µM 40.3RU? 
 Preconditioned the chip with 3x 1 minute injections of 1M NaCl + 50mM NaOH with 
HBS-EP RB. 
Change RB to Ap buffer for the Ap injection. The signal dropped drastically. Suspected 
binding of 40.3RU. But air bubbles hamper the actual signal diagnostic. 
Trial of SA chip after 
preconditioning 
8 
SA 
FC3 
Untreated Ap FC3 24.3  Fresh Ap buffers were made.  FC3 was not preconditioned to test the necessity of the 
preconditioning treatment.  2x10-12µM Ap injected. Some binding was present which 
remained stable. 
Testing the requirement of the 
Preconditioning of the SA 
chip with my Aptamer 
8 
SA 
BH treated Ap FC4  
-3.6 
 Engineers visit, new IFC.  Repeat of 8 SA FC2 with extra sonication of the fluids to prevent 
further air bubbles interfering with the signal. 
Preconditioned SA chip-
repeat of 8 SA FC2 
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FC4 2nd Ap 15 
3rd Ap 55.6 
HBS-EP RB, preconditioned chip.  The baseline signal was very unstable with both the 
HBS-EP buffer and the Ap buffer.  May need to make up fresh every day to prevent 
impurities forming.  
Injected 2x10-12µM Ap. No signal seen. 
A second Ap injection was made 2x10-12µM. 
A third Ap injection of 2x10-12µM.  No saturation of the chip reached. 
LZ sample made in Ap buffer, 0.05µg/ml.  Response of 1.7RU but the signal decreased 
over a couple of hours by 1000RU due to an air bubble. 
0.1µg/ml LZ injected, another air bubble disrupted the signal so no result. 
2nd LZ injection 20.9RU. 
9 
SA 
FC1+2 
BH treated Ap FC1+2 
620, 547 
Poly-T 
FC3 
1070.8 
Preconditions FC.  Injected 4x10-11µM Ap, good binding which remained stable after 
injection ended. 
Poly-T injection of 1µM.  1070.8RU produced but was obviously an air bubble disrupting 
the signal. 
FC4 had nothing immobilised-double negative control. 
0.01µg/ml LZ.  FC1-4, 235.9, 194, 1.9, 4.9. 
Regenerations, 1mM HCl 5µl, 5mM HCl 5µl, 10mM HClx3 5/10/20 µl, 20mM HClx2 5/10 
µl,  50% EtOH+NaOH x5 5/10/20/30/40 µl. after regenerations the LZ remaining was FC1-
4, 52.4, 6.7, -4.7, 93.7.  FC4 bound to the regen. solutions.  
(*Left to run in buffer over night) 
The flow path was changed and FC1 was regenerated alone with 50% EtOH+NaOH 20µl. 
This final regeneration was not actually required.  The starting baseline of FC1 was 
25834.9RU, the final baseline from the previous day (*) was 25916.7RU.  After this final 
regeneration the baseline was 25772.7RU; some Ap was lost due to this.  Regeneration 
appears to take place with prolonged buffer exposure. 
0.02µg/ml LZ injected.  FC1-4, -725.9, -613.7, -271.4, 22.9.  Again these results are due to 
air bubbles. 
2nd injection of 0.02µg/ml LZ FC1-4 1.8, 6.8, 19.6, 3.2.Regeneration 50% EtOH+NaOH 
10µl.  Further immobilised ligand was lost from all FC’s. 
3rd injection of 0.03µg/ml LZ.  FC1-4 -27.1, -29.4, 1, -35.6.  No LZ was binding. 
Increased concentration of Ap 
 
Trial of regeneration solutions 
& exposure limits 
10 
SA 
FC1+2 
BH treated Ap FC1 
491.5 
FC2 Poly-
T 176.5 
Preconditions FC 1+2.   
Injected 2x10-15 used to lower the signal.  (Conflicting ideas here, wasn’t sure who much 
Ap to immobilise.  At this point thought 50-100 was enough, hence the reduced amount of 
Ap immobilised.)  The difference between this result and the 9SAFC1+2 is that this was 
only injected onto 1 flow cell. 
The sensorgram was ended for the Poly-T injection.  When restarted the baseline had fallen 
by 291.4RU.  This may show a loss in Ap bound. 
Injected 0.1µM poly-T.  Good binding seen but an air bubble disrupted the signal. 
0.01µg/ml LZ injected.  FC1+2, 97.8, 186 
Regen. 5mM HCl x3, 20µl, 10mM HCl x3 10µl, 50% EtOH+NaOH  x2 10µl. 
Regeneration successful on FC1 but not on FC2.  Left in RB overnight.   
0.02µg/ml LZ injected.  FC1 dissociated gradually over several hours but FC2 remained 
stable & bound.  FC1+2, 8.8, 119.9. 
Regen, 10mM HCl x2 10µl.  Regeneration caused a small amount of AP loss & no 
reduction on FC2/ 
Injection of 0.03µl showed the AP was deactivated as no binding took place. 
To run experiment in full 
altering concentrations of 
Poly-T & Aptamer 
Appendix M 
10 
SA 
FC3+4 
BH treated Ap 15.3RU Poly-T 
FC3 104 
Preconditioned FC3+4 together.  FC4 does not get the thorough cleaning as FC3; need to 
precondition separately.   
RB Poly-T, 0.1µM injected.  Good binding seen. 
Injected 2x10-12 Ap.  Not much binding evident. 
Injected 0.01µg/ml LZ.  FC3+4 83.4, 45.9. 
Regeneration 0.1M C6H8O7 (sodium citrate) x2 10µl, 50µl, 1M C6H8O7 10µl, 50% 
EtOH+NaOH x2 10µl, 5µl. Regen successful on FC4 Ap but not on FC3. 
Injected 0.01µg/ml LZ FC3+4 377.4, 26.8. 
Regen. 50% EtOH+NaOH x3 10µl.  Regen successful on FC4. 
0.01µg/ml LZ injected, FC3+4 181.8, -65.2.  Ap activity was reducing with each 
regeneration until it finally deactivated. 
Try to get equal binding (in 
RU regardless of true conc.) 
of Poly-T & Ap 
 
Exploration of different 
regeneration solutions 
11 
SA 
FC1+2 
BH treated Ap FC2 
719.7 
Poly-T 
FC1 -
113.6 
Preconditioning took place on individual flow cells.    
Poly-T injected 2x10-6µM no binding present possibly due to air bubbles in the system 
again. 
2x10-6µM Ap injected.  Good binding curve seen. 
0.01µg/ml LZ injected.  FC1+2 61.8, 127.2. 
Regen.  50% EtOH+NaOH x4, 10µl, 5µl, 10µl x2. Fc1 was regenerated to -2.7, Fc2 
regenerated to 10.6 (not completely but hard to judge how much regen solution to use to 
prevent loss of Ap bound.) 
0.01µg/ml LZ injected. Fc1+2 40.3, 84.2 
Regen 50% EtOH+NaOH x2 10µl 
Regeneration not successful. Fc1 -99.8, Fc2 130.2. 
Ended sensorgram at this point and flushed to relieve air bubble. 
Restarted with 0.01µg/ml LZ. FC1+2 28.9, 115.8 
Regen. 50% EtOH+NaOH x7 10µl, 20µl x3, 10µl x3*.  lost -5.4 Ap with this final 
injection. 
*These injections were reduced due to a refill of the vial with fresh regen solution.  With 
exposure to air the ethanol evaporates making the regen solution weaker. 
RB overnight. 
Injected 0.02µg/ml LZ.  FC1+2 -1.6, 45.7. 
Regen 50% EtOH+NaOH 10µl. total loss of poly-T & Ap. FC1+2 -354.9, -220.7  
Use of the same concentration 
of Poly-T & Ap 
12 
CM5 
FC1 
 Poly-T 
FC1 FC1 -
30.7.  
2nd Poly-T 
FC1 -30.2 
Used an unmodified blank CM5 to test for NSB of Poly-T. 
Poly-T 0.1µl injected.  No binding 
2nd 0.1µl Poly-T injected.  No binding 
No binding took place showing Poly-T is not non-specifically binding to the chip. 
Test for Poly-T Non-Specific 
Binding 
13 
SA 
FC1+2 
BH treated Ap FC2 
232.7 
 Preconditioned FC’s separately. 
FC1=poly-T absent 
FC2 2x10-6µM injected. Not a good binding.  Think the RB had not been flushed through 
properly before it was changed to the Ap buffer. 
0.01µg/ml LZ injected FC1+2, 135.3, 151.1. 
Regeneration using 1M MgCl2 10µl-No major effect seen.  50% EtOH+NaOH 10µl x2, 5µl 
x2. 
0.1µg/ml LZ.  FC1+2, 95.5, 93. 
Regen, 50% EtOH+NaOH x3, 10µl x2, 5µl.  Lost -21.7 Ap on FC2. 
A blank chip used as a control 
instead of Poly-T to test for 
NSB of LZ  
Also regeneration scouting 
continued. 
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 0.01µg/ml LZ injected.  FC1+2 87.3, 50.2 
Regen. 50% EtOH+NaOH 10µl FC1+2 83.9, -28.7.  Aptamer loss. 
This work showed the difficulty in accurately regenerating the chip surface without loses 
bound aptamer.   
13 
SA 
FC3+4 
BH treated Ap FC4 
10.9 
2nd injection 47.7 
 Preconditioned FC’s separately. 
No Poly-T immobilised, to test for NSB of LZ. 
AP 2x10-6 injected FC4.  Not much binding took place, question the viability of the 
aptamer?  Or could have been day old buffer.  Need to remake buffer every week and 
change daily. 
0.01µg/ml LZ injected.  FC3+4 204.1, 189.7.  This shows NSB is taking place on FC3. 
Regen 50% EtOH+NaOH x4 10µl x2, 5µl x2. FC3+4 132.4, 12.8. 
0.01µg/ml LZ injected.  FC3+4 182.9, 60.2. reduced amount of LZ-Ap binding. 
Regen. 50% EtOH+NaOH x3, 10µl x2, 5µl. FC3+4 155.3, 11. 
Even without loss of Ap from the surface the small amount of remaining binding reduces 
the amount of potential binding.   
RB overnight. 
Huge difference in baselines, FC3+4 279.7, 182RU due to overnight soak in RB. 
0.01µg/ml LZ injected.  FC3+4 142.9, 107.1.  An overnight soak has removed the 
remaining LZ from the Ap of the previous day, rejuvenating the Ap’s binding potential. 
Regen. 50% EtOH+NaOH x7 10µl, 5ul x4, 10µl, 5µl. FC3+4 had 59.1, 10.5 LZ left bound. 
0.02µg/ml LZ injected.  FC3+4 58.9, 9.5.  After several regenerations the aptamer is no 
longer viable. 
Test to prevent Ap loss during 
regeneration.  Which is better 
a small amount of loss during 
regeneration or a little analyte 
still left bound?? 
14 
SA 
FC1+2 
 Poly-T 
FC1 30.6 
Preconditioned FC’s separately. 
FC1 Poly-T injected 2x10-6.  No binding took place after 2 injections so increased the 
concentration.  0.001µM injected.  Good binding produced. 
2x10-6 Ap injected FC2 48.4, 2nd injection 98.5.  This could show that layering is taking 
place, where aptamer is binding to the streptavidin, and then when a 2nd injection of Ap 
takes place the Ap is simply binding to the primary Ap layer. 
RB HBS-EP.  
0.01µg/ml LZ injected.  No binding took place.  The RI changed but after several minutes 
after the end of the injection the baseline retuned to the preinjection level.  This showed that 
binding is very buffer-sensitive. 
RB Ap buffer. 
Injected 0.01µg/ml LZ- no binding took place.  Flushed the system as the baseline appeared 
to be increased. 
Injected 0.01µg/ml LZ. FC1+2, 1.4, 10.6. 
Regen. 50% EtOH+NaOH x3 5µl x2, 5µl (fresh aliquot).  FC1+2 -75.3, -62.3 
Not convinced Ap was bound properly here so not a fair test. 
Replacement of the Ap 
running buffer used 
throughout all LZ injections 
with HBS-EP 
14 
SA 
FC3+4 
Ap untreated FC4 
308.7 
 
Poly-T 
FC3 80RU 
Preconditioned separetly FC3+4 
FC3 poly-t injected 100µl 0.1µM- good binding seen. 
Biotin used to block unbound strep sites, 1mM 10µl- this reduced bound poly-t slightly. 
Untreated Ap injected, 100µl 0.002pmol. the refractive index changed even though the Ap 
and RB were the same. Suspect Ap degradation at this point. Although good binding seen. 
LZ trial, 75µl 0.01µg/ml- not much binding, FC3+4 6.9, 7.3 
Regeneration 50% EtOH+NaOH, lost a lot of ap and poly-t binding, FC3+4 -53.9, -81.9 
Test to see if Biotin blocking 
on the Control FC reduces 
NSB 
Appendix M 
Left in RB over lunch. 
Tried a 2nd 0.01µg/ml FC3+4 4.1, 5.7.  As the binding in such a small amount did not want 
to risk losing any more Ap of poly-t so did not regenerate. 
3rd LZ 0.01µg/ml FC3+4 10.1, 8 Did not regenerate again as binding was so small. 
4th LZ 0.05µg.ml FC3+4 12.8, 6.6.  Again not much binding so no regeneration. 
5th LZ 0.05µg/ml FC3+4 18.2, 8.8.  Did not regenerate just left in standby mode overnight. 
It seems that the LZ is binding non specifically to the chip because even though a large 
amount of Ap and Poly-t was lost the LZ still bound.   
After another overnight soak in RB a further LZ injection was made to properly make sure 
the Ap was dead. 
0.01µg/ml LZ injected. 2RU bound on Ap but nothing on Poly-T.  The Ap must have been 
denatured. 
15 
CM5 
FC1 
  RB=HBS-EP 
NHS+EDC FC1+2, 480, 456 
Strep FC1+2, 629, 664 
Ethanolamine FC1+2, 570, 594.7 
Changed RB to Ap buffer, baseline to ages to stabilise. 
FC1 0.75µg/ml LZ injected.  FC1-0 binding 
2nd LZ injected FC1-0 binding 
3rd LZ injection FC1-0 binding. 
Therefore the LZ is specifically binding to the AP and poly-t.  Perhaps because of charge. 
Test to see if LZ  is non 
specifically binding to strep 
15 
CM5 
FC2&1 
(FC1 
reused as 
no binding) 
Ap FC2 untreated 
15.7RU 
 Immobilised 2x10-6pMol Ap 
Tested 0.05µg/ml LZ on to FC1+2, no binding on either. 
Suggesting that heating the Ap is needed or the Ap aliquots have denatured over time. 
Test to see if the CM5 chip 
(above) is working by 
immobilising Ap 
15 
CM5 
FC3+4 
  Primed with HBS-EP buffer. 
NHS+EDC FC3+4, 386, 383.5 
Strep FC3+4, 817, 833 
Ethanolamine FC3+4, 854, 872.4 
Changed buffer, primed, FC4 Poly-t 0.1µM immobilised 18RU.  Baseline 22312.8 
Changed buffer, primed FC3 2x10-6pMol 12RU.  Baseline 23147.5 
Left in RB for several hours 
(Computer crashed, restated and primed with Ap buffer) 
Baseline after several hours of RB FC3+4 23218.2, 21585.5 – Shows that some binding is 
lost over several hours, but the priming may also have caused a loss. 
0.02µg/ml 75µl injected LZ 
FC3+4, 11.3, 3.1. 
Left in buffer for several hours to see if binding dissociated over time. 
FC3+4 13.6, 0.7 
FC3+4 14.7, -1.6 
FC3+4 59.7, 10.8 
LZ stayed bound to the Ap but released from the poly-t. after several hours though binding 
of the buffer increased on both FC’s. 
To test whether the Ap and 
Poly-t are staying 
immobilised after prolonged 
exposure of RB 
 
 
 
Test with LZ to see if the Ap 
& Poly-t left bound are active 
Appendix M 
16  
SA 
FC1+2 
BH treated Ap  
2x10-3 pMol – 250RU 
Poly-t 
FC1 
242RU 
Forgot to precondition the chip. 
Fresh poly-t buffer, primed, flushed x2. 
0.1µM injected, only 75µl injected by mistake. 
Left in RB for a couple of hours-remained stabile. 
Primed with Ap buffer. Only injected 75µl. but got good binding that remained stabile over 
several hours. 
Made several LZ injections with binding increasing with the increasing concentration of LZ 
(but only on FC2). 
FC1, 2 0.02µg/ml- -0.7, 3 
FC1, 2 0.05µg/ml-  -1.3, 4.2 
FC1, 2 0.1µg/ml-  -2.7, 5.8 
FC1, 2 0.15µg/ml-  -2.9, 9.6 
FC1, 2 0.2µg/ml-  -5, 11.3 
FC1, 2 0.25µg/ml-  -7.5, 19.7 (left over night) 
FC1, 2 0.3µg/ml-  5.3, 15.7 
FC1, 2 0.4µg/ml-  4.8, 30.5 (flush) 
FC1, 2 0.5µg/ml-  -0.6, 13   calibration curve constructed. 
Overnight, primed, flushed with new buffer due to computer crash 
FC1, 2 0.01µg/ml-  10.4, 18.4 
FC1, 2 0.02µg/ml-  22.1, 39.5 
FC1, 2 0.03µg/ml-  54.3, 37.8 
FC1, 2 0.05µg/ml-  37.8, 67.6 
Regenerated with EtOH+NaOH (25mM 50%) 
FC1, 2 0.01µg/ml-  -69.4, -26.5= no binding Ap and poly-t lost off surface. 
Need to make regen solution up fresh each day as the ethanol seems to be evaporating. 
Test for stability of 
immobilised ligands. 
 
Test to see if a calibration 
curve could be produced 
(without regenerations 
inbetween). 
16 
SA 
FC3+4 
BH treated Ap  
2x10-3 pMol –80RU 
Poly-t 
FC3 85RU 
Again forgot to precondition chip. 
Poly-t buffer, primed, flushed x2, 
0.1µM poly-t injected, 75µl 
FC4 Ap buffer primed, flushed x2 
75µl Ap 2x10-3 injected 
FC3, 4 0.02µg/ml-  12, 11.9 
FC3, 4 0.05µg/ml-  41.7, 31.1 
FC3, 4 0.1µg/ml-  83.5, 60.4 
FC3, 4 0.15µg/ml-  21, 15 
FC3, 4 0.2µg/ml-  42.4, 30.2 
FC3, 4 0.25µg/ml-  66.5, 45.5 
FC3, 4 0.3µg/ml-  89.9, 61.7 
FC3, 4 0.4µg/ml-  105.3, 72.2 
FC3, 4 0.5µg/ml-  128.4, 87.8 
Regenerated, fresh 25mM 25% EtOH+NaOH, 5µl, 10µlx2, 5µl- successful regeneration 
back to baseline from previous day. 
Repeat calibration curve with 
regenerations 
   Ap RB 
X2 0.05µg/ml, FC3+4 12, 10.6, 27.5, 23.1 
Regenerated fresh 25mM 25% EtOH+NaOH but lost all binding of ligand. 
0.05µg/ml, FC3+4 -116.6, -41.5 
Show reproducibility of LZ 
binding after regeneration. 
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   Reused this damaged chip. 
All regeneration solutions were 25mM EtOH+NaOH, and various percentages of these. 
All were carried out on the Ap surface. 
Old=25mM 25% EtOH+NaOH 
New=25mM 25%, 50% & 100% EtOH+NaOH 
                                  Mid                    End 
Old 25%                   1248.3                38.1 
New 100%                233.5                 137 
New 50%                  1155.5                230 
New 25%                  1481.1                264.4 
This showed that regeneration is different depending on the surface as the poly-t surface 
gave much different results. Will try different percentages of 10mM. 
Tested the strength of 
regeneration solutions 
comparing old v newly made. 
17 
SA 
FC1+2 
Ap FC2  HB treated 
262.3RU 
Poly-t 
FC1 
255RU 
Preconditioned FC1, changed buffer to poly-t T RB, primed. 
Injected 75µl 0.1µM poly-t-good binding. 
Flushed with HBS-EP buffer, Preconditioned FC2.  Changed buffer to ap RB, primed. 
Injected 75µM 2x10-3pMol HB treated-good binding but did not save graph. 
0.02µg/ml FC1+2= -1.2, -1.1 
0.03µg/ml FC1+2=-2.7, 2.5 
0.05µg/ml FC1+2=-3.8, 8.2 
0.1µg/ml FC1+2=-6.9, 9.4 
0.15µg/ml FC1+2=-7.7, 10 
0.2µg/ml FC1+2=-12, 25 
0.25µg/ml FC1+2=-11.4, 28.7 
0.3µg/ml FC1+2=-10.7, 31.7 
0.4µg/ml FC1+2=-10.4, 34 
0.5µg/ml FC1+2=-1, 13.2  
As binding was increasing, tried to regenerate with 25% 10mM EtOH+NaOH but lost all 
bound. 
Repeat of calibration curve 
17 
SA 
FC3+4 
Ap FC4 BH treated 
111RU 
Poly-t 
FC3 
36.5RU 
Preconditioned FC3+4, Used week old poly-t buffer which limited binding of poly-t (pH 
must be affected in the tris, which affects the binding affinity). 
Used fresh ap buffer for analyte immobilisation. 
A negative analyte was used, BSA dilution.  Used because it was easily available, however 
MW was 66kDa 
0.01µM BSA (in water) x2 both removed aptamer/poly-t 
0.01µM Serum LZ  (200µl of LZ dilution + 1µl serum=1/200) 
0.1µM Serum LZ = both serum dilutions removed aptamer. 
Trial of a negative analyte  
BSA and serum sample 
18 
SA 
1+2 
Ap FC42BH treated 
259.8RU 
Poly-t 
FC1 
228.7RU 
Preconditioned FC1+2. 
Injected 75µl 0.1µM poly-t-good binding 
Injected 75µl 2x10-3pmol Ap, good binding 
0.01microg/ml LZ, Fc1+2 1.4, 4.1 
0.01microg/ml SLZ Fc1+2 14.4, 22.8 
0.01microg/ml LZ Fc1+2, 14.7, 22.7 
0.1microg/ml LZ Fc1+2, 16.3 29.1 
0.1microg/ml SLZ Fc1+2 17 32.9 
1mM HCl Fc1+2, 21.9 99.3  
To repeat the injection of 
serum samples and try 
regeneration 
Appendix M 
10mM HCl Fc1+2, 32 131.2 
1M NaCl2 Fc1+2 -15 156.2 
1M NaCl2  Fc1+2 -17 156.8 
1M NaOH  Fc1+2 -128.9 -284.5 
The final regeneration did  not reduce the amount of analyte bound but it reduced the signal 
too far destroying the receptor.  Will try a lower concentration in future. 
18 
SA 
3+4 
Ap FC4 156RU Poly-t 
FC3 
91.7RU 
(but 
falling) 
Preconditioned chip, changed buffer to poly-t and primed. 
0.1µM poly-t injected (this was old buffer which showed the poly-t slowly unbinding over 
time.) 
Changed buffer to Ap, primed. Injected 2x10-3 Ap. Again old buffer used so limited 
binding. 
Injected 0.1µg/ml LZ  FC3+4, 16.5, 5.8 
Signal was unstable to flushed. 
Injected 0.1µg/ml LZ  FC3+4, 20.5, 16.3 
5µl 1mM NaOH, -148, -113.8  -much binding lost. 
Injected 0.1µg/ml LZ  FC3+4, -128.3, -98 
NaOH destroyed chip 
Repeat of calibration curve 
with new regeneration 
solution 
19 
SA 
FC1+2 
Ap FC2 205RU Poly-t 
FC1 
237RU 
No preconditioning.  All fresh buffers used. 
FC1 primed with poly-t buffer, flushed, 0.1µM poly-t injected. 
FC2 Ap buffer primed, 75µl 2x10-3 Ap injected. 
Injected 0.1µg/ml LZ  FC1+2, 4.9, 5.  regenerated itself over 15 minutes of running buffer. 
Injected 0.2µg/ml LZ  FC1+2, 15.4, 1.9, left over lunch and baseline increased due to air 
bubble. 
Injected SLZ 1/200 FC3+4, not enough sample, so stopped injection. 
19µl injected of SLZ FC1+2, 566.7, 329.1 
Regenerated with 50% EtOH+NaOH 25mM- regeneration successful but the chip was 
unusable afterwards. 
Injected 0.1µg/ml LZ  FC1+2, 5.7, -12.5. 
Need to try reducing the concentration of regen solution as its too harsh for the aptamer. 
Trial of serum LZ samples 
with regeneration 
19 
SA 
FC3+4 
Ap FC4 195.9RU 
 
 
 
 
 
 
 
 
 
 
 
Ap FC3 173.1RU 
Poly-t 
FC3 
253RU 
 
 
 
 
 
 
 
 
 
Poly-t 
FC3 
91.5RU 
Ran unclog, as FC3 was producing a poor signal output. 
Preconditioned chip 
Changed buffer to poly-t, primed, injected poly-t 0.1µM 
Changed buffer, primed, injected 2x10-3 pMol Ap 
Injected 0.01µg/ml LZ  FC3+4, 9.5, 3.3- strange binding pattern-baseline set 
Injected 0.02µg/ml LZ  FC3+4, 12.8, 6.2 
Regeneration using 25mM EtOH+NaOH 25%, ~50RU lost on both FC’s-set baseline 
Injected 0.01µg/ml LZ  FC3+4, -10.1, 0.3 
Injected 0.01µg/ml LZ  FC3+4, 6.5, 4.6- binding does take place after the regeneration 
which suggests that the aptamer and poly-t might not be being removed. 
New sensorgram as signal was increasing. 
Injected 0.01µg/ml LZ  FC3+4- no binding 
Reinjected Ap on to FC3 and then changed buffer and reinjected poly-t. – good amount of 
binding of both. 
Injected 0.01µg/ml LZ  FC3+4, 4.9, 8.7-binding still took place be was not a clean as before 
as more binding was taking place on the control than before, but less compared to the Ap. 
Test for regeneration between 
analyte injections & whether 
a second injection of aptamer 
can be made after 
regeneration has failed. 
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20 
SA 
FC1+2 
Ap FC1 128.9RU Poly-t 
FC2 
110RU 
Preconditioned chip 
Changed buffer to poly-t, primed, injected poly-t 0.1µM 
Changed buffer, primed, injected 2x10-3 pMol Ap 
Injected 0.1µg/ml –ve analyte  FC1+2, 194, 138RU huge amount of binding present. 
Several regenerations carried out, 25% EtOH+NaOH, 5µlx2, 10µlx2, 20µlx6, 10µl, 5µl-
regeneration successful. 
Injected 0.2µg/ml LZ  FC1+2, 5.5, 3.3 hardly any binding 
Regeneration 25% EtOH+NaOH 5µlx2. no regeneration successful. 
Test for –ve analyte binding-
Myoglobin from Equine 
Heart 
20 
SA 
FC3+4 
Ap FC4 115.2RU Poly-t 
FC3 
123.9RU 
Preconditioned chip 
Changed buffer to poly-t, primed, injected poly-t 0.1µM 
Changed buffer, primed, injected 2x10-3 pMol Ap 
Injected 0.1µg/ml LZ  FC3+4 11.1, 2.8 
Injected 0.1µg/ml LZ  FC3+4 21.8, 4.8- regeneration not needed as after a while the LZ 
was freed. 
Injected 0.1µg/ml myoglobin  FC3+4, 243.4, 148.5-several regenerations carried out with 
25% EtPH+NaOH 10µl, 20µlx4, 10µl, 20µl regen successful. 
Injected 0.1µg/ml LZ  FC3+4-no binding. 
Test for –ve analyte binding 
21 
SA 
FC1+2 
Ap FC2 226.4 RU 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ap FC2-no binding 
 
 
Poly-t 
FC1 180.6 
RU 
Preconditioned chip separately. 
Changed buffer to poly-t, primed, injected poly-t 0.1µM 
Changed buffer, primed, injected 2x10-3 pMol Ap 
Injected 0.1µg/ml LZ  FC1+2, binding on both.  Left in continuous flow over lunch.  As 
binding was falling off, increased flow rate to 10µl.  left to see if ap and poly-t would 
regenerate.  (Buffer needs to be left on a magnetic stirrer.  No matter how long its sonicated 
for bubbles still appear.)  Signal did not reach the baseline as air bubbles increased the 
signal.  On FC1 binding was present but returned to the baseline after continuous flow.  Ap 
binding was stable at end of injection. 
Stopped sensor-gram and flushed, when restarted the baseline was not restored. 
Injected 0.1µg/ml LZ  FC1+2, 6.6, 7.3 regenerated with 25% EtOH+NaOH, regen 
successful. 
Injected 0.1µM myoglobin  FC1+2, 2295.7, 427.7.  Again left in continuous flow to see 
how much dissociation would occur. 
Binding on FC1 was very fast, lots of binding taking place  where as the binding on the Ap 
was much slower. As dissociation was occurring the flow rate was increased to 50µl.   
Dissociation stabilised after a few hours.  Stopped sensorgram and flushed. 
End of sensorgram FC1, 27277.2,  FC2, 26715.3 
Beginning of new sensorgram FC1, 27268.5, FC2, 26840.3 
Next day,  
Made fresh buffer.   
Injected 0.1µg/ml LZ  FC1+2, 4.6, 22.2 regenerated with 5µl 25% EtOH+NaOH, regen 
successful. 
Injected 0.1µg/ml LZ  FC1+2, 5.9, 19.9  regenerated with 5µlx2 and 10µlx2  25% 
EtOH+NaOH, regen not achieved. 
Preconditioned FC2 and reapplied aptamer.  
(Did not change buffer for preconditioning.) 
Injected 0.1µg/ml LZ  FC1+2, -1.7, 6.3 some binding taking place but is reduced. 5µl 25% 
EtOH+NaOH, regen successful. 
Regeneration with continuous 
buffer & 25% EtOH+NaOH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To test how many times LZ 
will bind and regenerate and 
test secondary Ap binding. 
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 Injected 0.1µg/ml LZ  FC1+2, 3.7, 9.1. 5µl 25% EtOH+NaOH, regen not successful. 
21 
SA 
FC4 
Ap FC4-66RU  No preconditioning of chip surface. 
Injected Ap. Strange binding, huge difference in refractive index even though the Ap was in 
the same buffer.   
Injected 0.1µg/ml LZ  FC4, 14RU 
Stopped sensorgram 26948.0 
Changed temperature to 40oC 
Restarted sensorgram 24931.9 
Difference of 2016.1RU, suggesting the Ap and LZ have both been removed. 
Need to try adding more Ap to surface to check if it’s still in tact. 
Then try a smaller temperature change.   
Does changing the 
temperature regenerate the 
chip? 
22 
SA 
FC1+2 
FC2 Ap 56.6RU 
 
 
 
 
 
 
 
FC2 Ap 92RU 
 
 
 
 
FC2 Ap  37.3RU 
FC1 Poly-
T 
201.2RU 
Queried the quality of the preconditioning step when both FC’s were preconditioned 
together. 
Preconditioned FC’s separately. 
Changed buffer, primed + flushed. 
Injected 0.1µM poly-t 
Changed buffer, primed, flushed. 
Injected 2x10-3 Ap.  Binding wasn’t great with the Ap.  No explanation for it. 
(Engineers visit) 
Injected a 2nd round of Ap, not much bound again.  Suspect that the aliquot in the small 
PCR tubes is hampering the binding.  The aliquot, once defrosted is pipetted into a second 
epindorf, is the Ap stuck to the plastic? 
Injected 0.1µg/ml LZ FC1+2, 42.5, 59.5. 
25% EtOH+NaOH regeneration.  Regenerated too far. 
Changed flow path and injected Ap 3rd round. Again not much bound, will try not changing 
the epindorf just in case the oligo is attracted to the plastic. 
Injected 0.1µg/ml LZ FC1+2, 27.6, 4.6.  Chip obviously not working, possibly because its 
one SN gave me and was sitting in ambient temperature for too long. 
Testing the quality of the 
preconditioning; does 
preconditioning the FC’s 
separately create a chip which 
binds to the ligand more 
affectively? 
22 
SA 
FC3+4 
FC4 Ap 111.8RU 
 
 
 
 
 
 
 
 
 
 
 
 
FC4 Ap 136.7RU 
 
 
 
FC3 Poly-
T 
334.7RU 
Preconditioned FC’s separately. 
Changed buffer, primed + flushed. 
Injected 0.1µM poly-t 
Changed buffer, primed, flushed. 
Injected 2x10-3 Ap.  Binding was better than before the preconditioning step was changed. 
Injected 0.1µg/ml LZ FC3+4, -41.1, 22.0RU 
Regenerated with 25% EtOH+NaOH (Change the flow path as only FC4 needed 
regenerating) Regen too far. 
Injected 0.1µg/ml LZ FC4, 3.8RU 
No binding took place on the FC4.  Changed flow path back to FC3+4 
Injected 0.2µg/ml LZ FC3+4, -33.7, 14.3 Allowed to dissociate over lunch, no dissociation 
took place. 
Regenerated with 25% EtOH+NaOH Fc3+4, -109.6, -11.5-remade fresh regen solution 
Changed flow path to FC4 only, Injected 2nd Ap. Good Ap binding. 
Injected 0.1µg/ml LZ FC3+4 20.9, 11.5RU 
Injected 0.2µg/ml LZ FC3+4, 17.9, 11.5RU 
Injected 0.3µg/ml LZ FC3+4, 19.0, 10.9 
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FC4 Ap 147RU 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FC4 Ap 76.9RU 
Next day. 
Changed buffer, primed. 
Injected 3rd Ap. Good binding. 
Injected 0.1µg/ml LZ FC3+4, 39.1, 0.3 
Regenerated with 25% EtOH+NaOH Fc3+4, -10.2, -82.4 
Injected 0.1µg/ml LZ FC3+4, 57.0, 35.4RU 
Regenerated with 25% EtOH+NaOH Fc3+4, 27.7, 6.0RU 
Injected 0.1µg/ml LZ FC3+4, 42.2, 22.5RU 
Regenerated with 25% EtOH+NaOH Fc3+4, 48.3, 5.7 
Injected 0.1µg/ml LZ FC3+4, 1.6, 2.1 
Regenerated with 25% EtOH+NaOH Fc3+4, -16.7, -13.7 
Injected 0.1µg/ml LZ FC3+4, 2.5, 2.2 
Regenerated with 25% EtOH+NaOH Fc3+4,-13.6, -13.9RU 
Made mistake and forgot to change flow path, injected onto both flow cells Stopped 
sensorgram. 
Next day. 
Injected fresh Ap onto FC4.  Hardly any binding. Stopped sensorgram. 
23 
CM5 
FC1 
  Docked CM5 chip. 
NHS+EDC 35µl, FC1, 560 
50µl streptavidin injection, FC1, 1113.4 
Followed by 35µl ethanolamine, FC1, 1064.6 
Injected 0.1µM Myoglobin, FC1 47.4RU. 
Test showed that myoglobin is very sticky and binds to the surface. 
Test for non specific binding 
of Myoglobin onto a mock 
SA chip 
24 
SA 
FC1+2 
  Preconditioned the FC’s separately. 
Changed buffer to poly-t and primed.  Injected 0.1µM poly-t. 
Changed buffer, injected 2x10-3 Ap. 
Injected 0.1µg/ml LZ FC1+2  
Stopped sensorgram. Increased temp.  This procedure was carried out for each temperature 
change. 
(Temperature was very unstable when changed by 0.05.  the Biacore tended to settle for 
temperature that were almost right.  All experiments were carried out only when the 
temperature was stable and set.) 
Change of temperature 
experiement.  Temp increased 
by 5oC to test for regeneration 
properties. 
 
 
LZ Baseline Before Temp Change 
Baseline After Temp 
Change 
Difference in Baselines Temp 
Change 
ºC 
Ap FC2 Poly-t FC1 FC1 FC2 FC1 FC2 FC1 FC2 FC1 FC2 
25-25.2 151 84.2 21 4.8 27171.8 27331.2 27171.9 27328.9 1 -2.3 
25-25.3 151 84.2 21 4.8 27171.8 27331.2 27164.8 27321.5 -7 -9.7 
25-25.4 151 84.2 21 4.8 27171.8 27331.2 27128.1 27285.2 -43.7 -46 
25-25.5 124 94.7 17 10 27183.8 27214.6 27119.0 27150.9 -64.8 -63.7 
25-26 79 222 39 26.6 27169.8 27105.9 27033.1 26972.2 -136.7 -133.7 
25-30 152.4 202 40 24 27146.3 27395 26443.7 26684 -702.6 -711 
25-35 176.1 87 -3.7 33.1 27101.7 27557.5 25708.2 26067.2 -1393.5 -1490.3 
25-40 109.2 61.2 8.5 19 27108.1 27539.2 24961.4 25381.0 -2146.7 -2158.2 
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24 
SA 
FC3+4 
FC4 Ap 176.5RU 
 
 
 
 
2nd Ap 131.8RU 
FC3 poly-t 
66RU 
Preconditioned FC3 and 4 separately. 
Injected 0.1µg/ml LZ- signal kept decreasing-rinsed, but signal still kept decreasing. 
Flushed 
Injected 0.1µg/ml, FC3+4, -1.2, -6.6 
Injected 0.25µg/ml FC3+4, 0.1, -0.3 
 
Changed flow path and injected a second Ap. 
Injected 0.1µg/ml-no binding, ended chip. 
(this chip was undocked and left in the fridge over the weekend in its original sealed packet.  
The exposure to buffer, undocking, drying out, then exposure to more buffer damages the 
chip in some why which inactivated its surface for further use. Chips therefore need to be 
fully exhausted of use before undocked.)   
Incorporation of regeneration 
by thermodynamics with 
protocol.  Try creating a 
calibration curve. 
25 
SA 
FC1+2 
FC1 Ap 188.6RU FC1 poly-t 
276.1RU 
Preconditioned FC1 and 2 separately. 
Made fresh buffer. 
 
 
Repeat of thermo 
regenerations using buffered 
LZ samples to produce a 
calibration curve. 
 
(*where a loss of -1.2 is seem, the baseline has increased by 1.2RU) 
Starting 
Baseline 
(FC1+2) 
LZ Bound 
(FC1+2 RU) 
Baseline after LZ Bound Baseline after 
Change of Temp 
(25.3oC) 
RU loss due to 
Temp Change 
Baseline after Temp is returned 
to 25oC 
Difference in 
Start & End 
Baselines (RU) 
27521.8 
27772.1 
0.1µg/ml 14.6 
26.7 
27536.4 
27798.8 
27493.3 
27753.6 
43.1 
45 
27518.9 
27780.4 
-2.9 
 -8.3 
27518.9 
27780.4 
0.15µg/ml 17.9 
27.1 
27536.8 
27807.5 
27496.6, 
27764.2 
40.2 
43.3 
27512.4 
27780.7 
-6.5 
-0.3 
27523.6 
27793.2 
0.15µg/ml 14.6 
22.7 
27538.2 
27815.9 
27503 
27792.8 
35.2 
23.1 
27530.5 
27822.2 
-6.9 
-29 
27530.5 
27822.2 
0.2µg/ml 11.5 
14.6 
27541.9 
27836.8 
27500 
27794.9 
41.9 
41.9 
27535 
27831.6 
-4.5 
-10.1 
27535 
27831.6 
0.25µg/ml 10.6 
14.8 
27545.7 
27846.4 
27514 
27818.6 
31.7 
27.8 
27540.3 
27847 
5.4 
-0.6 
25 
SA 
FC1 
Previously 
immobilised 
 Mass transfer=the ease in which the analyte moves out of solution and binds to the surface 
layer. 
Flow rates of 5,15 and 75µl/min are used.  All signals produced from the injection should 
give the same result showing mass transfer is not influenced by flow rate. 
 
The results here show mass transfer is not having an affect as all signals coincide with each 
other.  Results for 75µl/min show a spike of air.  So this will be repeated. 
Mass Transfer, Is Mass 
Transfer having an effect on 
analyte binding 
25 
SA 
FC3+4 
FC4 148.6RU FC3 
313.4RU 
Preconditioned FC3 and 4 separately. 
 
Continuation of regeneration 
by temp changes to construct 
a calibration curve. 
Starting 
Baseline 
(FC1+2) 
LZ Bound 
(FC1+2 RU) 
Baseline after LZ Bound Baseline after Change 
of Temp 
(25.3oC) 
Amount of RU 
loss due to 
Temp Change 
Baseline after 
Temp is 
returned to 
Difference in Start & 
End Baselines (RU) 
Appendix M 
25oC 
28116.7 
27854.9 
0.05µg/ml 1.2 
7.1 
28117.9 
27861.9 
25.2oC 28085 
27825.5 
32.9 
36.4 
28087.1 
27827.2 
29.6 
27.7 
28087.1 
27827.2 
0.1µg/ml  25.6 
30.5 
28112.6 
27857.7 
28081.9 
27826.5 
30.7 
31.2 
28085 
27828.8 
27.6 
28.9 
28085 
27828.8 
0.15µg/ml 34.7 
46.9  
28119.8 
27875.7 
28117.7 
27873.3 
2.1 
2.4 
28119 
27876.5 
-34 
-47.7 
28119 
27876.5 
0.2µg/ml 5 
12 
28124.1 
27888.5 
28089.6 
27853.9 
34.5 
34.6 
28090.3 
27854.6 
28.7 
21.9 
28090.3 
27854.6 
0.25µg/ml 36 
44.6 
28127.2 
27899.2 
28098.9 
27869.8 
28.3 
29.4 
28100.3 
27869.7 
-10 
-15.1 
28100.3 
27869.7 
0.2µg/ml 31 
37.2 
28131.3 
27907 
28129.1 
27903.5 
2.2 
3.5 
28127.1 
27901.3 
-26.8 
-31.6 
28127.1 
27901.3 
0.15µg/ml 9.7 
15 
28136.9 
27916.2 
28131.7 
27909.6 
5.2 
6.6 
28127.6 
27904.1 
-0.1 
-2.8 
28189.8 
28035.7 
0.1µg/ml  15.9 
16 
28205.6 
28052.3 
28200.2 
28043.6 
5.4 
8.7 
28200.3 
28041.6 
-10.5 
-5.9 
28066.1 
28223.9 
19.6 
21.1 
28085.7 
28245 
28050.2 
28207 
35.5 
38 
28051.3 
28210.2 
14.8 
13.7 
26 
FC1&2 
FC2 225RU FC1 
200RU 
Made fresh buffers. Docked new chip and preconditioned flow cells separately.   
Injected 0.1µg/ml SLZ -11.4, 2.4 
Changed buffer to poly-t to stop any nucleases in the serum from destroying the aptamer 
and poly-t 
Calibration curve of serum 
spiked samples with heat 
regen. 
 
Starting 
Baseline 
(FC1+2) 
LZ Bound (FC1+2 
RU) 
Baseline 
after LZ 
Bound 
Baseline after Change of Temp 
(25.3oC) 
Amount of 
RU loss due 
to Temp 
Change 
Baseline after Temp 
is returned to 25oC 
Difference in Start 
& End Baselines 
(RU) 
25075.6 
24954.1 
0.1µg/ml 50.9   46 25126.1   
24996.3 
25.2 oC  25114.3   24983.3 
25.3 oC   25098.5   24968.5 
25.4 oC 25066.9   24938 
11.8   13 
27.6   27.8 
59.2   58.3 
 
 
25071.1   24946.8 
 
 
-4.5   -7.3 
25087.1 
24963.2 
0.2µg/ml 28   31 25115.1   
24994.2 
25.3 oC 25109.4   24986 
25.4 oC 25063.8   24942.8 
5.7   8.2 
45.6   43.2 
 
25094.4   24970.6 
 
+7.3   +7.4 
25094.4 
24970.6 
0.05µg/ml 14.6   26.5 25109   
24997.1 
25.3 oC 23103.8   24988.9 
25053.9   24941.3 
5.2   8.2 
55.1   55.8 
 
25092.8   24979.1 
 
-1.6   +8.5 
SA26 
FC3&4 
Ap FC4 57.3RU Poly-t 
FC3 29RU 
Preconditioned chip.  Poor binding, no explanation for it.   
Running buffer poly-T buffer to reduce nuclease damage to Ap and poly-T. 
Injected 1/200 0.2µg/ml SLZ FC3&4, -3.8, -4.5 
Injected 1/100 0.2µg/ml SLZ FC3&4, 1.1, 10 
Injected 1/50 0.2µg/ml SLZ FC3&4, 1.0, 18.5 
Injected 1/25 0.2µg/ml SLZ FC3&4, -1.2, 29.6 
 
Left over night in buffer 
Injected  1/400 0.2µg/ml SLZ FC3&4, -4.2, -2.0 
Experiment to test which is 
the best dilution of serum to 
use. 
Appendix M 
SA 27 
FC1&2 
FC2 138.1RU FC1 71RU Preconditioned Fc’s separately. 
FC1 poly t unusually low binding again. 
FC2 ap, slightly lower than usual but not too bad. 
Baseline FC1&2,  25739.8, 25705.9 
Injected 0.2µg/ml SLZ 1/100, 0.7, 25740.6, -7.0, 25699  -hardly any binding 
Injected 0.25µg/ml SLZ 1/100, 3.2, 25744.3, 2.4, 25698.9 
Injected 0.25µg/ml SLZ 1/100, -5.9, 6.3 
Try applying LZ, 0.2µg/ml -5.0, -4.1 
Injected 0.25µg/ml SLZ 1/100, 0.7, 1.6 
Injected 0.25µg/ml SLZ 1/100, 0.7, 3 
Gave up as nothing was binding- no explanation. 
Serum samples, unspiked, naturally containing high lysozyme levels 
Defrosted samples, D4 10.3, D22 9.2, D54 9.8, D52 9.6, D55 20, D56 10.4, D58 12, N26 8, 
A15 9.2, A17 8. 
All samples were diluted 5/500 and spun. 
Injected 75µl unspiked serum. Massive change in refractive index.  Positive samples must 
contain more crap/bacteria than a negative serum sample. 
A17 FC1&2, -0.7, 1.8. 
Continuation of calibration 
curve 
 
 
 
 
 
 
 
 
 
 
 
Lysozyme positive samples 
tested with the biacore 
method 
SA 27 
FC3&4 
FC4 81Ap FC3 
33.3polyt 
Preconditioned both FC’s separately.  
Low binding again, no explanation as buffers were fresh. 
Injected unspun 0.1µg/ml SLZ FC3&, 0.5, -4.7 
 
 
Starting Baseline 
(FC1+2) 
LZ Bound (FC1+2 RU) Baseline after LZ Bound Baseline after Change of Temp 
(25.3oC) 
Amount of RU loss due 
to Temp Change 
25653.5 
25283.7 
0.05µg/ml SLZ 3101.9 
2458.7 
28761.2 
27743.5 
26oC 28465.3   27501.4 
27oC 28268.6   27326.8 
29oC 27899.9   26985.1 
35oC 26988.6   26093.6 
40oC 26147.8   25264.2 
304.9   242.1 
492.6   416.7 
861.3   758.4 
1772.6   1649.9 
2613.4   2479.3 
     
SA28 
FC1&2 
FC2 Ap 200.8 FC1 Polyt 
239.1 
Preconditioned chip and used fresh buffers.  Also ELISA result and Actual BIAcore result 
Result ELISA Final Biacore 
D4 FC3&4, 9.6, 21 10.3 7 
D22 FC3&4, 10.6, 22.9 9.2 7.8 
D52 FC3&4, 11.3, 25 9.8 8.3 
D54 FC3&4, 10.7, 58.1 9.6 26 
D55 FC3&4, 8, 23.8 20 10 
D46 FC3&4, 7.4, 14.5 10.4 5 
D58 FC3&4, 10.5, 32.8 12 16 
N26 FC3&4, 6.6, 17.6 8 7 
A15 FC3&4, 12.3, 20 9.2 5.5 
A17 FC3&4, 3.7, 11.4 8 5.5  
Repeat of clinical samples 
SA 29 
FC 1&2 
FC2 209RU Ap Blank Calibration curve using a blank surface as the control.  (No poly-t used) 
0.05µg/ml  1.8, 56.5 
Calibration curve for buffered 
LZ  
Appendix M 
 
 
0.1µg/ml -0.2, 61.0 
0.15µg/ml -5.3, 66.3 
0.2µg/ml -3.1, 71.1 
0.25µg/ml -5.8, 54.2 
0.3µg/ml 33.4, 89.4 
0.4µg/ml 36.4, 95.3 
0.5µg/ml 36.1, 62.9 
1.0µg/ml air disrupted signal-possibly reached limit. 
Serum was diluted 1/200 and spin filtered in the usual way.  The filtrate was then used both 
with the ELISA and with injected onto a sensor chip for comparison.   
Sample V1 FC1&2, 14.4, 37.9  ELISA result 0.063=0LZ 
Sample V2 FC1&2, 4.3, 34.8 ELISA result 0.068=0LZ 
 
 
 
 
 
 
 
 
 
Cross reference of spiked 
clinical samples with ELISA 
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6.0 Final Discussion & Conclusions 
The focus of this project was to produce a diagnostic test for the determination and 
quantification of lysozyme in clinical samples.  Currently diagnosis involves collation 
of signs and symptoms from the patient, along with blood analysis and blood cultures 
for bacterial presence.  Current high mortality rates for sepsis show that the diagnostic 
and management tools used need immediate improvement. 
 
6.1.1 ELISA (Chapter 2) 
The aim of the ELISA work was to produce and optimise an ELISA for the 
quantification of lysozyme in serum samples.  A reference range for lysozyme in buffer 
was also produced for use with the ELISA and the clinical samples.  The reference 
range is test-specific, but proved to be reliable when compared to clinical samples 
wherein the highest lysozyme levels tallied with diagnosis of sepsis. 
 
The freeze-thaw experiments showed no detrimental effects were being caused by the 
storage and the repeated thawing of the samples.  This therefore should not have caused 
any ill effects when the clinical samples were processed with a commercially available 
kit.  The commercially available kit was purchased and compared with the ELISA in 
terms of sensitivity, ease of use and cost. The commercial kit did not have the degree of 
sensitivity of the ELISA, could not compete on price and was far more complex to 
execute. 
 
Serum samples were provided by septic patients at the Great Western Hospital and these 
were compared with both hospitalised non-septic samples and non-hospitalised healthy 
volunteer samples (total = 274).  The lysozyme levels from the ELISA assay were also 
compared with the results from routine blood analysis and overall diagnosis carried out 
at the hospital.  The results showed a statistically significant difference between healthy 
patients’ lysozyme levels and septic patients. 
 
The advantage of the ELISA system is that is uses very small blood samples.  This is 
particularly useful with patients who are reluctant to give blood, who are anaemic or 
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who have to have several blood samples taken daily.  At present this assay is working 
and could be incorporated into the routine work-up of a patient suspected of sepsis.   
 
6.1.2 ELIFA (Chapter 3) 
The aim of the ELIFA work was to develop on the ELISA success and to use the basic 
assay format to produce a faster, cheaper, and easier to use detection system for 
lysozyme.  A method for quantifying the results produced from the ELIFA was also 
sought.  The total ELIFA time was reduced to 40 minutes and the reusable flow cells 
made this assay far faster and cheaper to run compared to the ELISA. 
 
The initial aim when the ELIFA was up and running, was to produce a calibration curve 
of lysozyme in buffer.  The intention was to process the clinical samples used in the 
ELISA.  Production of a calibration curve using the ELIFA was attempted, but due to 
the problem of non-specific binding was unsuccessful.  Consideration of the exact 
nature of the problem suggests that the intense washing of the flow cells may have 
heightened the problem.  However, these problems were tackled with success in Chapter 
4. 
 
6.1.3 Mini-ELIFA (Chapter 4) 
The main aim of the Mini-ELIFA work was to build on the progress made on the 
ELIFA system and to correct the problems faced with the non-specific binding.  The 
Swinnex filters were purchased because of their ability to be autoclaved.  This 
eliminated the problem of non-specific binding and the problem of the harsh wash 
solutions degrading the filter plastic.  Another aim was to produce a calibration curve of 
lysozyme/bacteria in buffer and to establish a method of measuring the results 
produced.   
 
The bacterial mini-ELIFA produced a series of membranes which showed 
discolouration dependent on the concentration of bacteria in the sample.  These 
membranes could then form a colour chart which could be used for unknown samples, 
as the discolouration was very distinguishable.  The lysozyme mini-ELIFA however, 
did not produce staining to such a degree.  A possible reason for this was a result of a 
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conformational change in the lysozyme when it bound to the membrane.  The 
deactivated lysozyme simply did not bind and therefore did not produce reliable results. 
The bacterial mini-ELIFA did show promising results and with more work the 
lysozyme mini-ELIFA also has the potential to become a fast test for lysozyme 
determination. 
 
6.1.4 Lysozyme Biosensor (Chapter 5) 
The main aim of the biosensor work was to develop a further detection system that was 
a real time assessment, with greater through-put and a greater limit of detection.  A 
further aim of this chapter was to incorporate the use of aptamers as an artificial 
receptor into the biosensor.  The biosensor is a working system for the detection of 
lysozyme in buffer.  The anti-lysozyme aptamer was incorporated with success.  The 
aptamer was also successfully regenerated using a heat change within the BIAcore.  
This allowed the aptamer to be reused for other lysozyme in buffer determination.  
Control of non-specific binding was also successful with experiments showing that the 
lysozyme in buffer was specifically binding to the aptamer.   
 
The final objective of this work was to test the clinical samples with the lysozyme 
biosensor.  The serum posed a specific problem with contaminants within the serum 
binding to the sensor chip surface.  This meant that the lysozyme was not detectable in 
serum.  A better method for extracting the lysozyme prior to injection is needed for the 
biosensor to be viable. 
 
The advantage of the lysozyme biosensor is that no radioactivity is used during the 
testing and once established the test is a single step, reagentless assay.  This suggests the 
test would be very simple to use, requiring very little training for the operator.  The 
BIAcore 3000 produces 2 replicates of each sample, but a better system such as the 
T100 model would allow multiple testing of many samples, making it usable in a 
hospital environment. 
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6.2 Conclusions & Significance of the Project 
The main focus of this project was to produce a test to indicate the onset of sepsis which 
would be used to aid in the management of treatment and recovery of patients.  The 
lysozyme tests in this project would not be used on their own to indicate the positive 
presence of sepsis, but the aim was to provide more information for the clinician and 
increase diagnostic certainty with the hope of lowering mortality rates.  The test would 
provide additional information, which along with signs and symptoms and blood 
analysis, would be used for patients who were too ill for routine imaging investigation 
and would confirm or refute the need for surgery.  Time, in the case of sepsis, is not in 
abundance, therefore during this project the need for a test which could be carried out in 
real-time, ideally at the patient’s bedside was of great importance.  Throughout the 
development of each test (ELISA, ELIFA, Mini-ELIFA and the Biosensor) the remit 
always involved a reduction in the total test time.  The biosensor has the potential to 
become a real-time test for lysozyme, which would enable multiple testing for each 
patient during the course of their illness so their lysozyme levels could be directly 
monitored.  An objective within the ELISA work was to further the knowledge of 
lysozyme involvement in sepsis.  This was done by collecting the data from routine 
blood analysis and making comparisons with the lysozyme levels from the ELISA 
assay.  Adding lysozyme determination to the usual work-up of critically ill patient’s, 
using techniques from this project, would give greater confidence in diagnosis. 
 
6.3 Future Work 
This project still has huge potential.  If more time was allowed several additional 
experiments would have been included to both extend work executed in Chapters 2, 3, 4 
and 5 and also to explore other avenues in the hope of producing better tests.  Some key 
areas are as follows: 
 Aptamers Incorporated in the ELISA – This has the potential of creating a 
reusable assay.  The benefits of aptamers described in section 5.4.6.2 would be 
harnessed and incorporated producing a very reliable, reusable and stable assay. 
 Using Lysozyme to Distinguish between forms of Sepsis – The blood samples 
provided in this project were randomly chosen from a range of patients during 
their stay in hospital.  If more time was available, then several blood samples 
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could be taken from patients throughout the course of their illness.  Samples 
would be specifically taken from septic patients at the start of their stay in 
hospital and the same patients would be monitored until they improved, left 
hospital or died.  The analysis of these samples could show a difference in 
lysozyme levels, distinguishing between the progressive forms of sepsis; i.e. 
septic shock, severe sepsis and therefore help in the diagnosis and prognosis of 
the patient and also improve understanding of lysozyme further. 
 Mini-ELIFA Clinical Sample Testing – The mini-ELIFA should be tested with 
clinical samples.  The bacterial mini-ELIFA has the potential of becoming a 
very fast, novel test for E. coli in urine samples.  If more time was available 
urine samples from both healthy controls and septic patients would be tested. 
 Mini-ELIFA for UTI Bacteria – Further work in this area would include 
developing the test for more than one UTI causing bacterium.  The test would 
have to be converted to a sandwich immunoassay format where several different 
bacterial antigens were seeded onto a membrane and actively captured bacteria 
from the urine sample i.e. the membrane divided into 4 segments and a different 
antigen adhered to each quarter.  The degree of staining on each quarter of the 
membrane would indicate the quantities of each bacterium present.  This would 
then produce a fast, multi-bacterial test useable in GP surgeries or at the hospital 
bedside. 
 Lysozyme Mini-ELIFA – This test needs further work to improve sensitivity to 
become a viable assay in the management of sepsis.  Speculation over the 
lysozyme binding to the membrane in this test may be overcome by changing 
the format to a sandwich immunoassay.  This would mean an anti-lysozyme 
molecule being adhered to the membrane to actively capture the lysozyme from 
the sample.  Due to the speed of the assay, when working this test has the 
potential to become a bedside test for better management of sepsis. 
 Lysozyme Biosensor – More serum samples needed to be tested with the 
lysozyme biosensor, to produce a test which can be used in a clinical 
environment.  A method for extracting the lysozyme from the serum is also 
required.  This may involve affinity column purification prior to injection onto 
the biosensor.  Hansen & Andersen (1973) also mention in their study of 
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lysozyme extraction methods using n-Butanol.  This may eliminate all other 
factors, such as residual bacteria in the serum which cannot be spin-filtered out, 
from interfering with the ligand so accurate serum lysozyme measurements can 
be achieved. 
 Comparison between an Aptamer and an Antibody Biosensor - An anti-
lysozyme antibody could have been immobilised onto the surface of a CM5 
sensor chip and the effectiveness in terms of binding ability of lysozyme could 
be compared with the aptamer biosensor.  This would have given first hand 
evidence to back up the claims mentioned in section 5.4.6.2 on the advantages of 
aptamers over antibodies. 
 Lysozyme Biosensor Spreeta Modification – Ideally the lysozyme biosensor 
method would be transferred to the Spreeta (Appendix L).  The Spreeta system 
is a low cost, miniature biosensor.  Transferring and adapting the lysozyme 
biosensor method to this system would produce a technique which was 
inexpensive to develop and run, making it a realistic system for hospital use, 
have the speed of the BIAcore system and be miniaturised for bedside/GP 
surgery use. 
 A final thought for lysozyme detection would include coupling the technology 
of aptamers with cantilevers.  A cantilever sensor has two sensing arms which 
cantilever together in response to changes in surface stress which is caused by 
adsorption of biomolecules.  Cantilevers have the advantage of high-throughput 
label-free detection and differential sensing whereby disturbances from non-
specific molecules are suppressed directly during the measurement of the 
analyte.  Combining the advantages of aptamers (high specificity, in vitro 
production, resistance to denaturation and long shelf life) with the benefits of 
cantilevers would produce an easy to engineer and highly advanced sensor for 
lysozyme. 
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